


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update December 27 - January 02, 2021,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 52 2021 845 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashbord](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMEA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[German \(ICU\) bed capacity](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford Universtiy Press](#)

[Cambridge Univeristy Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[Retracted papers](#)

[AAN - Neurology resources](#)

[COVID-19 risk tools - Apps](#)

[COVID-19 resources \(Harvard\)](#)

[Web app for SARS-CoV2 mutations](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRE\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

[COVID-19 prevention network](#)

[Covid-Plex trial - \(plasma exchange & convalescent plasma trial\)](#)

Media digest

New York Times - Corona update

[Judge lets seven Virginia school districts keep their mask policies in place.](#)
[Those with weakened immune systems are urged to get additional shots sooner.](#)
[A Pennsylvania doctor accused of prescribing ivermectin for Covid-19 is fired.](#)
[C.D.C. data through December show boosters offer fewer gains for those under 65.](#)
[I Had Breakthrough Covid. Can I Start Living Like It's 2019?](#)
[Coronavirus in the U.S.: Latest Map and Case Count](#)
[Charting an Omicron Infection](#)
[The Covid Vaccine We Need Now May Not Be a Shot](#)

Washington Post - Corona update

[N95, KN95 masks provide best protection against covid, CDC study shows](#)
[How fast the omicron variant is spreading around the world](#)
[CDC to expand wastewater monitoring to help track coronavirus trends](#)
[WHO says Europe entering a 'cease-fire' in battle with covid as protection grows](#)
[What 'live with the virus' means may depend on where you live](#)
[Yes, it's still a pandemic of the unvaccinated — arguably even more so now](#)

Guardian - Corona update

[Joni Mitchell joins Neil Young's Spotify protest over anti-vax content](#)
['Like sewage and rotting flesh': Covid's lasting impact on taste and smell](#)
[Schools in England reinstate mask wearing rules as Covid cases soar](#)
[Safe passage optional? Cruise industry heaps more misery on its passengers](#)
['The case for masks became hugely stronger': scientists admit their Covid mistakes](#)

Key Articles

- 1. Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel.** [Prev. Med. 2021; 155:106947](#)Saciuk Y, Kertes J, Mandel M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34974072>
Israel rolled out a successful vaccination campaign in 2021. The efficacy of the Pfizer-BioNTech vaccine was evaluated in 1.6 million participants During the first phase (18-01-2021 to 25-4-2021). Vaccine efficacy for infection, hospitalization, and mortality was (adjusted) 93.0%, 93.4%, and 91.1%. Respectively. Elderly and patients with hypertension, diabetes, or obesity were less protected from infections.
- 2. Molnupiravir: A new candidate for COVID-19 treatment.** [Pharmacol Res Perspect 2022; 10:e00909](#)Pourkarim F, Pourtaghi-Anvarian S, Rezaee H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34968008>
Molnupiravir is a new antiviral pro-drug that, once converted to the active nucleoside analogue, shows impressive potential to combat a wide range of viruses, including SARS-CoV-2 infections. This review summarizes current published literature on efficacy, safety, mechanism of action, and clinical trial evidence

3. **COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021.** Osong Public Health Res Perspect 2021; 12:396-402 Hwang I, Park K, Kim TE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34965689>
This large Korean registry was used to evaluate the safety of the four commonly used COVID-19 vaccines, based on almost 78.5 million doses (February 26 -October 31, 2021). In total, 353 535 (0.45%) adverse events were reported. The majority were non-serious adverse events (96.4%). Of the 835 reported deaths after vaccination, 2 deaths were confirmed. Anaphylaxis was confirmed in 454 cases (5.8/1000 000). More women reported adverse events compared to men, 581 vs. 315 per 100 000 vaccinations
4. **The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients. A systematic review, meta-analysis and meta-regression.** Diabetes Metab Res Rev 2021:e3517 Tentolouris N, Samakidou G, Eleftheriadou I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965318>
5. **Successful endovascular mechanical thrombectomy in anticoagulation-resistant COVID-19 associated cerebral venous sinus thrombosis.** BMJ Case Rep 2021; 14 Sajjad A, Khan AF, Jafri L, Kamal AK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34972772>
6. **Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?** Viruses 2021; 13 Parra-Lucare A, Toro L, Weitz-Muñoz S, Ramos C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960761>
7. **Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients-Is It Related to Immunosuppression Only?** Vaccines (Basel) 2021; 9 Nazaruk P, Monticcolo M, Jędrzejczak AM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960200>
8. **Occupation and COVID-19 mortality in England: a national linked data study of 14.3 million adults.** Occup. Environ. Med. 2021; Nafilyan V, Pawelek P, Ayoubkhani D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965981>
9. **Melting and Re-Freezing Leads to Irreversible Changes in the Morphology and Molecular-Level Dynamics of Pfizer-BioNTech COVID-19 Vaccine.** Medicina (Kaunas) 2021; 57 Mamontov E, Daemen LL, Novak E, Stone MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946288>
10. **Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response.** Cell Host Microbe 2022; 30:83-96. Lin CY, Wolf J, Brice DC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34965382>
11. **Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy**

Population. Vaccines (Basel) 2021; 9Intapiboon P, Seepathomnarong P, Ongarj J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960122>

12. **IDbSV: An Open-Access Repository for Monitoring SARS-CoV-2 Variations and Evolution.** Front Med (Lausanne) 2021; 8:765249Essabbar A, Kartti S, Alouane T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966754>
 13. **COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information.** Rev. Recent Clin. Trials 2021; Davide M, Kamposioras K, Lampriani T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967300>
 14. **Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis.** Brain Behav Immun 2021; 101:93-135Ceban F, Ling S, Lui LMW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973396>
 15. **How many lives do COVID vaccines save? Evidence from Israel.** Am. J. Infect. Control 2021; Arbel R, Moore CM, Sergienko R, Pliskin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971714>
-

Omicron (3 articles)

1. **Omicron and S-gene target failure cases in the highest COVID-19 case rate region in Canada-December 2021.** J Med Virol 2021; Li A, Maier A, Carter M, Guan TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964500>
2. **Importation and Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern in Korea, November 2021.** J Korean Med Sci 2021; 36:e346Lee JJ, Choe YJ, Jeong H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962117>
3. **Mind the "worry fatigue" amid Omicron scares.** Brain Behav Immun 2021; 101:60-61Su Z, McDonnell D, Ahmad J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973394>

Basic Science (36 articles)

1. **Antibody-Dependent Enhancement of SARS-CoV-2 Infection of Human Immune Cells: In Vitro Assessment Provides Insight in COVID-19 Pathogenesis.** Viruses 2021; 13Shen XR, Li Q, Li HL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960752>
2. **Nucleocapsid (N) Gene Mutations of SARS-CoV-2 Can Affect Real-Time RT-PCR Diagnostic and Impact False-Negative Results.** Viruses 2021; 13Lesbon JCC, Poleti MD, de Mattos Oliveira EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960743>
3. **Letter to the Editor: SFlt-1 and PlGF Levels in Pregnancies Complicated by SARS-CoV-2 Infection.** Viruses 2021; 13Giardini V, Ornaghi S, Acampora E *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960646>
4. **JAK-STAT Pathway: A Novel Target to Tackle Viral Infections.** *Viruses* 2021; 13Ezeonwumelu IJ, Garcia-Vidal E, Ballana E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960648>
 5. **Semi-Supervised Pipeline for Autonomous Annotation of SARS-CoV-2 Genomes.** *Viruses* 2021; 13Beck KL, Seabolt E, Agarwal A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960694>
 6. **Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection.** *Viruses* 2021; 13Bauer W, Weber M, Diehl-Wiesenecker E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960725>
 7. **VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.** *Vaccines (Basel)* 2021; 9Prates-Syed WA, Chaves LCS, Crema KP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960155>
 8. **[Andrological aspects of new coronavirus infection Covid-19].** *Urologija* 2021;130-135Akhvlediani ND, Reva IA, Chernushenko AS, Pushkar DY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967175>
 9. **Human Body Performance with COVID-19 Affection According to Virus Specification Based on Biosensor Techniques.** *Sensors (Basel)* 2021; 21Alathari MJA, Al Mashhadany Y, Mokhtar MHH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960456>
 10. **Understanding COVID-19 Pathogenesis: A Drug-Repurposing Effort to Disrupt Nsp-1 Binding to Export Machinery Receptor Complex.** *Pathogens* 2021; 10Vasudevan S, Baraniuk JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959589>
 11. **Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets.** *Molecules* 2021; 26Yapasert R, Khaw-On P, Banjerdpongchai R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946543>
 12. **Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.** *Molecules* 2021; 26Elzupir AO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946540>
 13. **A Dispersion Corrected DFT Investigation of the Inclusion Complexation of Dexamethasone with β -Cyclodextrin and Molecular Docking Study of Its Potential Activity against COVID-19.** *Molecules* 2021; 26Belhocine Y, Rahali S, Allal H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946702>
 14. **Human Endogenous Retroviruses as Gene Expression Regulators: Insights from Animal Models into Human Diseases.** *Mol. Cells* 2021; 44:861-878Durnaoglu S, Lee SK, Ahnn J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963103>
 15. **Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources.** *Microorganisms* 2021; 9Razali R, Asis H, Budiman C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946083>
 16. **Simplified Point-of-Care Full SARS-CoV-2 Genome Sequencing Using Nanopore Technology.** *Microorganisms* 2021; 9Pembaur A, Sallard E, Weil PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946199>
 17. **Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs "Remdesivir and Favipiravir": Green assessment with application to pharmaceutical formulations and human plasma.** *Microchem. J.* 2022; 174:107101Noureldeen DAM, Boushra JM, Lashien AS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955554>

18. **Nanotechnology-Based Strategies for Effective and Rapid Detection of SARS-CoV-2.** Materials (Basel) 2021; 14:Moabelo KL, Martin DR, Fadaka AO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34947447>
19. **Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.** MAbs 2022; 14:2002236Yuan TZ, Garg P, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967699>
20. **Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor.** J King Saud Univ Sci 2022; 34:101773Gurung AB, Ali MA, Lee J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955621>
21. **SARS-CoV-2-host cell surface interactions and potential antiviral therapies.** Interface Focus 2022; 12:20200081Butnariu AB, Look A, Grillo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956606>
22. **Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters.** Gut Microbes 2022; 14:2018900Sencio V, Machelart A, Robil C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965194>
23. **Interpretable network propagation with application to expanding the repertoire of human proteins that interact with SARS-CoV-2.** Gigascience 2021; 10Law JN, Akers K, Tasnina N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966926>
24. **Screening of Microbial Natural Products and Biological Evaluation of Trichomicin as Potential Anti-Cytokine Storm Agents.** Front. Pharmacol. 2021; 12:770910Chen Y, Zhuang Z, Yang J, Bai L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955842>
25. **Association of the Serum Levels of the Nucleocapsid Antigen of SARS-CoV-2 With the Diagnosis, Disease Severity, and Antibody Titers in Patients With COVID-19: A Retrospective Cross-Sectional Study.** Front. Microbiol. 2021; 12:791489Yokoyama R, Kurano M, Nakano Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956158>
26. **A Case Report: Genetically Distinct Severe Acute Respiratory Syndrome Coronavirus-2 Variant Causing Reinfection.** Front. Microbiol. 2021; 12:792514Hossain ME, Rahman MM, Alam MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956160>
27. **IDbSV: An Open-Access Repository for Monitoring SARS-CoV-2 Variations and Evolution.** Front Med (Lausanne) 2021; 8:765249Essabbar A, Kartti S, Alouane T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966754>
28. **Extracellular Vesicle Associated miRNAs Regulate Signaling Pathways Involved in COVID-19 Pneumonia and the Progression to Severe Acute Respiratory Corona Virus-2 Syndrome.** Front. Immunol. 2021; 12:784028Meidert AS, Hermann S, Brandes F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956213>
29. **Updated picture of SARS-CoV-2 variants and mutations.** Diagnosis (Berl) 2021; Lippi G, Mattiuzzi C, Henry BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958184>
30. **Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE Monte Carlo simulations, and in vitro activity inhibition.** Chem. Phys. Lett. 2021:139294Liang JJ, Pitsillou E, Ververis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961797>
31. **Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern.** Cell Rep. 2022; 38:110210Li

- W, Chen Y, Prévost J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971573>
32. **Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers.** Cell Host Microbe 2022; 30:69-82.e10Vanshylla K, Fan C, Wunsch M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973165>
 33. **Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent manner.** Br. J. Haematol. 2021; Garnier Y, Claude L, Hermand P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962643>
 34. **Development of a recombinant nucleocapsid protein-based ELISA for the detection of IgM and IgG antibodies to SARS-CoV-2.** Biotechnol. Appl. Biochem. 2021; Ranjbar M, Asadi M, Nourigorji M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965611>
 35. **Direct capture and smartphone quantification of airborne SARS-CoV-2 on a paper microfluidic chip.** Biosens. Bioelectron. 2022; 200:113912Kim S, Akarapipad P, Nguyen BT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973565>
 36. **Establishment of Human Pluripotent Stem Cell-Derived Skin Organoids Enabled Pathophysiological Model of SARS-CoV-2 Infection.** Adv Sci (Weinh) 2021:e2104192Ma J, Liu J, Gao D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971128>

Biomarkers - Genetics (107 articles)

1. **SARS-CoV-2 and Variant Diagnostic Testing Approaches in the United States.** Viruses 2021; 13Thomas E, Delabat S, Carattini YL, Andrews DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960762>
2. **Microarray-Based Detection of Antibodies against SARS-CoV-2 Proteins, Common Respiratory Viruses and Type I Interferons.** Viruses 2021; 13Savvateeva E, Filippova M, Valuev-Elliston V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960822>
3. **Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity.** Viruses 2021; 13Rahman M, Irmmler M, Keshavan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960806>
4. **Fast, Reliable, and Simple Point-of-Care-like Adaptation of RT-qPCR for the Detection of SARS-CoV-2 for Use in Hospital Emergency Departments.** Viruses 2021; 13Pavletić M, Mazor M, Lerga M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960682>
5. **Iron Related Biomarkers Predict Disease Severity in a Cohort of Portuguese Adult Patients during COVID-19 Acute Infection.** Viruses 2021; 13Moreira AC, Teles MJ, Silva T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960751>
6. **A Large Cohort Study of SARS-CoV-2 Detection in Saliva: A Non-Invasive Alternative Diagnostic Test for Patients with Bleeding Disorders.** Viruses 2021; 13Lopes JIF, da Costa Silva CA, Cunha RG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960630>
7. **Nucleocapsid (N) Gene Mutations of SARS-CoV-2 Can Affect Real-Time RT-PCR Diagnostic and Impact False-Negative Results.** Viruses 2021; 13Lesbon JCC, Poleti MD, de Mattos Oliveira EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960743>

8. **Sampling for SARS-CoV-2 Aerosols in Hospital Patient Rooms.** *Viruses* 2021; 13Lane MA, Walawender M, Webster AS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960615>
9. **Inflammasomes and SARS-CoV-2 Infection.** *Viruses* 2021; 13Kaivola J, Nyman TA, Matikainen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960782>
10. **Letter to the Editor: SFlt-1 and PlGF Levels in Pregnancies Complicated by SARS-CoV-2 Infection.** *Viruses* 2021; 13Giardini V, Ornaghi S, Acampora E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960646>
11. **Modeling the Influence of Vaccine Administration on COVID-19 Testing Strategies.** *Viruses* 2021; 13Forde JE, Ciupe SM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960814>
12. **COVID-19 Modulates Inflammatory and Renal Markers That May Predict Hospital Outcomes among African American Males.** *Viruses* 2021; 13Fonseca W, Asai N, Yagi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960684>
13. **The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries.** *Viruses* 2021; 13Dos Santos Ferreira CE, Gómez-Dantés H, Junqueira Bellei NC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960660>
14. **sTREM-1 Predicts Disease Severity and Mortality in COVID-19 Patients: Involvement of Peripheral Blood Leukocytes and MMP-8 Activity.** *Viruses* 2021; 13da Silva-Neto PV, de Carvalho JCS, Pimentel VE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960790>
15. **Semi-Supervised Pipeline for Autonomous Annotation of SARS-CoV-2 Genomes.** *Viruses* 2021; 13Beck KL, Seabolt E, Agarwal A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960694>
16. **Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection.** *Viruses* 2021; 13Bauer W, Weber M, Diehl-Wiesenecker E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960725>
17. **Single-Cell and Bulk RNASeq Profiling of COVID-19 Patients Reveal Immune and Inflammatory Mechanisms of Infection-Induced Organ Damage.** *Viruses* 2021; 13Bass A, Liu Y, Dakshanamurthy S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960687>
18. **Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers.** *Vaccines (Basel)* 2021; 9Trunfio M, Verga F, Ghisetti V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960123>
19. **VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.** *Vaccines (Basel)* 2021; 9Prates-Syed WA, Chaves LCS, Crema KP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960155>
20. **[Features of a new coronavirus infection course and options therapy Depending on the androgenic status (FOUNDER): androgenic status in men with COVID-19 and its relationship with the disease severity].** *Urologija* 2021;85-99Kamalov AA, Mareev VY, Orlova IA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967512>
21. **[Andrological aspects of new coronavirus infection Covid-19].** *Urologija* 2021;130-135Akhvlediani ND, Reva IA, Chernushenko AS, Pushkar DY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967175>
22. **Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?** *Tumori*

- 2021:3008916211067825Gattuso G, Schiavello E, Oltolini C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34965799>
23. **Molecular detection of SARS-CoV-2 strains and differentiation of Delta variant strains.** *Transbound Emerg Dis* 2021; Hamill V, Noll L, Lu N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34964565>
 24. **Predictive Machine Learning Models and Survival Analysis for COVID-19 Prognosis Based on Hematochemical Parameters.** *Sensors (Basel)* 2021; 21Altini N, Brunetti A, Mazzoleni S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960595>
 25. **Human Body Performance with COVID-19 Affection According to Virus Specification Based on Biosensor Techniques.** *Sensors (Basel)* 2021; 21Alathari MJA, Al Mashhadany Y, Mokhtar MHH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960456>
 26. **Impacts of COVID-19 lockdown on private domestic groundwater sample numbers, E. coli presence and E. coli concentration across Ontario, January 2020-March 2021: An interrupted time-series analysis.** *Sci Total Environ* 2021; 814:152634Latchmore T, Lavallee S, Boudou M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34974018>
 27. **Incidence of COVID-19 after pulmonary function tests: a retrospective cohort study.** *Rev. Fac. Cien. Med. Univ. Nac. Cordoba* 2021; 78:367-370Wainstein EJ, Peroni HJ, Ferreyro BL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962729>
 28. **A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune-epithelial interface.** *Proc Natl Acad Sci U S A* 2022; 119Leon J, Michelson DA, Olejnik J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969849>
 29. **Relation of interleukin-6 levels in COVID-19 patients with major adverse cardiac events.** *Proc. (Bayl. Univ. Med. Cent.)* 2022; 35:6-9Nguyen N, Nguyen H, Ukoha C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966215>
 30. **High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients.** *Pathogens* 2021; 10Minutolo A, Petrone V, Fanelli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959594>
 31. **Immunological and Genetic Investigation of SARS-CoV-2 Reinfection in an Otherwise Healthy, Young Marine Recruit.** *Pathogens* 2021; 10Letizia AG, Arnold CE, Adhikari BN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959544>
 32. **Comparative Diagnostic Performance of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) Kit for the Rapid Detection of SARS-CoV-2.** *Pathogens* 2021; 10Domnich A, Orsi A, Panatto D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34959584>
 33. **A brief report: Cerebrospinal fluid rhinorrhea after repetitive nasal swab testing for coronavirus disease 2019(COVID-19).** *Otolaryngol Case Rep* 2021; 20:100313Yilmaz M, Bahadır Z, Madendere B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957362>
 34. **CSF rhinorrhea after nasopharyngeal swab testing for COVID-19: A case report and review of literature.** *Otolaryngol Case Rep* 2021; 21:100370Samadian M, Maroufi SF, Taheri MS, Jafari A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957364>
 35. **Role of the otolaryngologist in nasopharyngeal swab training: A case report and review of the literature.** *Otolaryngol Case Rep* 2021; 20:100316Liu M, Roychowdhury P, Ito CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957363>

36. **Vitamin D Dosing: Basic Principles and a Brief Algorithm (2021 Update).** Nutrients 2021; 13Bleizgys A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959969>
37. **Reassessment of contact restrictions and testing campaigns against COVID-19 via spatio-temporal modeling.** Nonlinear Dyn 2021;1-25Ganegoda NC, Wijaya KP, Páez Chávez J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955605>
38. **Polyphenols as Potential Inhibitors of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp).** Molecules 2021; 26Wu Y, Crich D, Pegan SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946521>
39. **Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection.** Mol. Med. 2021; 27:162Chapoval SP, Keegan AD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961486>
40. **The MicroRNA Days: The COVID-19 Pandemic from the Point of View of Short RNAs.** Microna 2021; 10:226-228Izzotti A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963439>
41. **Simplified Point-of-Care Full SARS-CoV-2 Genome Sequencing Using Nanopore Technology.** Microorganisms 2021; 9Pembaur A, Sallard E, Weil PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946199>
42. **History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic.** Microorganisms 2021; 9Meybeck A, Huleux T, Tétart M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946093>
43. **Multicenter Technical Validation of 30 Rapid Antigen Tests for the Detection of SARS-CoV-2 (VALIDATE).** Microorganisms 2021; 9Greub G, Caruana G, Schweitzer M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946190>
44. **High Rates of Bacterial Pulmonary Co-Infections and Superinfections Identified by Multiplex PCR among Critically Ill COVID-19 Patients.** Microorganisms 2021; 9Cohen R, Babushkin F, Finn T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946086>
45. **Which criteria were used to describe patients with COVID-19? A systematic review and meta analysis of clinical, laboratory, and imaging features.** Med. J. Islam. Repub. Iran 2021; 35:112Amanollahi A, Sotoodeh Ghorbani S, Basir Ghafouri H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956958>
46. **Nanotechnology-Based Strategies for Effective and Rapid Detection of SARS-CoV-2.** Materials (Basel) 2021; 14Moabelo KL, Martin DR, Fadaka AO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34947447>
47. **A high neutrophil to lymphocyte ratio at ICU admission is associated with nutritional risk in COVID-19 patients.** JPEN J. Parenter. Enteral Nutr. 2021; Martins PM, Gomes TLN, Franco EP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961953>
48. **Validation of the COVID-19 Exposure and Family Impact Scales.** J. Pediatr. Psychol. 2021; Enlow PT, Phan TT, Lewis AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969064>
49. **Hyperglycemia and blood glucose deterioration are risk factors for severe COVID-19 with diabetes: A two-center cohort study.** J Med Virol 2021; Xiao F, Zhou YC, Zhang MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967028>
50. **Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor.** J King Saud Univ Sci 2022; 34:101773Gurung AB, Ali MA, Lee J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955621>

51. **Nasopharyngeal microbiota as an early severity biomarker in COVID-19 hospitalised patients: A retrospective cohort study in a Mediterranean area.** J Infect 2021; Ventero MP, Moreno-Perez O, Molina-Pardines C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963638>
52. **Analysis of Some Physiological and Biochemical Indices in Patients with Covid-19 Pneumonia Using Mathematical Methods.** J. Evol. Biochem. Physiol. 2021; 57:1394-1407 Gromov MS, Rogacheva SM, Barulina MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955552>
53. **Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses.** J Clin Virol 2022; 146:105060 Anantharaj A, Gujjar S, Verma N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971849>
54. **A rapid and highly effective approach for SARS-CoV-2 nucleic acid daily testing in more than four thousand single-tube samples.** J. Clin. Lab. Anal. 2021:e24211 Zhou Y, Han C, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967040>
55. **Platelets mediate inflammatory monocyte activation by SARS-CoV-2 Spike protein.** J. Clin. Invest. 2021; Li T, Yang Y, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964720>
56. **Menthol-assisted homogenous liquid-liquid microextraction for HPLC/UV determination of favipiravir as an antiviral for COVID-19 in human plasma.** J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2022; 1189:123087 Abdallah IA, Hammad SF, Bedair A, Mansour FR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974319>
57. **An update on host immunity correlates and prospects of re-infection in COVID-19.** Int. Rev. Immunol. 2021:1-26 Negi N, Maurya SP, Singh R, Das BK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961403>
58. **Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt.** Int J Surg 2022; 97:106198 Dhawan M, Priyanka, Choudhary OP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958967>
59. **Performance of colorimetric reverse transcription loop-mediated isothermal amplification as a diagnostic tool for SARS-CoV-2 infection during the fourth wave of COVID-19 in Thailand.** Int J Infect Dis 2021; 116:133-137 Promlek T, Thanunchai M, Phumisantiphong U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958929>
60. **Differing Sensitivity of COVID-19 PCR Tests and Consequences of the False-negative Report: A Small Observation.** Indian J. Crit. Care Med. 2021; 25:1077-1078 Garg SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963733>
61. **Presepsin as a Predictive Biomarker of Severity in COVID-19: A Systematic Review.** Indian J. Crit. Care Med. 2021; 25:1051-1054 Ahmed S, Mansoor M, Shaikh MS, Siddiqui I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963726>
62. **The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.** In Vivo 2022; 36:13-29 Gintoni I, Adamopoulou M, Yapijakis C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972696>
63. **Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters.** Gut Microbes 2022; 14:2018900 Sencio V, Machelart A, Robil C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965194>
64. **Detection of SARS-CoV-2-RNA in post-mortem samples of human eyes.** Graefes Arch Clin Exp Ophthalmol 2021:1-9 Penkava J, Muenchhoff M, Badell I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962592>

65. **Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19.** Front Public Health 2021; 9:778340Luo K, Chen Y, Yang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970527>
66. **COVID-19 Outcome Relates With Circulating BDNF, According to Patient Adiposity and Age.** Front Nutr 2021; 8:784429Minuzzi LG, Seelaender M, Silva BSA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957187>
67. **Association of the Serum Levels of the Nucleocapsid Antigen of SARS-CoV-2 With the Diagnosis, Disease Severity, and Antibody Titers in Patients With COVID-19: A Retrospective Cross-Sectional Study.** Front. Microbiol. 2021; 12:791489Yokoyama R, Kurano M, Nakano Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956158>
68. **A Case Report: Genetically Distinct Severe Acute Respiratory Syndrome Coronavirus-2 Variant Causing Reinfection.** Front. Microbiol. 2021; 12:792514Hossain ME, Rahman MM, Alam MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956160>
69. **IDbSV: An Open-Access Repository for Monitoring SARS-CoV-2 Variations and Evolution.** Front Med (Lausanne) 2021; 8:765249Essabbar A, Kartti S, Alouane T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966754>
70. **SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After Vaccination.** Front. Immunol. 2021; 12:798859Pinilla YT, Heinzl C, Caminada LF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956236>
71. **Extracellular Vesicle Associated miRNAs Regulate Signaling Pathways Involved in COVID-19 Pneumonia and the Progression to Severe Acute Respiratory Corona Virus-2 Syndrome.** Front. Immunol. 2021; 12:784028Meidert AS, Hermann S, Brandes F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956213>
72. **Vascular Damage, Thromboinflammation, Plasmablast Activation, T-Cell Dysregulation and Pathological Histiocytic Response in Pulmonary Draining Lymph Nodes of COVID-19.** Front. Immunol. 2021; 12:763098Haslbauer JD, Zinner C, Stalder AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966385>
73. **Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.** Front. Immunol. 2021; 12:707159Cyprian FS, Suleman M, Abdelhafez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966381>
74. **Host Genetic Liability for Severe COVID-19 Associates with Alcohol Drinking Behavior and Diabetic Outcomes in Participants of European Descent.** Front Genet 2021; 12:765247Wendt FR, De Lillo A, Pathak GA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966408>
75. **High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome.** Front. Endocrinol. (Lausanne) 2021; 12:791476Wang W, Chai Z, Cooper ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956098>
76. **Epidemiology of COVID-19 after Emergence of SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020-2021.** Emerg Infect Dis 2021; 28Nicolette VC, Rodrigues PT, Fernandes ARJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963505>
77. **Airborne Transmission of SARS-CoV-2 Delta Variant within Tightly Monitored Isolation Facility, New Zealand (Aotearoa).** Emerg Infect Dis 2021; 28Fox-Lewis

- A, Williamson F, Harrower J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965365>
78. **PEDOT-AuNPs-based impedimetric immunosensor for the detection of SARS-CoV-2 antibodies.** Electrochim Acta 2022; 404:139757 Lorenzen AL, Dos Santos AM, Dos Santos LP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955549>
 79. **Accuracy and ease-of-use of seven point-of-care SARS-CoV-2 antigen-detecting tests: A multi-centre clinical evaluation.** EBioMedicine 2021; 75:103774 Krüger LJ, Tanuri A, Lindner AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959134>
 80. **Updated picture of SARS-CoV-2 variants and mutations.** Diagnosis (Berl) 2021; Lippi G, Mattiuzzi C, Henry BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958184>
 81. **Inflammatory but not respiratory symptoms are associated with ongoing upper airway viral shedding in outpatients with uncomplicated COVID-19.** Diagn. Microbiol. Infect. Dis. 2021; 102:115612 Jacobson KB, Purington N, Parsonnet J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974350>
 82. **Utility of MGG and Papanicolaou stained smears in the detection of Mucormycosis in nasal swab/scraping/biopsy samples of COVID 19 patients.** Diagn. Cytopathol. 2021; Philip AC, Madan P, Sharma S, Das S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967146>
 83. **Neuroinflammation, diabetes, and COVID-19: Perspectives coming from Ca²⁺/cAMP signalling.** Curr Drug Res Rev 2021; Bergantin LB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970961>
 84. **Clinical and Laboratory Factors in Predicting Mortality Among COVID-19 RT-PCR Positive Patients: A Retrospective Observational Study From a Tertiary Care Center.** Cureus 2021; 13:e19791 Sundaramurthy R, Balasubramanian S, Ganesan V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956783>
 85. **Hematological Manifestations of COVID-19 and Their Prognostic Significance in an Intensive Care Unit: A Cross-Sectional Study.** Cureus 2021; 13:e19887 Bawiskar N, Talwar D, Acharya S, Kumar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966605>
 86. **Comparative mutational analysis of SARS-CoV-2 isolates from Pakistan and structural-functional implications using computational modelling and simulation approaches.** Comput. Biol. Med. 2021; 141:105170 Shah A, Rehmat S, Aslam I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968862>
 87. **Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring.** Clin Immunol 2022; 234:108918 Cristiano A, Pieri M, Sarubbi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971839>
 88. **Not all SARS-CoV-2 IgG and neutralizing antibody assays are created equal.** Clin Chim Acta 2021; 526:81-82 Lippi G, Plebani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958752>
 89. **Evolving Applications of Artificial Intelligence and Machine Learning in Infectious Diseases Testing.** Clin Chem 2021; 68:125-133 Tran NK, Albahra S, May L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969102>
 90. **Recruitment of highly cytotoxic CD8(+) T cell receptors in mild SARS-CoV-2 infection.** Cell Rep. 2022; 38:110214 Wagner KI, Mateyka LM, Jarosch S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968416>

91. **Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern.** Cell Rep. 2022; 38:110210Li W, Chen Y, Prévost J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971573>
92. **The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.** Cell Rep. 2022; 38:110218Kimura I, Kosugi Y, Wu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968415>
93. **Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers.** Cell Host Microbe 2022; 30:69-82.e10Vanshylla K, Fan C, Wunsch M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973165>
94. **Effusion fluid cytology and COVID-19 infection.** Cancer Cytopathol 2021; Xia R, Hsu Lin L, Sun W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958719>
95. **Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent manner.** Br. J. Haematol. 2021; Garnier Y, Claude L, Hermand P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962643>
96. **Prolonged viral shedding of SARS-CoV-2 and related factors in symptomatic COVID-19 patients: a prospective study.** BMC Infect. Dis. 2021; 21:1282Long H, Zhao J, Zeng HL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961470>
97. **Development of a recombinant nucleocapsid protein-based ELISA for the detection of IgM and IgG antibodies to SARS-CoV-2.** Biotechnol. Appl. Biochem. 2021; Ranjbar M, Asadi M, Nourigorji M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965611>
98. **A rapid RNA extraction-free lateral flow assay for molecular point-of-care detection of SARS-CoV-2 augmented by chemical probes.** Biosens. Bioelectron. 2022; 200:113900Dighe K, Moitra P, Alafeef M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959185>
99. **A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.** Biomed. Pharmacother. 2022; 146:112550Li CX, Noreen S, Zhang LX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959116>
100. **Airborne particles and cardiovascular morbidity in severe inherited hypercholesterolemia: Vulnerable endothelium under multiple attacks.** Bioessays 2021:e2100273Vuorio A, Budowle B, Kovanen PT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967031>
101. **The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males.** Autophagy 2021:1-11Crocì S, Venneri MA, Mantovani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964709>
102. **Pre-infection HDL-cholesterol levels and mortality among elderly patients infected with SARS-CoV-2.** Atherosclerosis 2022; 341:13-19Mostaza JM, Salinero-Fort MA, Cardenas-Valladolid J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959204>
103. **Impact of COVID-19 lockdown on glycemic control in type 1 diabetes.** Arch. Pediatr. 2022; 29:27-29Duarte V, Mota B, Ferreira S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955306>
104. **Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.** Ann. Clin. Microbiol. Antimicrob. 2021; 20:85Taha Y, Wardle H, Evans AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969393>

105. **[POCT-management during the first wave of Covid-19 in France. Results of a national survey led by the SFBC-POCT Working Group].** Ann. Biol. Clin. (Paris) 2021; 79:535-549 Glady L, Moal V, Benz-De Bretagne I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961737>
106. **Comprehensive serologic profile and specificity of maternal and neonatal cord blood SARS-CoV-2 antibodies.** AJOG Glob Rep 2022; 2:100046 Boelig RC, Chaudhury S, Aghai ZH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961853>
107. **African countries established COVID-19 testing in one month: Here's how they did it.** Afr J Lab Med 2021; 10:1457 Amukele T, Spence RN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956851>

Children (36 articles)

1. **Impact of the Coronavirus (COVID-19) Pandemic on the Care of Pediatric Acute Appendicitis.** Am. Surg. 2021;31348211067995 Head WT, Parrado RH, Cina RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957861>
2. **COVID-19 distress, negative parenting, and child behavioral problems: The moderating role of parent adverse childhood experiences.** Child Abuse Negl. 2021;105450 Hails KA, Petts RA, Hostutler CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969517>
3. **Perceived impact of lockdown on daily life in children with physical disabilities and their families during the COVID-19 pandemic.** Child Care Health Dev. 2021; Varengue R, Brochard S, Bouvier S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964148>
4. **Impact of COVID-19 on Children's and Adolescent's Mental Health in Saudi Arabia.** Cureus 2021; 13:e19786 Almhizai RA, Almogren SH, Altwijery NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963826>
5. **Impact of COVID-19 on Saudi Children: Special Focus on Behavioral, Social, and Emotional Aspects, 2020-2021.** Cureus 2021; 13:e19856 Almugti HS, Alotaibi A, Almohammed A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963861>
6. **Phased Return of Students to 77 Transitional Kindergarten-8th Grade Schools With Cohesive Mitigation Strategies Serving as Protective Factors Against the Increase of COVID-19 Cases in Marin County: September 2020-January 2021.** Cureus 2021; 13:e19821 Paff SQ, Ereman R, Santora L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963838>
7. **Impact of the French National Lockdown on Admissions to 14 Pediatric Intensive Care Units During the 2020 COVID-19 Pandemic-A Retrospective Multicenter Study.** Front Pediatr 2021; 9:764583 Breinig S, Mortamet G, Brossier D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956977>
8. **The social smile in infants during the COVID-19 pandemic.** Heliyon 2021; 7:e08648 Romeo DM, Apicella M, Leo G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957340>
9. **Evaluating child maltreatment and family violence risk during the COVID-19 Pandemic: Using a telehealth home visiting program as a conduit to families.** Infant Ment Health J 2021; Bullinger LR, Marcus S, Reuben K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969151>
10. **When the Bough Breaks: A systematic review and meta-analysis of mental health symptoms in mothers of young children during the COVID-19**

- pandemic.** Infant Ment Health J 2021; Racine N, Eirich R, Cooke J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34962649>
11. **Increased behavioral health needs and continued psychosocial stress among children with medical complexity and their families during the COVID-19 pandemic.** Infant Ment Health J 2022; von Schulz J, Serrano V, Buchholz M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34973062>
 12. **Current Recommendations on the Management of Pediatric Asthma and Allergic Rhinitis during the COVID-19 Pandemic versus Real-Life Practice.** Int. Arch. Allergy Immunol. 2021;1-8Gokmirza Ozdemir P, Celik V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34963116>
 13. **Pediatric otolaryngology telemedicine amid a pandemic - And beyond.** Int J Pediatr Otorhinolaryngol 2021; 153:111014McCoy JL, Shaffer AD, Dohar JE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34974276>
 14. **Abol-Enein pouch modification after radical cystectomy in bladder rhabdomyosarcoma in 5 years old child during COVID-19 pandemic: A case report.** Int. J. Surg. Case Rep. 2022; 90:106701Ginting JT, Sigumonrong Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956826>
 15. **Children and Adolescents' Behavioral Patterns in Response to Escalating COVID-19 Restriction Reveal Sex and Age Differences.** J. Adolesc. Health 2021; Paulsen M, Zychlinsky Scharff A, de Cassan K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34972613>
 16. **The thoughts of parents to vaccinate their children against COVID-19: An assessment of situations that may affect them.** J. Child Adolesc. Psychiatr. Nurs. 2021; Çelik MY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962336>
 17. **Should coronavirus policies remain in place to prevent future paediatric influenza deaths?** J. Med. Ethics 2021; Perdomo D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969776>
 18. **The COVID-19 Pandemic Impact on Households of Young Children With Special Healthcare Needs.** J. Pediatr. Psychol. 2021; Liu S, Lombardi J, Fisher PA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957525>
 19. **Testing Our Children When the World Shuts Down: Analyzing Recommendations for Adapted Tele-Assessment during COVID-19.** J. Psychoeduc. Assess. 2020; 38:923-941Krach SK, Paskiewicz TL, Monk MM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955591>
 20. **Facts and Challenges about Asthma and COVID-19 among the Paediatric Population: A Systematic Literature Review.** Medicina (Kaunas) 2021; 57Moreno-Sánchez E, Castillo-Viera E, Vélez-Moreno E, Gago-Valiente FJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946251>
 21. **Comprehensive Contact Tracing, Testing and Sequencing Show Limited Transmission of SARS-CoV-2 between Children in Schools in Norway, August 2020 to May 2021.** Microorganisms 2021; 9Winje BA, Ofitserova TS, Brynildsrud OB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946187>
 22. **COVID-19 Pandemic as Risk Factors for Excessive Weight Gain in Pediatrics: The Role of Changes in Nutrition Behavior. A Narrative Review.** Nutrients 2021; 13Cena H, Fiechtner L, Vincenti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959805>
 23. **The Impact of COVID-19 on Eating Environments and Activity in Early Childhood Education and Care in Alberta, Canada: A Cross-Sectional Study.**

- Nutrients 2021; 13Lafave LMZ, Webster AD, McConnell C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34959799>
24. **Pediatric bilateral vocal cord granulomas presenting as airway foreign body following prolonged intubation due to COVID-19 related multisystem inflammatory syndrome.** Otolaryngol Case Rep 2021; 20:100311Shah VN, Suresh NV, Pasick LJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957360>
 25. **Sudden anosmia and ageusia in a child: A COVID-19 case report.** Otolaryngol Case Rep 2021; 18:100267Wang E, Ulualp SO, Liu C, Veling M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957358>
 26. **Impact of coronavirus disease-2019 on pediatric nephrology practice and education: an ESPN survey.** Pediatr. Nephrol. 2021; Yazıcıoğlu B, Bakkaloğlu SA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34971403>
 27. **The return of RSV during the COVID-19 pandemic.** Pediatr Pulmonol 2021; Ferrero F, Ossorio MF, Rial MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951156>
 28. **The optical coherence tomography angiography study on paediatric COVID-19 cases.** Photodiagnosis Photodyn. Ther. 2021; 37:102710Au SCL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34974164>
 29. **Severe post-COVID-19 costochondritis in children.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:56-57Collins RA, Ray N, Ratheal K, Colon A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966216>
 30. **Missed and Delayed Preventive Health Care Visits Among US Children Due to the COVID-19 Pandemic.** Public Health Rep. 2021:333549211061322Lebrun-Harris LA, Sappenfield OR, Warren MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969335>
 31. **Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?** Tumori 2021:3008916211067825Gattuso G, Schiavello E, Oltolini C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34965799>
 32. **Investigating the Influence of Vaccine Literacy, Vaccine Perception and Vaccine Hesitancy on Israeli Parents' Acceptance of the COVID-19 Vaccine for Their Children: A Cross-Sectional Study.** Vaccines (Basel) 2021; 9Gendler Y, Ofri L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960137>
 33. **Parents' Decisions to Vaccinate Children against COVID-19: A Scoping Review.** Vaccines (Basel) 2021; 9Pan F, Zhao H, Nicholas S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960221>
 34. **Intention of Parents to Immunize Children against SARS-CoV-2 in Italy.** Vaccines (Basel) 2021; 9Russo L, Croci I, Campagna I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960215>
 35. **[Possibilities of therapeutic correction of ENT pathology associated with COVID-19 in children on an outpatient basis].** Vestn. Otorinolaringol. 2021; 86:69-73Golovacheva EG, Afanasyeva OI, Goncharova ES *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34964333>
 36. **Clinical Picture and Risk Factors of Severe Respiratory Symptoms in COVID-19 in Children.** Viruses 2021; 13Mania A, Faltin K, Mazur-Melewska K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960635>

Clinical Features (21 articles)

1. **Clinical characteristics of patients with confirmed and suspected COVID-19.** Am J Transl Res 2021; 13:12897-12904 Wang H, Shao G, Zhang K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956505>
2. **Clinical and imaging features of adult COVID-19 patients with and without comorbidities.** Asian J. Surg. 2021; Xing LH, Xie RM, Ni ZY, Yin XP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969576>
3. **Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis.** Brain Behav Immun 2021; 101:93-135 Ceban F, Ling S, Lui LMW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973396>
4. **Clinical-Pathological Correlations in the Acute Surgical Abdomen in the Pre and Post-Pandemic Period Covid-19.** Chirurgia (Bucur.) 2021; 116:748-755 Nicolescu C, Butiurca VO, Cosma C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967719>
5. **Persistent Parosmia Caused By COVID-19 Infection: An Emerging Symptom.** Cureus 2021; 13:e19921 Khalifah W, Damanhoury B, Abushal B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966613>
6. **Clinical and Laboratory Factors in Predicting Mortality Among COVID-19 RT-PCR Positive Patients: A Retrospective Observational Study From a Tertiary Care Center.** Cureus 2021; 13:e19791 Sundaramurthy R, Balasubramanian S, Ganesan V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956783>
7. **Inflammatory but not respiratory symptoms are associated with ongoing upper airway viral shedding in outpatients with uncomplicated COVID-19.** Diagn. Microbiol. Infect. Dis. 2021; 102:115612 Jacobson KB, Purington N, Parsonnet J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974350>
8. **Analysis of thyroid function in Japanese patients with coronavirus disease 2019.** Endocr. J. 2021; Nakamura S, Kido N, Watanabe M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955465>
9. **Clinical Characteristics and Outcomes of COVID-19 Patients Hospitalized in Intensive Care Unit.** Indian J. Crit. Care Med. 2021; 25:992-1000 Pandit RA, Gagana BN, Vaity C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963716>
10. **Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa.** Int J Infect Dis 2021; 116:38-42 Abdullah F, Myers J, Basu D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971823>
11. **Analysis of Some Physiological and Biochemical Indices in Patients with Covid-19 Pneumonia Using Mathematical Methods.** J. Evol. Biochem. Physiol. 2021; 57:1394-1407 Gromov MS, Rogacheva SM, Barulina MA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955552>
12. **Which criteria were used to describe patients with COVID-19? A systematic review and meta analysis of clinical, laboratory, and imaging features.** Med. J. Islam. Repub. Iran 2021; 35:112 Amanollahi A, Sotoodeh Ghorbani S, Basir Ghafouri H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956958>
13. **Association between Prehospital Hypoxemia and Admission to Intensive Care Unit during the COVID-19 Pandemic: A Retrospective Cohort Study.** Medicina (Kaunas) 2021; 57 Midez R, Fehlmann CA, Marti C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946307>
14. **History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of**

- the Pandemic.** *Microorganisms* 2021; 9:9. Meybeck A, Huleux T, Tétart M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946093>
15. **Nonepileptic Myoclonus in COVID-19: Case Report.** *Neurohospitalist* 2022; 12:86-89. Hewan H, Yang A, Vaddiparti A, Keung B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950392>
 16. **Is COVID-19 infection triggering oral herpes zoster? A case report.** *SAGE Open Med Case Rep* 2021; 9:2050313x2111065793. Saleh W, Ata F, Elashry MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956645>
 17. **Heparin and SARS-CoV-2: Multiple Pathophysiological Links.** *Viruses* 2021; 13:13. Di Micco P, Imbalzano E, Russo V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960754>
 18. **Characteristics and Factors Associated with SARS-CoV-2 Infections in Individuals That Attended Referral Hospitals from Southern Region of Bahia State, Brazil: A Surveillance Network Retrospective Study.** *Viruses* 2021; 13:13. Ferreira FB, Barbosa Costa G, Sevá ADP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960731>
 19. **Clinical Picture and Risk Factors of Severe Respiratory Symptoms in COVID-19 in Children.** *Viruses* 2021; 13:13. Mania A, Faltin K, Mazur-Melewska K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960635>
 20. **Clinical Manifestation of Subacute Thyroiditis Triggered by SARS-CoV-2 Infection Can Be HLA-Dependent.** *Viruses* 2021; 13:13. Stasiak M, Zawadzka-Starczewska K, Lewiński A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960716>
 21. **WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation - Updates in COVID-19.** *World Allergy Organ J* 2021; 14:100618. Rouadi PW, Idriss SA, Bousquet J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963794>

CNS (17 articles)

1. **Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.** *Acta Neurol. Scand.* 2021; Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967005>
2. **A case of aseptic meningitis following AZD1222 COVID-19 vaccination.** *Am J Emerg Med* 2021; Zavari A, Hamidabad NM, Hassanzadeh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955313>
3. **Starting the first robotic lobectomy program in the Eastern Europe during Coronavirus disease-2019 pandemic.** *Bratisl. Lek. Listy* 2022; 123:61-65. Stolz A, Kolarik J, Vachtenheim J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967660>
4. **Management of COVID-19 post-vaccine Bell's palsy in an outpatient.** *Clin Imaging* 2021; Cellina M, D'Arrigo A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972630>
5. **SARS-CoV-2 vaccination triggered Guillain-Barre syndrome.** *Clin. Neurol. Neurosurg.* 2021; 213:107106. Scorza FA, Finsterer J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974378>
6. **COVID-19-Induced Guillain-Barré Syndrome.** *Cureus* 2021; 13:e19809. Brooks JE, Mix FM, Buck JC, Walters RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956793>

7. **Neuroinflammation, diabetes, and COVID-19: Perspectives coming from Ca²⁺/cAMP signalling.** Curr Drug Res Rev 2021; Bergantin LB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34970961>
8. **Suspend or amend? Randomized controlled trial on neuropsychological rehabilitation for epilepsy: A COVID-19 impact.** Epilepsy Behav Rep 2022; 17:100516 Sharma S, Nehra A, Pandey S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957386>
9. **Neuroleptic Malignant Syndrome due to Atypical Antipsychotics in a COVID-19-positive Pregnant Woman.** Indian J. Crit. Care Med. 2021; 25:1073-1074 Burad J, Kodange S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963731>
10. **Peripheral neurological complications during COVID-19: A single center experience.** J Neurol Sci 2021; 434:120118 Michaelson NM, Malhotra A, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971857>
11. **COVID-19-associated necrotizing encephalopathy presenting without active respiratory symptoms: a case report with histopathology.** J. Neurovirol. 2021:1-5 Rettenmaier LA, Abdel-Wahed L, Abdelmotilib H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34970720>
12. **Electroencephalographic (EEG) features of encephalopathy in COVID-19.** Klinische Neurophysiologie 2021; 52:237-238.
13. **COVID-19 Induced Miller Fisher Syndrome Presenting With Autonomic Dysfunction: A Unique Case Report and Review of Literature.** Neurohospitalist 2022; 12:111-116 Biswas S, Ghosh R, Mandal A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34950397>
14. **Incidence, Predictors and Outcomes of Delirium in Critically Ill Patients With COVID-19.** Neurohospitalist 2022; 12:31-37 Williamson CA, Faiver L, Nguyen AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950384>
15. **Feasibility of online PD SAFEx™ exercise rehabilitation for symptom improvements of Parkinson's disease: A pilot study.** NeuroRehabilitation 2021; Almeida QJ, Jarvis C, Sangarapillai K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957956>
16. **A brief report: Cerebrospinal fluid rhinorrhea after repetitive nasal swab testing for coronavirus disease 2019(COVID-19).** Otolaryngol Case Rep 2021; 20:100313 Yilmaz M, Bahadır Z, Madendere B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957362>
17. **Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination.** Vaccines (Basel) 2021; 9 Bagella CF, Corda DG, Zara P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960248>

Coagulation (17 articles)

1. **Covid-19 responsible for acute limb ischemia twice at 2 different stages in a patient on anticoagulation: A case report.** Ann Med Surg (Lond) 2022; 73:103194 Banana Y, Hafhaf O, Boukabous S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956641>
2. **Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine.** BMJ Case Rep. 2021; 14 Atta SN, Othman N, Babar M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969796>
3. **Successful endovascular mechanical thrombectomy in anticoagulation-resistant COVID-19 associated cerebral venous sinus thrombosis.** BMJ Case

- Rep. 2021; 14Sajjad A, Khan AF, Jafri L, Kamal AK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34972772>
4. **Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients.** Br. J. Clin. Pharmacol. 2021; van der Heijden C, Ter Heine R, Kooistra EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965610>
 5. **Cerebral Venous Sinus Thrombosis in a Patient With Mild Symptoms of COVID-19 Pneumonia.** Cureus 2021; 13:e19885Chohan A, Chohan F, Rad P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966603>
 6. **Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases.** Egypt J Neurol Psychiatr Neurosurg 2021; 57:179Finsterer J, Zarrouk S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955632>
 7. **Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial.** Eur. J. Clin. Invest. 2021:e13735Morici N, Podda G, Birocchi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958123>
 8. **Vascular Damage, Thromboinflammation, Plasmablast Activation, T-Cell Dysregulation and Pathological Histiocytic Response in Pulmonary Draining Lymph Nodes of COVID-19.** Front. Immunol. 2021; 12:763098Haslbauer JD, Zinner C, Stalder AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966385>
 9. **Portal Vein Thrombosis Might Develop by COVID-19 Infection or Vaccination: A Systematic Review of Case-Report Studies.** Front Med (Lausanne) 2021; 8:794599Kheyrandish S, Rastgar A, Arab-Zozani M, Sarab GA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970570>
 10. **Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination.** Int J Infect Dis 2021; 116:114-121Hwang J, Han YJ, Yon DK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958931>
 11. **A case of spontaneous thoracolumbar epidural hematoma in Covid-19 pneumonia.** Int. J. Surg. Case Rep. 2022; 90:106719Zübeyde Ö, Adem K, Samet D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961838>
 12. **Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register.** Intern Emerg Med 2022;1-9Poli D, Antonucci E, Ageno W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973126>
 13. **Platelets mediate inflammatory monocyte activation by SARS-CoV-2 Spike protein.** J. Clin. Invest. 2021; Li T, Yang Y, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964720>
 14. **Imaging findings in invasive rhino-orbito-cerebral mucormycosis in post-COVID-19 patients.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:32-34Jindal G, Sethi A, Bhargarva K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970028>
 15. **Enoxaparin dose impacts blood cell phenotypes during mild SARS-CoV-2 infection: the observational single-center study.** Rev Cardiovasc Med 2021; 22:1685-1691Buryachkovskaya L, Lomakin N, Melkumyants A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957811>
 16. **Immune Thrombocytopenia Induced by the Chimpanzee Adenovirus-Vectored Vaccine against SARS-CoV-2 Infection.** Vaccines (Basel) 2021; 9Liao PW, Teng CJ, Chou CW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960232>
 17. **COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and**

Complications 55 articles)

1. **Impact of COVID-19 Pandemic on Hospital Onset Bloodstream Infections (HOBIS) at a Large Health System.** Am. J. Infect. Control 2021; Sturm LK, Saake K, Roberts P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971717>
2. **Tracheostomy care and communication during COVID-19: Global interprofessional perspectives.** Am. J. Otolaryngol. 2021; 43:103354 Moser CH, Freeman-Sanderson A, Keeven E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968814>
3. **Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.** Ann. Clin. Microbiol. Antimicrob. 2021; 20:85 Taha Y, Wardle H, Evans AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969393>
4. **Association between tracheostomy timing and outcomes for older critically ill COVID-19 patients: prospective observational study in European intensive care units.** Br J Anaesth 2021; Polok K, Fronczek J, van Heerden PV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955167>
5. **Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients.** Br. J. Clin. Pharmacol. 2021; van der Heijden C, Ter Heine R, Kooistra EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965610>
6. **Reverse Takotsubo Cardiomyopathy as a Cause of Acute Chest Pain in a Young Woman Following COVID-19 Vaccination.** Circ. Cardiovasc. Imaging 2022; 15:e013661 Yamaura H, Ishikawa H, Otsuka K, Kasayuki N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961327>
7. **Oxygen: Friend or foe in the COVID-19 battle.** Clin Case Rep 2021; 9:e05254 Chudasama K, Sangey E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963816>
8. **COVID-19 case of ventilator-induced lung injury on extracorporeal membrane oxygenation: Physicians' clinical struggle and ethical conflict in a novel pandemic.** Clin Case Rep 2021; 9:e05223 Ishisaka Y, Nosaka N, Mishima Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963808>
9. **Emerging Fungal Infections: New Species, New Names, and Antifungal Resistance.** Clin Chem 2021; 68:83-90 Wiederhold NP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969112>
10. **Hospitalization and death after recovery from acute COVID-19 among renal transplant recipients.** Clin. Transplant. 2021:e14572 Basic-Jukic N, Racki S, Tolj I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967958>
11. **Incidence, Risk Factors, and Outcomes of Rhabdomyolysis in Hospitalized Patients With COVID-19 Infection.** Cureus 2021; 13:e19802 Albaba I, Chopra A, Al-Tarbsheh AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956789>
12. **Hematological Manifestations of COVID-19 and Their Prognostic Significance in an Intensive Care Unit: A Cross-Sectional Study.** Cureus 2021; 13:e19887 Bawiskar N, Talwar D, Acharya S, Kumar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966605>

13. **Cerebral Venous Sinus Thrombosis in a Patient With Mild Symptoms of COVID-19 Pneumonia.** Cureus 2021; 13:e19885Chohan A, Chohan F, Rad P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966603>
14. **Impact of Latent Tuberculosis on Severity and Outcomes in Admitted COVID-19 Patients.** Cureus 2021; 13:e19882Madan M, Baldwa B, Raja A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966601>
15. **Utility of MGG and Papanicolaou stained smears in the detection of Mucormycosis in nasal swab/scraping/biopsy samples of COVID 19 patients.** Diagn. Cytopathol. 2021; Philip AC, Madan P, Sharma S, Das S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967146>
16. **Increased Incidence of Tapia's Syndrome Cases Since the COVID-19 Pandemic.** Ear Nose Throat J 2021:1455613211068570Mat Q, Hamdar A, Mehta R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969313>
17. **Adverse Outcome in COVID-19 Is Associated With an Aggravating Hypo-Responsive Platelet Phenotype.** Front Cardiovasc Med 2021; 8:795624Schrottmaier WC, Pirabe A, Pereyra D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957266>
18. **Case Report: Necrotizing Stomatitis as a Manifestation of COVID-19-Associated Vasculopathy.** Front Pediatr 2021; 9:800576Emeršič N, Tomažević T, Točkova O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966708>
19. **Early Occurrence of Adverse Events in Hospitalized Patients With COVID-19 and Beneficial Effect of Anticoagulation.** In Vivo 2022; 36:381-383Dimakakos E, Kollias A, Rapti V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972738>
20. **Prone Positioning in Patients With COVID-19: Analysis of Multicenter Registry Data and Meta-analysis of Aggregate Data.** In Vivo 2022; 36:361-370Kollias A, Kyriakoulis KG, Rapti V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972735>
21. **"Compassion Cannot Choose:" A Call for Family-centered Critical Care during the COVID-19 Pandemic.** Indian J. Crit. Care Med. 2021; 25:1049-1050Mohan M, Joy LF, Sivasankar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963725>
22. **Mucormycosis in COVID-19: Is Zinc a Silent Killer in India?** Indian J. Crit. Care Med. 2021; 25:1079-1080Nath S, Baidya DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963734>
23. **Clinical Characteristics and Outcomes of COVID-19 Patients Hospitalized in Intensive Care Unit.** Indian J. Crit. Care Med. 2021; 25:992-1000Pandit RA, Gagana BN, Vaity C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963716>
24. **Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa.** Int J Infect Dis 2021; 116:38-42Abdullah F, Myers J, Basu D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971823>
25. **A case of spontaneous thoracolumbar epidural hematoma in Covid-19 pneumonia.** Int. J. Surg. Case Rep. 2022; 90:106719Zübeyde Ö, Adem K, Samet D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961838>
26. **Risk factors for Coronavirus disease-associated mucormycosis.** J Infect 2021; Arora U, Priyadarshi M, Katiyar V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974056>
27. **Invasive Candida kefyr infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case report and review of the literature.** J. Mycol. Med. 2021; 32:101236Spiliopoulou A, Kolonitsiou F, Vrioni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974339>

28. **A Challenge of COVID-19: Associated Infective Endocarditis with *Streptococcus gordonii* in a Young Immunocompetent Patient.** Medicina (Kaunas) 2021; 57Arbune M, Iancu AV, Lupasteanu G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946243>
29. **High Rates of Bacterial Pulmonary Co-Infections and Superinfections Identified by Multiplex PCR among Critically Ill COVID-19 Patients.** Microorganisms 2021; 9Cohen R, Babushkin F, Finn T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946086>
30. **COVID-19 Induced Miller Fisher Syndrome Presenting With Autonomic Dysfunction: A Unique Case Report and Review of Literature.** Neurohospitalist 2022; 12:111-116Biswas S, Ghosh R, Mandal A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34950397>
31. **Cryptococcal Meningoencephalitis During Convalescence From Severe COVID-19 Pneumonia.** Neurohospitalist 2022; 12:96-99Thota DR, Ray B, Hasan M, Sharma K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950394>
32. **Nursing Surge Capacity Strategies for Management of Critically Ill Adults with COVID-19.** Nurs Rep 2020; 10:23-32Al Mutair A, Amr A, Ambani Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34968261>
33. **Retropharyngeal abscess- An unusual complication in a COVID-19 patient.** Otolaryngol Case Rep 2021; 20:100312Awobajo MD, Agarwal AN, Hackman SD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957361>
34. **Undetectable viral load within the mastoid during cochlear implantation in a patient with COVID-19.** Otolaryngol Case Rep 2021; 19:100273Kimura KS, Smetak MR, Freeman MH, Wootten CT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957359>
35. **Pediatric bilateral vocal cord granulomas presenting as airway foreign body following prolonged intubation due to COVID-19 related multisystem inflammatory syndrome.** Otolaryngol Case Rep 2021; 20:100311Shah VN, Suresh NV, Pasick LJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957360>
36. **Sudden anosmia and ageusia in a child: A COVID-19 case report.** Otolaryngol Case Rep 2021; 18:100267Wang E, Ulualp SO, Liu C, Veling M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957358>
37. **Increasing incidence of lung transplantation in patients with post-COVID-19 pulmonary fibrosis.** Pan Afr. Med. J. 2021; 40:169Khajotia R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34970411>
38. **Severe post-COVID-19 costochondritis in children.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:56-57Collins RA, Ray N, Ratheal K, Colon A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966216>
39. **Progression to a severe form of COVID-19 among patients with chronic respiratory diseases.** Respir Med Res 2021; 81:100880Basin S, Valentin S, Maurac A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974204>
40. **The deuce-ace of Lassa Fever, Ebola virus disease and COVID-19 simultaneous infections and epidemics in West Africa: clinical and public health implications.** Trop Med Health 2021; 49:102Nnaji ND, Onyeaka H, Reuben RC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965891>
41. **Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?** Tumori 2021;3008916211067825Gattuso G, Schiavello E, Oltolini C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34965799>

42. **[Features of a new coronavirus infection course and options therapy depending on the androgenic status (FOUNDER): androgenic status in men with COVID-19 and its relationship with the disease severity].** Urologija 2021;85-99 Kamalov AA, Mareev VY, Orlova IA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967512>
43. **Bilateral renal Mucor mycosis presenting as anuria in a Covid 19 recovered patient: A case report and review of literature.** Urology 2021; Vaddi SP, Khetavath SM, Babu DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968570>
44. **Reduced COVID-19 hospitalizations among New York City residents following age-based SARS-CoV-2 vaccine eligibility: Evidence from a regression discontinuity design.** Vaccine X 2022; 10:100134 Greene SK, Levin-Rector A, McGibbon E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961848>
45. **Evaluation of Treatment Outcome for Pneumonia among Pre-Vaccinated COVID-19 Patients with/without Comorbidity in a Public Hospital in Bengkulu, Indonesia.** Vaccines (Basel) 2021; 9 Ramatillah DL, Gan SH, Sulaiman SAS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960157>
46. **[Anterior eye segment damage in coronavirus infection (COVID-19)].** Vestn. Oftalmol. 2021; 137:142-148 Marchenko NR, Kasparova EA, Budnikova EA, Makarova MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965080>
47. **[Possibilities of therapeutic correction of ENT pathology associated with COVID-19 in children on an outpatient basis].** Vestn. Otorinolaringol. 2021; 86:69-73 Golovacheva EG, Afanasyeva OI, Goncharova ES *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34964333>
48. **Incidence and Outcome of Coinfections with SARS-CoV-2 and Rhinovirus.** Viruses 2021; 13 Le Glass E, Hoang VT, Boschi C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960797>
49. **Clinical Picture and Risk Factors of Severe Respiratory Symptoms in COVID-19 in Children.** Viruses 2021; 13 Mania A, Faltin K, Mazur-Melewska K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960635>
50. **Fast, Reliable, and Simple Point-of-Care-like Adaptation of RT-qPCR for the Detection of SARS-CoV-2 for Use in Hospital Emergency Departments.** Viruses 2021; 13 Pavletić M, Mazor M, Lerga M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960682>
51. **[The open observational study of aceclofenac and vinpocetine effectiveness and tolerability in treatment of patients with chronic cerebrovascular disease after COVID-19 (AQUA study)].** Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2021; 121:s1-s8 Samartsev IN, Zhivolupov SA, Butakova JS, Parshin MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34968019>

Cured – Recovered (12 articles)

1. **Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis.** Brain Behav Immun 2021; 101:93-135 Ceban F, Ling S, Lui LMW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973396>
2. **Mind the "worry fatigue" amid Omicron scares.** Brain Behav Immun 2021; 101:60-61 Su Z, McDonnell D, Ahmad J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973394>

3. **Utility of MGG and Papanicolaou stained smears in the detection of Mucormycosis in nasal swab/scraping/biopsy samples of COVID 19 patients.** Diagn. Cytopathol. 2021; Philip AC, Madan P, Sharma S, Das S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967146>
4. **Early Experience of High-dose Intravenous Mycobacterium w in Critically Ill Patients of COVID-19.** Indian J. Crit. Care Med. 2021; 25:1066-1068 Patel PS, Patel S, Shah V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963729>
5. **An update on host immunity correlates and prospects of re-infection in COVID-19.** Int. Rev. Immunol. 2021:1-26 Negi N, Maurya SP, Singh R, Das BK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961403>
6. **Clinical and Functional Predictors of Response to a Comprehensive Pulmonary Rehabilitation in Severe Post-COVID-19 Patients.** Microorganisms 2021; 9 Spielmanns M, Buelow MM, Pekacka-Egli AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946054>
7. **Immunological and Genetic Investigation of SARS-CoV-2 Reinfection in an Otherwise Healthy, Young Marine Recruit.** Pathogens 2021; 10 Letizia AG, Arnold CE, Adhikari BN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959544>
8. **Severe post-COVID-19 costochondritis in children.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:56-57 Collins RA, Ray N, Ratheal K, Colon A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966216>
9. **Risk of post-traumatic stress symptoms in hospitalized and non-hospitalized COVID-19 recovered patients. A cross-sectional study.** Psychiatry Res 2021; 308:114353 Craparo G, La Rosa VL, Marino G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968807>
10. **Progression to a severe form of COVID-19 among patients with chronic respiratory diseases.** Respir Med Res 2021; 81:100880 Basin S, Valentin S, Maurac A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974204>
11. **Rehabilitation in post acute COVID-19.** Sports Orthopaedics and Traumatology 2021; 37:242-248 Jarosch I, Koczulla AR.
12. **[Hyperbaric oxygenation in outpatient rehabilitation of COVID-19 convalescents].** Vopr. Kurortol. Fizioter. Lech. Fiz. Kult. 2021; 98:16-21 Turova EA, Shchikota AM, Pogonchenkova IV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965691>

Cardiovascular disease (38 articles)

1. **Covid-19 responsible for acute limb ischemia twice at 2 different stages in a patient on anticoagulation: A case report.** Ann Med Surg (Lond) 2022; 73:103194 Banana Y, Hafhaf O, Boukabous S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956641>
2. **Cardiac rehabilitation in the COVID-19 time. Programs. Results.** Arch Cardiol. Mex. 2021; 91:25-33 Maroto-Montero J, Coello-Cremades M, Martín-Argomanid L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968381>
3. **Treatment of adult, child and newborn cardiac arrest victims with COVID-19. Recommendations from the Interamerican Society of Cardiology / Sociedad Interamericana de Cardiología (SIAC), Mexican National Cardiologists Association / Asociación Nacional de Cardiólogos de México (ANCAM) and Mexican Society of Cardiology / Sociedad Mexicana de Cardiología (SMC).**

- Arch Cardiol. Mex. 2021; 91:64-73 Rodríguez-Reyes H, Ortiz-Galván F, Ibarrola M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968378>
4. **Airborne particles and cardiovascular morbidity in severe inherited hypercholesterolemia: Vulnerable endothelium under multiple attacks.** Bioessays 2021:e2100273 Vuorio A, Budowle B, Kovanen PT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967031>
 5. **Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine.** BMJ Case Rep. 2021; 14:Atta SN, Othman N, Babar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969796>
 6. **Successful endovascular mechanical thrombectomy in anticoagulation-resistant COVID-19 associated cerebral venous sinus thrombosis.** BMJ Case Rep. 2021; 14:Sajjad A, Khan AF, Jafri L, Kamal AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972772>
 7. **Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study.** BMJ Open 2021; 11:e050051 Wallace AW, Cirillo PM, Ryan JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972763>
 8. **Impact of COVID-19 pandemic on the management of nonculprit lesions in patients presenting with ST-elevation myocardial infarction: Outcomes from the pan-London heart attack centers.** Catheter. Cardiovasc. Interv. 2021; Demir OM, Little CD, Jabbour R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967091>
 9. **Reverse Takotsubo Cardiomyopathy as a Cause of Acute Chest Pain in a Young Woman Following COVID-19 Vaccination.** Circ. Cardiovasc. Imaging 2022; 15:e013661 Yamaura H, Ishikawa H, Otsuka K, Kasayuki N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961327>
 10. **Clinically suspected myocarditis in COVID-19 patients: Case series and review of the literature.** Clin Case Rep 2021; 9:e05236 Amin A, Eftekhari SP, Ziaie N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963812>
 11. **Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?** Cureus 2021; 13:e19919 Maheshwari M, Athiraman H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956798>
 12. **Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial.** Eur. J. Clin. Invest. 2021:e13735 Morici N, Podda G, Birocchi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958123>
 13. **Portal Vein Thrombosis Might Develop by COVID-19 Infection or Vaccination: A Systematic Review of Case-Report Studies.** Front Med (Lausanne) 2021; 8:794599 Kheyrandish S, Rastgar A, Arab-Zozani M, Sarab GA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970570>
 14. **COVID-19: A New Horizon in Congenital Heart Diseases.** Front Pediatr 2021; 9:582043 Aghaei Moghadam E, Mohammadzadeh S, Sattarzadeh Badkoubbeh R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956968>
 15. **Clinical benefits in patients with home-based cardiac rehabilitation in the era of COVID-19 pandemic.** Heart Lung 2021; Kawada T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972589>
 16. **Acute ischemic events after COVID-19 infection in patients undergoing maintenance hemodialysis.** Hemodial Int 2021; Ozkaya E, Taskent I, Somay R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962048>

17. **Patients hospitalised with heart failure across different waves of the COVID-19 pandemic show consistent clinical characteristics and outcomes.** Int J Cardiol 2021; 350:125-129 Rind IA, Cannata A, McDonough B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971665>
18. **Relationship Between Myocardial Injury During Index Hospitalization for SARS-CoV-2 Infection and Longer-Term Outcomes.** J Am Heart Assoc 2022; 11:e022010 Weber B, Siddiqi H, Zhou G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970914>
19. **Effect of the COVID-19 pandemic on complications and mortality of patients with cardiac surgery.** J. Cardiothorac. Surg. 2021; 16:361 Wang X, Gao H, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972531>
20. **Cardiovascular and haematological events post COVID-19 vaccination: A systematic review.** J Cell Mol Med 2021; Al-Ali D, Elshafeey A, Mushannen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967105>
21. **Acute Mesenteric Ischemia in Patients with COVID-19: Review of the literature.** J. Natl. Med. Assoc. 2021; Chen C, Li YW, Shi PF, Qian SX. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973847>
22. **If Your Heart Were to Stop: Characterization and Comparison of Code Status Orders in Adult Patients Admitted with COVID-19.** J. Palliat. Med. 2021; Epler K, Lenhan B, O'Callaghan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967678>
23. **Reduced Vascular Practice and Increased Cardiovascular Mortality for COVID-19-Negative Patients.** J. Surg. Res. 2021; 272:146-152 Bozzani A, Arici V, Ticozzelli G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973548>
24. **Acute Limb Ischemia Related to Neutrophil Extracellular Traps in a Patient With COVID-19.** JACC Cardiovasc Interv 2022; 15:223-226 Ozawa T, Kimura M, Yoshimura J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973911>
25. **COVID-19 patients may present with myocarditis: A case report emphasizing the cardiac involvement of SARS-CoV-2.** Med. J. Islam. Repub. Iran 2021; 35:104 Salavati E, Hajirezaee H, Niazkar HR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956950>
26. **Increase of Myocardial Ischemia Time and Short-Term Prognosis of Patients with Acute Myocardial Infarction during the First COVID-19 Pandemic Wave.** Medicina (Kaunas) 2021; 57 Budrys P, Lizaitis M, Cerlinskaite-Bajore K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946241>
27. **Healthcare Worker With Large Vessel Acute Ischemic Stroke Likely Related to Mild SARS-CoV-2 Infection.** Neurohospitalist 2022; 12:48-56 Castillo-Pinto C, Lamotte G, Mehta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950386>
28. **Infective endocarditis following COVID-19 pneumonia: about two cases.** Pan Afr. Med. J. 2021; 40:152 Ouarradi AE, Kantri A, Agrad K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970394>
29. **The optical coherence tomography angiography study on paediatric COVID-19 cases.** Photodiagnosis Photodyn. Ther. 2021; 37:102710 Au SCL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974164>
30. **Acute aortic dissection in the Marfan syndrome during the COVID-19 epidemic.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:88-90 Basheer A, Rasool M, Amin H, Saucier S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970047>
31. **Relation of interleukin-6 levels in COVID-19 patients with major adverse cardiac events.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:6-9 Nguyen N, Nguyen H,

- Ukoha C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966215>
32. **Taming the Storm in the Heart: Exploring Different Therapeutic Choices Against Myocardial Inflammation in COVID-19.** Recent Adv Antiinfect Drug Discov 2021; 16:89-93 Choudhury A, Mukherjee S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961430>
 33. **Racial differences in cardiopulmonary outcomes of hospitalized COVID-19 patients with acute kidney injury.** Rev Cardiovasc Med 2021; 22:1667-1675 Egbuche O, Abe T, Nwokike SI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957809>
 34. **Acute cardiovascular events triggered by the COVID-19 pandemic-related stress in non-infected individuals. The Jordan COVID-19 Acute Cardiovascular Events (JoCORE) study.** Rev Cardiovasc Med 2021; 22:1677-1683 Hammoudeh AJ, Madanat E, Tabbalat R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957810>
 35. **Exercise-based cardiac rehabilitation programs in the era of COVID-19: a critical review.** Rev Cardiovasc Med 2021; 22:1143-1155 Stefanakis M, Batalik L, Papathanasiou J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957758>
 36. **COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination.** Vaccines (Basel) 2021; 9 Wieteska-Milek M, Szmit S, Florczyk M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960141>
 37. **Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?** Viruses 2021; 13 Parra-Lucare A, Toro L, Weitz-Muñoz S, Ramos C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960761>
 38. **[The open observational study of aceclofenac and vinpocetine effectiveness and tolerability in treatment of patients with chronic cerebrovascular disease after COVID-19 (AQUA study)].** Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2021; 121:s1-s8 Samartsev IN, Zhivolupov SA, Butakova JS, Parshin MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34968019>

Diagnosis (6 articles)

1. **Diagnostic performance of the RSNA-proposed classification for COVID-19 pneumonia versus pre-pandemic controls.** Braz. J. Infect. Dis. 2021; 26:101665 Rocha CO, Prioste TAD, Faccin CS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34958741>
2. **A computer-aided diagnosis system for the classification of COVID-19 and non-COVID-19 pneumonia on chest X-ray images by integrating CNN with sparse autoencoder and feed forward neural network.** Comput. Biol. Med. 2021; 141:105134 J LG, Abraham B, M SS, Nair MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34971978>
3. **Diagnostic value of 12-zone lung ultrasound protocol for diagnosing COVID-19-associated pneumonia in outpatients.** J Ultrason 2021; 21:e271-e276 Haurylenka D, Damantsevich V, Filustsin A, Damantsevich A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34970436>
4. **Automatic coronavirus disease 2019 diagnosis based on chest radiography and deep learning - Success story or dataset bias?** Med. Phys. 2021; Dhont J, Wolfs C, Verhaegen F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951033>

5. **Adaptive UNet-based Lung Segmentation and Ensemble Learning with CNN-based Deep Features for Automated COVID-19 Diagnosis.** Multimed Tools Appl 2021;1-35Das A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955679>
6. **Diagnostic Approach for Accurate Diagnosis of COVID-19 Employing Deep Learning and Transfer Learning Techniques through Chest X-ray Images Clinical Data in E-Healthcare.** Sensors (Basel) 2021; 21Haq AU, Li JP, Ahmad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960313>

DM-MS-Obesity (14 articles)

1. **Changes in the body mass of adult residents of rural and urban areas in the initial months of the COVID-19 pandemic vs. their mental, physical and sexual health.** Ann. Agric. Environ. Med. 2021; 28:667-675Białorudzki M, Izdebski Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969227>
2. **Experiences with alternative online lectures in medical education in obstetrics and gynecology during the COVID-19 pandemic-possible efficient and student-orientated models for the future?** Arch. Gynecol. Obstet. 2021;1-13Riedel M, Eisenkolb G, Amann N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961899>
3. **Impact of COVID-19 lockdown on glycemic control in type 1 diabetes.** Arch. Pediatr. 2022; 29:27-29Duarte V, Mota B, Ferreira S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955306>
4. **Neuroinflammation, diabetes, and COVID-19: Perspectives coming from Ca²⁺/cAMP signalling.** Curr Drug Res Rev 2021; Bergantin LB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970961>
5. **Overweight and Obesity Are Associated With Acute Kidney Injury and Acute Respiratory Distress Syndrome, but Not With Increased Mortality in Hospitalized COVID-19 Patients: A Retrospective Cohort Study.** Front. Endocrinol. (Lausanne) 2021; 12:747732van Son J, Oussaada SM, Şekercan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970220>
6. **High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome.** Front. Endocrinol. (Lausanne) 2021; 12:791476Wang W, Chai Z, Cooper ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956098>
7. **Ketogenic Diet for Obese COVID-19 Patients: Is Respiratory Disease a Contraindication? A Narrative Review of the Literature on Ketogenic Diet and Respiratory Function.** Front Nutr 2021; 8:771047Gangitano E, Tozzi R, Mariani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957183>
8. **COVID-19 Outcome Relates With Circulating BDNF, According to Patient Adiposity and Age.** Front Nutr 2021; 8:784429Minuzzi LG, Seelaender M, Silva BSA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957187>
9. **Association Between Metformin Use and Mortality among Patients with Type 2 Diabetes Mellitus Hospitalized for COVID-19 Infection.** J ASEAN Fed Endocr Soc 2021; 36:133-141Ong AN, Tan CC, Cañete MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966196>
10. **Hyperglycemia and blood glucose deterioration are risk factors for severe COVID-19 with diabetes: A two-center cohort study.** J Med Virol 2021; Xiao F, Zhou YC, Zhang MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967028>
11. **Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us.** Metab Syndr Relat Disord 2021; Stoian AP, Kempler P, Stulnig T *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967689>

12. **COVID-19 Pandemic as Risk Factors for Excessive Weight Gain in Pediatrics: The Role of Changes in Nutrition Behavior. A Narrative Review.** Nutrients 2021; 13Cena H, Fiechtner L, Vincenti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959805>
13. **COVID-19 In-Hospital Mortality in People with Diabetes Is Driven by Comorbidities and Age-Propensity Score-Matched Analysis of Austrian National Public Health Institute Data.** Viruses 2021; 13Aziz F, Aberer F, Bräuer A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960670>
14. **Excess Body Mass-A Factor Leading to the Deterioration of COVID-19 and Its Complications-A Narrative Review.** Viruses 2021; 13Gryczyńska W, Litvinov N, Bitew B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960696>

Education and training and science (42 articles)

1. **Covid-19: exploring the "new normal" in gastroenterology training.** Acta Gastroenterol. Belg. 2021; 84:627-635Ekmektzoglou K, Tziatzios G, Siau K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965045>
2. **Essential reading from the editor's desk.** Acta Gastroenterol. Belg. 2021; 84:539-540Vanuytsel T, Reenaers C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965033>
3. **Interpreting recent clinical studies for COVID-19: A continual process with more new data.** Anaesth Crit Care Pain Med 2021; 41:101016Connors JM, Moll M, Levy JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958999>
4. **Impact of COVID-19 pandemic on cardiology fellows academic training: beyond the clinical impact.** Arch Cardiol. Mex. 2021; 91:18-24Persia-Paulino YR, Pascual I, Fernández-Asensio R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968379>
5. **Influencing Factors on Nursing Students' Learning Flow during the COVID-19 Pandemic: A Mixed Method Research.** Asian Nurs. Res. (Korean Soc. Nurs. Sci.) 2021; Park J, Seo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974178>
6. **COVID-19 publications in anaesthesiology journals: a bibliometric analysis.** Br J Anaesth 2021; Martinez-Simon A, Honorato-Cia C, Cacho-Asenjo E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955168>
7. **Radiology During the COVID-19 Pandemic: Mapping Radiology Literature in 2020.** Curr Med Imaging 2021; Al-Ryalat N, Malkawi L, Abu Salhiyeh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967299>
8. **Synchronous online learning during movement control order in higher education institutions: a systematic review.** F1000Res 2021; 10:1056Lee YW, Dorasamy M, Bin Ahmad AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950456>
9. **Editorial: A Compendium of Recent Research on Stem Cell-Based Therapy for Covid-19.** Front Cell Dev Biol 2021; 9:813384Hmadcha A, Soria B, Zhao RC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970555>
10. **IDbSV: An Open-Access Repository for Monitoring SARS-CoV-2 Variations and Evolution.** Front Med (Lausanne) 2021; 8:765249Essabbar A, Kartti S, Alouane T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966754>
11. **A Phenomenological Study on the Positive and Negative Experiences of Chinese International University Students From Hong Kong Studying in the U.K. and U.S. in the Early Stage of the COVID-19 Pandemic.** Front Psychiatry

- 2021; 12:738474Lai AY, Sit SM, Lam SK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966299>
12. **Teaching and Learning in COVID-19 Lockdown in Scotland: Teachers' Engaged Pedagogy.** *Front. Psychol.* 2021; 12:733633Colville T, Hulme S, Kerr C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955961>
 13. **Push-Pull-Mooring Analysis of Massive Open Online Courses and College Students During the COVID-19 Pandemic.** *Front. Psychol.* 2021; 12:755137Kang K, Wang T, Chen S, Su YS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955974>
 14. **Cognitive and Affective-Motivational Factors as Predictors of Students' Home Learning During the School Lockdown.** *Front. Psychol.* 2021; 12:751120Lockl K, Attig M, Nusser L, Wolter I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955970>
 15. **Risk Perception and Knowledge, Attitudes, and Practices Against COVID-19 in a Hypertensive Population From a Semi-Urban City of Ecuador.** *Front Public Health* 2021; 9:734065Aumala T, Cardenas M, Vergara D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34970523>
 16. **Impact of the COVID-19 Pandemic on Cancer Researchers in 2020: A Qualitative Study of Events to Inform Mitigation Strategies.** *Front Public Health* 2021; 9:741223Fox L, Beyer K, Rammant E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966713>
 17. **Re: Evaluation of a telemedicine-based training for final-year medical students including simulated patient consultations, documentation, and case presentation.** *GMS J Med Educ* 2021; 38:Doc113Harendza S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957318>
 18. **Letter to the editor regarding "Evaluation of a telemedicine-based training for final-year medical students including simulated patient consultations, documentation, and case presentation".** *GMS J Med Educ* 2021; 38:Doc114Majeed M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957319>
 19. **Teacher's perceptions, institutional challenges, and educational sustainability during Covid-19 in Ecuador.** *Heliyon* 2021; 7:e08596Andrade-Vargas L, Estevao-Romeiro A, Iriarte-Solano M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957339>
 20. **Prevalence, attitude, knowledge, and risk perception towards COVID-19 in COPD patients associated to biomass exposure.** *Int. J. Environ. Health Res.* 2021;1-10Montiel-Lopez F, Rodríguez-Ramírez D, Miranda-Márquez MC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34965789>
 21. **What the COVID-19 pandemic reveals about science, policy and society.** *Interface Focus* 2021; 11:20210022Ball P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956594>
 22. **How COVID-19 has changed medical research funding.** *Interface Focus* 2021; 11:20210025Chinnery PF, Pearce JJ, Kinsey AM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956595>
 23. **Our mutual fiends: cancer research in a time of COVID-19.** *Interface Focus* 2021; 11:20210052Dabin K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956603>
 24. **Personal observations on COVID-19 and the conduct and application of biomedical science.** *Interface Focus* 2021; 11:20210053Smith JC, Goodhew DW.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956604>
 25. **Formal and informal science advice in emergencies: COVID-19 in the UK.** *Interface Focus* 2021; 11:20210059Whitty CJM, Collet-Fenson LB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956605>

26. **Perceptions and attitudes of University of Johannesburg chiropractic students toward a blended learning approach and a shift to an e-learning approach necessitated by the COVID-19 pandemic.** J Chiropr Educ 2021; Ismail F, Yelverton C, Rademan R, Peterson C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965578>
27. **Impact of COVID-19 pandemic on plastic surgery training in Europe.** J. Plast. Reconstr. Aesthet. Surg. 2021; Paskal AM, Jaremków P, Małyszczak P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973932>
28. **Positive impact of a telemedicine education program on practicing health care workers during the COVID-19 pandemic in Ontario, Canada: A mixed methods study of an Extension for Community Healthcare Outcomes (ECHO) program.** J Telemed Telecare 2021;1357633x211059688Zhao QJ, Rozenberg D, Nourouzpour S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962167>
29. **The Impact of COVID-19 on Medical Dosimetry Education: Students' Perception on the Effectiveness of Program's Immediate Response.** Med. Dosim. 2021; Dehghanpour M, Baker J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963567>
30. **Nursing Students' Practicums during the COVID-19 Crisis and the Effect on Infection-Prevention Behavior in Students: A Mixed-Method Approach.** Medicina (Kaunas) 2021; 57Nakagawa H, Sasai H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946299>
31. **Nurses' Knowledge and Anxiety Levels toward COVID-19 in Saudi Arabia.** Nurs Rep 2021; 11:356-363Alsharif F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968212>
32. **Novice Nurses' Experiences Caring for Acutely Ill Patients during a Pandemic.** Nurs Rep 2021; 11:382-394Naylor H, Hadenfeldt C, Timmons P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968215>
33. **Development and Validation of a Questionnaire to Measure Knowledge of and Attitude toward COVID-19 among Nursing Students in Greece.** Nurs Rep 2020; 10:82-94Patelarou AE, Konstantinidis T, Kartsoni E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968353>
34. **Role of the otolaryngologist in nasopharyngeal swab training: A case report and review of the literature.** Otolaryngol Case Rep 2021; 20:100316Liu M, Roychowdhury P, Ito CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957363>
35. **Awareness, knowledge, attitudes, and behaviors related to COVID-19 in Libya: a nation-wide online survey.** Pan Afr. Med. J. 2021; 40:156Jahan A, Mohamed M, Alabani E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970398>
36. **Alternative publication metrics in the time of COVID-19.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:43-45Peterson CJ, Anderson C, Nugent K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970030>
37. **Covid-19 and school closure: Examining the impact on private mid-range and low-fee private basic schools in Ghana.** Prospects (Paris) 2021:1-18Juvenile Ehwi L, Ehwi RJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955562>
38. **[Remote presentation of thesis and final postgraduate works during the COVID-19 pandemic. Are there advantages in the non-face-to-face presentations?].** Rev. Fac. Cien. Med. Univ. Nac. Cordoba 2021; 78:353-358Soto Perez AR, Eymann A, Ladenheim R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962732>
39. **Health crisis: What opportunities for clinical drug research?** Therapie 2021; Deplanque D, Cviklinski S, Bardou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962732>

term=34973823

40. **Effects of the COVID-19 pandemic on obstetrics and gynecology residency training in Turkey.** Turk J Obstet Gynecol 2021; 18:304-310 Topçu G, Özçivit İ B, Erkılınç S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955024>
41. **Role of Vaccine Hesitancy, eHealth Literacy, and Vaccine Literacy in Young Adults' COVID-19 Vaccine Uptake Intention in a Lower-Middle-Income Country.** Vaccines (Basel) 2021; 9 Nath R, Imtiaz A, Nath SD, Hasan E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960151>
42. **Data-Driven Decision Making and Proactive Citizen-Scientist Communication: A Cross-Sectional Study on COVID-19 Vaccination Adherence.** Vaccines (Basel) 2021; 9 Syundyukov E, Mednis M, Zaharenko L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960129>

Elderly (9 articles)

1. **Ageing policy in Poland during the COVID-19 pandemic.** Ann. Agric. Environ. Med. 2021; 28:551-557 Lutomski P, Kaczoruk M, Florek-Łuszczki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969210>
2. **Pre-infection HDL-cholesterol levels and mortality among elderly patients infected with SARS-CoV-2.** Atherosclerosis 2022; 341:13-19 Mostaza JM, Salinero-Fort MA, Cardenas-Valladolid J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959204>
3. **A Systematic Review of Telemedicine for Older Adults With Dementia During COVID-19: An Alternative to In-person Health Services?** Front. Neurol. 2021; 12:761965 Elbaz S, Cinalioglu K, Sekhon K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970210>
4. **Correlates of Social Isolation Among Community-Dwelling Older Adults During the COVID-19 Pandemic.** Front Public Health 2021; 9:702965 Adepoju OE, Chae M, Woodard L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956998>
5. **Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study.** Lancet Reg Health Am 2022; 6:100154 Cerqueira-Silva T, Oliveira VA, Boaventura VS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957437>
6. **[Development of loneliness in old age in times of COVID-19].** OZS Osterr Z Soziol 2021; 46:443-455 Richter L, Heidinger T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955620>
7. **Older Americans' Perceptions of the Federal Government's Pandemic Response: Voices From the COVID-19 Coping Study.** Res. Aging 2021; 1640275211062111 Gallo HB, Kobayashi LC, Finlay JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967234>
8. **Coping strategies moderate the effect of perceived stress on sleep and health in older adults during the COVID-19 pandemic.** Stress Health 2021; Tracy EL, Chin B, Lehrer HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951930>
9. **Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population.** Vaccines (Basel) 2021; 9 Weinberger B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960181>

Epidemiology (36 articles)

1. **Ethnic Disparities in Coronavirus Disease 2019 after the Implementation of Universal Screening in Hartford, Connecticut.** AJP Rep 2021; 11:e147-e153 Pimentel VM, Jackson FI, Ferrante AD, Figueroa R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966566>
2. **COVID-19 - Infection prevention in prisons and jails in Poland.** Ann. Agric. Environ. Med. 2021; 28:621-626 Augustynowicz A, Wójcik M, Bachurska B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969220>
3. **No Effects of Meteorological Factors on the SARS-CoV-2 Infection Fatality Rate.** Biomed. Environ. Sci. 2021; 34:871-880 Solanes A, Laredo C, Guasp M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955147>
4. **Regional mobility during the Covid-19 pandemic: Analysis of trends and repercussions using mobile phones data across the EU.** Case Stud Transp Policy 2021; Christidis P, Ciuffo B, Vespe M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956834>
5. **The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.** Cell Rep. 2022; 38:110218 Kimura I, Kosugi Y, Wu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968415>
6. **Ziegler and Nichols meet Kermack and McKendrick: Parsimony in dynamic models for epidemiology.** Comput. Chem. Eng. 2022; 157:107615 Nikolaou M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961800>
7. **An Epidemiological Study of COVID-19 Cases in Al-Leith, Saudi Arabia.** Cureus 2021; 13:e20457 Elawad M, Al-Thubyani D, Almhdawi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956802>
8. **Phased Return of Students to 77 Transitional Kindergarten-8th Grade Schools With Cohesive Mitigation Strategies Serving as Protective Factors Against the Increase of COVID-19 Cases in Marin County: September 2020-January 2021.** Cureus 2021; 13:e19821 Paff SQ, Ereman R, Santora L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963838>
9. **Epidemiology of COVID-19 after Emergence of SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020-2021.** Emerg Infect Dis 2021; 28 Nicolette VC, Rodrigues PT, Fernandes ARJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963505>
10. **Influence of meteorological patterns on the 2020 COVID-19 pandemic in the Mexico City region.** Environ Adv 2022; 7:100157 Salcido A, Castro T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957431>
11. **The Second Wave of COVID-19 in South and Southeast Asia and the Effects of Vaccination.** Front Med (Lausanne) 2021; 8:773110 Song H, Fan G, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970562>
12. **Strategies to Estimate Prevalence of SARS-CoV-2 Antibodies in a Texas Vulnerable Population: Results From Phase I of the Texas Coronavirus Antibody Response Survey.** Front Public Health 2021; 9:753487 Valerio-Shewmaker MA, DeSantis S, Swartz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970525>
13. **Commissioning Clinical Spaces During a Pandemic: Merging Methodologies of Human Factors and Simulation.** Herd 2021:19375867211066933 Fuselli T, Raven A, Milloy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961357>
14. **SARS-CoV-2 infections in households in a peri-urban community of Lima, Peru: A prospective cohort study.** Influenza Other Respir Viruses 2021; Lanata CF, Gil AI, Ecker L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962079>

15. **Forecasting the spread of the third wave of COVID-19 pandemic using time series analysis in Bangladesh.** Inform Med Unlocked 2022; 28:100815Kibria HB, Jyoti O, Matin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961844>
16. **The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome.** Interface Focus 2021; 11:20210008Anderson RM, Vegvari C, Hollingsworth TD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956588>
17. **Disease transmission and control modelling at the science-policy interface.** Interface Focus 2021; 11:20210013McCabe R, Donnelly CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956589>
18. **New ways: the pandemics of science fiction.** Interface Focus 2021; 11:20210027Morgan G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956596>
19. **Importation and Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern in Korea, November 2021.** J Korean Med Sci 2021; 36:e346Lee JJ, Choe YJ, Jeong H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962117>
20. **Omicron and S-gene target failure cases in the highest COVID-19 case rate region in Canada-December 2021.** J Med Virol 2021; Li A, Maier A, Carter M, Guan TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964500>
21. **Epidemiology of influenza under the coronavirus disease 2019 pandemic in Nanjing, China.** J Med Virol 2021; Wu K, Wu X, Wang W, Hong L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964514>
22. **Validation of the COVID-19 Exposure and Family Impact Scales.** J. Pediatr. Psychol. 2021; Enlow PT, Phan TT, Lewis AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969064>
23. **Are There Global Syndemics?** Med. Anthropol. 2021:1-15Singer M, Bulled N, Leatherman T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958607>
24. **Epidemiological characteristics of patients with COVID-19 in Southwest of Iran from February 19 to June 20, 2020.** Med. J. Islam. Repub. Iran 2021; 35:116Azarbakhsh H, Jokari K, Moftakhar L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956962>
25. **The Effects of COVID-19 on Healthcare Workers and Non-Healthcare Workers in Mexico: 14 Months into the Pandemic.** Medicina (Kaunas) 2021; 57Esquivel-Chirino C, Valero-Princet Y, Gaitán-Cepeda LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946297>
26. **Comprehensive Contact Tracing, Testing and Sequencing Show Limited Transmission of SARS-CoV-2 between Children in Schools in Norway, August 2020 to May 2021.** Microorganisms 2021; 9Winje BA, Ofitserova TS, Brynildsrud OB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946187>
27. **Reassessment of contact restrictions and testing campaigns against COVID-19 via spatio-temporal modeling.** Nonlinear Dyn 2021:1-25Ganegoda NC, Wijaya KP, Páez Chávez J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955605>
28. **Possible future trajectory of COVID-19: emphasis on Africa.** Pan Afr. Med. J. 2021; 40:157Amponsah SK, Tagoe B, Afriyie DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970399>
29. **Estimating the impact of influenza on the epidemiological dynamics of SARS-CoV-2.** PeerJ 2021; 9:e12566Domenech de Cellès M, Casalegno JS, Lina B, Opatowski L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950537>
30. **Disaggregating Asian Race Reveals COVID-19 Disparities Among Asian American Patients at New York City's Public Hospital System.** Public Health

- Rep. 2021:333549211061313Kalyanaraman Marcello R, Dolle J, Tariq A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34965776>
31. **EPIDEMIOLOGICAL DETERMINANTS FOR THE SPREAD OF COVID-19 IN RIYADH PROVINCE OF SAUDI ARABIA.** Saudi J. Biol. Sci. 2021; Al-Yamani MJ, Imam Rabbani S, Mohammed Basheeruddin Asdaq S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955667>
 32. **Mathematical modelling of the epidemiology of COVID-19 infection in Ghana.** Sci Afr 2022; 15:e01070Barnes B, Ackora-Prah J, Boateng FO, Amanor L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961847>
 33. **Impacts of COVID-19 lockdown on private domestic groundwater sample numbers, E. coli presence and E. coli concentration across Ontario, January 2020-March 2021: An interrupted time-series analysis.** Sci Total Environ 2021; 814:152634Latchmore T, Lavallee S, Boudou M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34974018>
 34. **The unequal burden of the Covid-19 pandemic: Capturing racial/ethnic disparities in US cause-specific mortality.** SSM Popul Health 2022; 17:101012Luck AN, Preston SH, Elo IT, Stokes AC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961843>
 35. **COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhône-Alpes region (France): An ecological study.** Vaccine 2022; 40:695-700Romain-Scelle N, Elias C, Vanhems P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969543>
 36. **Emerging Trends in the Epidemiology of COVID-19: The Croatian 'One Health' Perspective.** Viruses 2021; 13Vilibic-Cavlek T, Stevanovic V, Brlek-Gorski D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960623>

Gastro-enterology (17 articles)

1. **Essential reading from the editor's desk.** Acta Gastroenterol. Belg. 2021; 84:539-540Vanuytsel T, Reenaers C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965033>
2. **Impact of the Coronavirus (COVID-19) Pandemic on the Care of Pediatric Acute Appendicitis.** Am. Surg. 2021:31348211067995Head WT, Parrado RH, Cina RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957861>
3. **Acute liver injury in the course of COVID-19.** Ann. Agric. Environ. Med. 2021; 28:729-732Grzywa-Celińska A, Emeryk-Maksymiuk J, Szewczyk K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969237>
4. **The histologic and molecular correlates of liver disease in fatal COVID-19 including with alcohol use disorder.** Ann. Diagn. Pathol. 2021; 57:151881Nuovo GJ, Suster D, Awad H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968863>
5. **Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases.** Clin Gastroenterol Hepatol 2021; Baiges A, Cerda E, Amicone C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34968728>
6. **Resuming post living donor liver transplantation in the COVID-19 pandemic: real-life experience, single-center experience.** Egypt Liver J 2021; 11:92Abdellatif AA, Mogawer MS, El-Shazli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956680>
7. **How Does COVID-19 Pandemic Impact on Incidence of Clostridioides difficile Infection and Exacerbation of Its Gastrointestinal Symptoms?** Front Med (Lausanne) 2021; 8:775063Azimirad M, Noori M, Raeisi H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966759>

8. **Impact of the Lockdown Due to the COVID-19 Pandemic on Patients With Inflammatory Bowel Disease.** Front Med (Lausanne) 2021; 8:649759Nishida Y, Hosomi S, Fujimoto K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957131>
9. **Carbon Ion Radiotherapy Acts as the Optimal Treatment Strategy for Unresectable Liver Cancer During the Coronavirus Disease 2019 Crisis.** Front Public Health 2021; 9:767617Li Z, Li Q, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957022>
10. **Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19.** Front Public Health 2021; 9:778340Luo K, Chen Y, Yang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970527>
11. **Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic.** Frontline Gastroenterol. 2022; 13:77-81Din S, Gaya D, Kammermeier J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966535>
12. **Colonoscopy in the post-COVID-19 era.** Frontline Gastroenterol. 2022; 13:3-4Everett SM, Burr NE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966528>
13. **Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters.** Gut Microbes 2022; 14:2018900Sencio V, Machelart A, Robil C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965194>
14. **Acute Necrotizing Pancreatitis and Coronavirus Disease-2019 (COVID-19).** Korean J. Gastroenterol. 2021; 78:353-358Aday U, Gedik E, Kafadar MT, Özbek E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955513>
15. **Utilization of a SARS-CoV-2-positive donor for liver transplantation.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:62-63Wall AE, McKenna GJ, Onaca N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970035>
16. **Position statement of the Latin American Dysphagia Society for the management of oropharyngeal and esophageal dysphagia during the COVID-19 pandemic.** Rev Gastroenterol Mex (Engl Ed) 2021; 87:63-79Manzano-Aquihuatl C, Tobar-Fredes R, Zavala-Solares MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973937>
17. **Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients.** Vaccines (Basel) 2021; 9Timmermann L, Globke B, Lurje G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960168>

Guidelines (6 articles)

1. **Exploration of implementation, financial and technical considerations within allied health professional (AHP) telehealth consultation guidance: a scoping review including UK AHP professional bodies' guidance.** BMJ Open 2021; 11:e055823Leone E, Eddison N, Healy A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969656>
2. **Diagnostic value of 12-zone lung ultrasound protocol for diagnosing COVID-19-associated pneumonia in outpatients.** J Ultrason 2021; 21:e271-e276Haurylenka D, Damantsevich V, Filustsin A, Damantsevich A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970436>
3. **Social determinants of adherence to COVID-19 preventive guidelines: a comprehensive review.** Osong Public Health Res Perspect 2021; 12:346-360Shushtari ZJ, Salimi Y, Ahmadi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965686>

4. **Position statement of the Latin American Dysphagia Society for the management of oropharyngeal and esophageal dysphagia during the COVID-19 pandemic.** Rev Gastroenterol Mex (Engl Ed) 2021; 87:63-79Manzano-Aquihuatl C, Tobar-Fredes R, Zavala-Solares MR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34973937>
5. **COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information.** Rev. Recent Clin. Trials 2021; Davide M, Kamposioras K, Lampriani T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967300>
6. **Implications of WHO COVID-19 interim guideline 2020.5 on the comprehensive care for infected persons in Africa Before, during and after clinical management of cases.** Sci Afr 2022; 15:e01083Fagbamigbe AF, Tolba MF, Amankwaa EF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957351>

Imaging (17 articles)

1. **Clinical and imaging features of adult COVID-19 patients with and without comorbidities.** Asian J. Surg. 2021; Xing LH, Xie RM, Ni ZY, Yin XP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969576>
2. **A computer-aided diagnosis system for the classification of COVID-19 and non-COVID-19 pneumonia on chest X-ray images by integrating CNN with sparse autoencoder and feed forward neural network.** Comput. Biol. Med. 2021; 141:105134J LG, Abraham B, M SS, Nair MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34971978>
3. **Development of computer-aided model to differentiate COVID-19 from pulmonary edema in lung CT scan: EDECOVID-net.** Comput. Biol. Med. 2021; 141:105172Velichko E, Shariaty F, Orooji M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34973585>
4. **Radiology During the COVID-19 Pandemic: Mapping Radiology Literature in 2020.** Curr Med Imaging 2021; Al-Ryalat N, Malkawi L, Abu Salhiyeh A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967299>
5. **Clinical Value of COVID-19 Chest Radiography and High-Resolution CT Examination.** Curr Med Imaging 2021; Wang D, Shang Y, Chen Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967290>
6. **xViTCOS: Explainable Vision Transformer Based COVID-19 Screening Using Radiography.** IEEE J Transl Eng Health Med 2022; 10:1100110Mondal AK, Bhattacharjee A, Singla P, Prathosh AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956741>
7. **Impact of Pectoral Muscle Values on Clinical Outcomes in Patients With Severe Covid-19 Disease.** In Vivo 2022; 36:375-380Kardas H, Thormann M, Bär C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972737>
8. **Does the initial chest radiograph severity in COVID-19 impact the short- and long-term outcome? - a perspective from India.** Infect Dis (Lond) 2021;1-10D'Souza M M, Kaushik A, Dsouza JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961400>
9. **Diagnostic value of 12-zone lung ultrasound protocol for diagnosing COVID-19-associated pneumonia in outpatients.** J Ultrason 2021; 21:e271-e276Haurylenka D, Damantsevich V, Filustsin A, Damantsevich A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34970436>

10. **Which criteria were used to describe patients with COVID-19? A systematic review and meta analysis of clinical, laboratory, and imaging features.** Med. J. Islam. Repub. Iran 2021; 35:112Amanollahi A, Sotoodeh Ghorbani S, Basir Ghafouri H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956958>
11. **Automatic coronavirus disease 2019 diagnosis based on chest radiography and deep learning - Success story or dataset bias?** Med. Phys. 2021; Dhont J, Wolfs C, Verhaegen F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951033>
12. **Adaptive UNet-based Lung Segmentation and Ensemble Learning with CNN-based Deep Features for Automated COVID-19 Diagnosis.** Multimed Tools Appl 2021;1-35Das A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955679>
13. **The optical coherence tomography angiography study on paediatric COVID-19 cases.** Photodiagnosis Photodyn. Ther. 2021; 37:102710Au SCL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974164>
14. **Imaging findings in invasive rhino-orbito-cerebral mucormycosis in post-COVID-19 patients.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:32-34Jindal G, Sethi A, Bhargarva K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970028>
15. **Diagnostic Approach for Accurate Diagnosis of COVID-19 Employing Deep Learning and Transfer Learning Techniques through Chest X-ray Images Clinical Data in E-Healthcare.** Sensors (Basel) 2021; 21Haq AU, Li JP, Ahmad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960313>
16. **Medical imaging of pulmonary disease in SARS-CoV-2-exposed non-human primates.** Trends Mol. Med. 2021; Stammes MA, Lee JH, Meijer L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955425>
17. **The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries.** Viruses 2021; 13Dos Santos Ferreira CE, Gómez-Dantés H, Junqueira Bellei NC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960660>

Immune response (50 articles)

1. **Comprehensive serologic profile and specificity of maternal and neonatal cord blood SARS-CoV-2 antibodies.** AJOG Glob Rep 2022; 2:100046Boelig RC, Chaudhury S, Aghai ZH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961853>
2. **The Perioperative Patient Experience During COVID-19.** Am. Surg. 2021;31348211061100Dippre AT, Quinn KM, Walto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965161>
3. **COVID-19 vaccination and breakthrough infections in patients with cancer.** Ann Oncol 2021; Schmidt AL, Labaki C, Hsu CY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958894>
4. **Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.** BMC Cancer 2021; 21:1354Greenberg RS, Ruddy JA, Boyarsky BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961488>
5. **COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoral and cellular immunity.** Br. J. Haematol. 2021; Shen Y, Freeman JA, Holland J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962656>
6. **Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response.** Cell Host

- Microbe 2022; 30:83-96.e84Lin CY, Wolf J, Brice DC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34965382>
7. **Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers.** Cell Host Microbe 2022; 30:69-82.e10Vanshylla K, Fan C, Wunsch M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973165>
 8. **Not all SARS-CoV-2 IgG and neutralizing antibody assays are created equal.** Clin Chim Acta 2021; 526:81-82Lippi G, Plebani M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34958752>
 9. **Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring.** Clin Immunol 2022; 234:108918Cristiano A, Pieri M, Sarubbi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971839>
 10. **Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Healthcare Workers After Vaccine Administration in an Intensive Care Unit.** Cureus 2021; 13:e20579Lemos C, Ferreira S, Gouveia C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34963873>
 11. **Immunity to SARS CoV-2 - Strengths and weaknesses.** Deutsche Medizinische Wochenschrift 2021; 146:1624-1635Niehues T.
 12. **PEDOT-AuNPs-based impedimetric immunosensor for the detection of SARS-CoV-2 antibodies.** Electrochim Acta 2022; 404:139757Lorenzen AL, Dos Santos AM, Dos Santos LP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955549>
 13. **SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After Vaccination.** Front. Immunol. 2021; 12:798859Pinilla YT, Heinzel C, Caminada LF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956236>
 14. **Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.** Front. Immunol. 2021; 12:781843Pitzalis M, Idda ML, Lodde V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956211>
 15. **Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.** Front. Immunol. 2021; 12:790469Zhang L, Poorbaugh J, Dougan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956222>
 16. **Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants.** Front Med (Lausanne) 2021; 8:769845Seree-Aphinan C, Chanprapaph K, Rattanakaemakorn P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957149>
 17. **Strategies to Estimate Prevalence of SARS-CoV-2 Antibodies in a Texas Vulnerable Population: Results From Phase I of the Texas Coronavirus Antibody Response Survey.** Front Public Health 2021; 9:753487Valerio-Shewmaker MA, DeSantis S, Swartz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970525>
 18. **Kinetics and persistence of anti-SARS-CoV-2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort.** Immun Inflamm Dis 2021; Šošić L, Paolucci M, Duda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965032>
 19. **Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare**

- Workers in Foggia, Italy.** *Infect Dis Ther* 2021;1-9Homan T, Fortunato F, Corso G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964938>
20. **Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis.** *Int J Infect Dis* 2021; 116:59-67Jahan N, Brahma A, Kumar MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968773>
 21. **Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses.** *J Clin Virol* 2022; 146:105060Anantharaj A, Gujjar S, Verma N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971849>
 22. **Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naïve and COVID-19 convalescent individuals.** *J Infect Dis* 2021; Luczkowiak J, Labiod N, Rivas G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963008>
 23. **The changing dynamics of neutralizing antibody response within 10 months of SARS-CoV-2 infections.** *J Med Virol* 2021; Bastug A, Bodur H, Aydos O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967013>
 24. **Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection.** *J Transl Med* 2021; 19:524Liu Y, Ebinger JE, Mostafa R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965855>
 25. **Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study.** *Lancet Reg Health Am* 2022; 6:100154Cerqueira-Silva T, Oliveira VA, Boaventura VS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957437>
 26. **Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study.** *Lancet Reg Health Eur* 2021:100287Lombardi A, Butta GM, Donnici L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961855>
 27. **Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.** *Medicina (Kaunas)* 2021; 57Olariu TR, Ursoniu S, Marincu I, Lupu MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946275>
 28. **Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients.** *Medicina (Kaunas)* 2021; 57Vaiciuniene R, Sitkauskienė B, Bumblyte IA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946272>
 29. **Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.** *Nat Cancer* 2021; 2:1321-1337Fendler A, Shepherd STC, Au L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950880>
 30. **Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials.** *Pathogens* 2021; 10Ma KS, Lee CC, Liu KJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959492>
 31. **Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel.** *Prev. Med.* 2021; 155:106947Saciuk Y, Kertes J, Mandel M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974072>
 32. **A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune-epithelial interface.** *Proc Natl Acad Sci U S A* 2022; 119Leon J, Michelson DA, Olejnik J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969849>
 33. **Impairment of T cells' antiviral and anti-inflammation immunities may be critical to death from COVID-19.** *R Soc Open Sci* 2021; 8:211606Zhang L, Li R,

Song G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950497>

34. **Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.** *Vaccine* 2022; 40:587-593 Manomaipiboon A, Phumisantiphong U, Maneerit J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969542>
35. **Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis.** *Vaccines (Basel)* 2021; 9Achtenichts L, Jakopp B, Oberle M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960216>
36. **Humoral Immune Response to SARS-CoV-2 Vaccination after a Booster Vaccine Dose in Two Kidney Transplant Recipients with Fabry Disease and Variable Secondary Immunosuppressive Regimens.** *Vaccines (Basel)* 2021; 9Bernea L, Ailioaie OR, Benhamouda N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960158>
37. **Comparison of the Development of SARS-Coronavirus-2-Specific Cellular Immunity, and Central Memory CD4+ T-Cell Responses Following Infection versus Vaccination.** *Vaccines (Basel)* 2021; 9Dennehy KM, Löll E, Dhillon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960185>
38. **Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study.** *Vaccines (Basel)* 2021; 9Firin D, Perra A, Campagna M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960224>
39. **Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection.** *Vaccines (Basel)* 2021; 9Guerrieri M, Francavilla B, Fiorelli D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960244>
40. **Comparison of SARS-CoV-2-Specific Antibodies in Human Milk after mRNA-Based COVID-19 Vaccination and Infection.** *Vaccines (Basel)* 2021; 9Juncker HG, Mulleners SJ, van Gils MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960222>
41. **Overview of Neutralizing Antibodies and Their Potential in COVID-19.** *Vaccines (Basel)* 2021; 9Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960121>
42. **Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients-Is It Related to Immunosuppression Only?** *Vaccines (Basel)* 2021; 9Nazaruk P, Monticolo M, Jędrzejczak AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960200>
43. **Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.** *Vaccines (Basel)* 2021; 9Shehab M, Alrashed F, Alfadhli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960217>
44. **Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients.** *Vaccines (Basel)* 2021; 9Timmermann L, Globke B, Lurje G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960168>
45. **Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers.** *Vaccines (Basel)* 2021; 9Trunfio M, Verga F, Ghisetti V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960123>

46. **Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection.** Vaccines (Basel) 2021; 9Wolszczak-Biedrzycka B, Bieńkowska A, Dorf J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960254>
47. **Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant.** Vaccines (Basel) 2021; 9Zhang R, Khong KW, Leung KY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960189>
48. **Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).** Viruses 2021; 13Ruetalo N, Flehmig B, Schindler M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960605>
49. **Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population.** Viruses 2021; 13Sariol CA, Serrano-Collazo C, Ortiz EJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960674>
50. **Microarray-Based Detection of Antibodies against SARS-CoV-2 Proteins, Common Respiratory Viruses and Type I Interferons.** Viruses 2021; 13Savvateeva E, Filippova M, Valuev-Elliston V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960822>

Management miscellaneous diseases (45 articles)

1. **Impact of the COVID-19 pandemic on the stage and the type of surgical treatment of laryngeal cancer.** Am. J. Otolaryngol. 2021; 43:103319Akbari M, Motiee-Langroudi M, Heidari F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968815>
2. **COVID-19 and varicocele: the possible overlap factors and the common therapeutic approaches.** Am. J. Reprod. Immunol. 2021; Mahdavinezhad F, Farmani AR, Pakniat H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967487>
3. **Lessons learnt from emergency medicine services during the COVID-19 pandemic: A case study of India and the United States.** Ann Med Surg (Lond) 2022; 73:103197Sarfraz Z, Sarfraz A, Sarfraz M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956642>
4. **Impact of the COVID-19 pandemic on drug-related problems and pharmacist interventions in geriatric acute care units.** Ann. Pharm. Fr. 2021; Chappe M, Corvaisier M, Brangier A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968479>
5. **[Impact of the COVID-19 pandemic on patient-reported patient safety in Primary Care].** Aten. Primaria 2021; 53 Suppl 1:102222Fiol-deRoque MA, Serrano-Ripol MJ, Gens-Barberà M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961582>
6. **[Patient safety incidents reported before and after the start of the COVID-19 pandemic in Primary Care in Tarragona].** Aten. Primaria 2021; 53 Suppl 1:102217Gens-Barberà M, Hernández-Vidal N, Castro-Muniain C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961580>
7. **Primary health care response in the management of pandemics: Learnings from the COVID-19 pandemic.** Aten. Primaria 2021; 53 Suppl 1:102226Li D, Howe

- AC, Astier-Peña MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961573>
8. **[A safe use of medications in Primary Care, in COVID-19 pandemic as well].** Aten. Primaria 2021; 53 Suppl 1:102223Torijano Casalengua ML, Calvo Pita C, Maderuelo-Fernández J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961581>
 9. **New-onset haemoptysis and associated lung mass in the setting of dental care avoidance during the COVID-19 pandemic.** BMJ Case Rep. 2021; 14Palmer G, Jamous F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969784>
 10. **Thoracic transplantation during the COVID-19 pandemic.** Clin. Transplant. 2021:e14575Ganapathi AM, Henn MC, Lampert BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964517>
 11. **Emergency Medical Service Utilization and Response Following COVID-19 Emergency and Stay-at-Home Policies: An Interrupted Time-Series Analysis.** Cureus 2021; 13:e19794O'Connor AW, Hannah HA, Burnor EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956784>
 12. **Radiology During the COVID-19 Pandemic: Mapping Radiology Literature in 2020.** Curr Med Imaging 2021; Al-Ryalat N, Malkawi L, Abu Salhiyeh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967299>
 13. **Combating the opioid epidemic in the United States.** Drugs Context 2021; 10Pickard AS, Lee TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970324>
 14. **How Does COVID-19 Pandemic Impact on Incidence of Clostridioides difficile Infection and Exacerbation of Its Gastrointestinal Symptoms?** Front Med (Lausanne) 2021; 8:775063Azimirad M, Noori M, Raeisi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966759>
 15. **Impact of the French National Lockdown on Admissions to 14 Pediatric Intensive Care Units During the 2020 COVID-19 Pandemic-A Retrospective Multicenter Study.** Front Pediatr 2021; 9:764583Breinig S, Mortamet G, Brossier D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956977>
 16. **Increased Use of Antibiotics in the Intensive Care Unit During Coronavirus Disease (COVID-19) Pandemic in a Brazilian Hospital.** Front. Pharmacol. 2021; 12:778386Silva ARO, Salgado DR, Lopes LPN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955847>
 17. **Does Confinement Affect Treatment Dropout Rates in Patients With Gambling Disorder? A Nine-Month Observational Study.** Front. Psychol. 2021; 12:761802Baenas I, Etxandi M, Codina E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970193>
 18. **Solidarity and HIV Testing Willingness During the COVID-19 Epidemic: A Study Among Men Who Have Sex With Men in China.** Front Public Health 2021; 9:752965Lyu H, Zhou Y, Dai W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957014>
 19. **From Pandemic to Endemic-Redefining Excellence in Thoracic Surgery Service Delivery.** Front Surg 2021; 8:741366Leow L, Tam JKC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957198>
 20. **Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic.** Frontline Gastroenterol. 2022; 13:89-90McGoran J, Wilson A, McErlain S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966537>
 21. **A European approach to infection prevention and control goals.** GMS Hyg Infect Control 2021; 16:Doc29Exner M, Christiansen B, Cocconi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956821>

22. **Drug markets and COVID-19: A spatiotemporal study of drug offence detection rates in Brisbane, Australia.** Int. J. Drug Policy 2021; 101:103561Payne JL, Langfield CT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965491>
23. **Bloodstream infections in hospitalized patients before and during the COVID-19 surge in a community hospital in the South Bronx.** Int J Infect Dis 2021; 116:43-46Afzal A, Gutierrez VP, Gomez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958930>
24. **Pediatric otolaryngology telemedicine amid a pandemic - And beyond.** Int J Pediatr Otorhinolaryngol 2021; 153:111014McCoy JL, Shaffer AD, Dohar JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974276>
25. **Recurrent appendicitis following successful drainage of appendicular abscess in adult without interval appendectomy during COVID-19. Prospective cohort study.** Int J Surg 2022; 97:106200Habeeb T, Hussain A, Schlottmann F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971815>
26. **Abol-Enein pouch modification after radical cystectomy in bladder rhabdomyosarcoma in 5 years old child during COVID-19 pandemic: A case report.** Int. J. Surg. Case Rep. 2022; 90:106701Ginting JT, Sigumonrong Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956826>
27. **Should coronavirus policies remain in place to prevent future paediatric influenza deaths?** J. Med. Ethics 2021; Perdomo D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969776>
28. **Epidemiology of influenza under the coronavirus disease 2019 pandemic in Nanjing, China.** J Med Virol 2021; Wu K, Wu X, Wang W, Hong L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964514>
29. **Nationwide analysis of plastic and reconstructive procedural volume in the United States during the COVID-19 pandemic.** J. Plast. Reconstr. Aesthet. Surg. 2021; Mehrabian D, Liu IZ, Pakhchanian HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955397>
30. **High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer.** J. Surg. Oncol. 2021; Crozier JA, Barone J, Whitworth P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964996>
31. **An Epidemic Within the Pandemic: The Rising Tide of Trauma During COVID-19.** J. Surg. Res. 2021; 272:139-145Mazzolini K, Dzubnar J, Kwak H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971837>
32. **Steroid injections in pain management: influence on coronavirus disease 2019 vaccines.** Korean J. Pain 2022; 35:14-21Hong SM, Park YW, Choi EJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966008>
33. **Impact of the COVID-19 pandemic on HIV testing rates across four geographically diverse urban centres in the United States: An observational study.** Lancet Reg Health Am 2022; 7:100159Moitra E, Tao J, Olsen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961858>
34. **The priority of audiological procedures during the COVID-19 pandemic.** Med. J. Islam. Repub. Iran 2021; 35:99Saki N, Topsakal V, Amiri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956945>
35. **Double Negative (DN) B cells: A connecting bridge between rheumatic diseases and COVID-19?** Mediterr J Rheumatol 2021; 32:192-199Sachinidis A, Garyfallos A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964023>

36. **Hip fracture care during the COVID-19 pandemic: retrospective cohort and literature review.** OTA Int 2022; 5:e165Topor L, Wood L, Switzer JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964041>
37. **Understanding the impact of the Covid-19 pandemic on delivery of rehabilitation in specialist palliative care services: An analysis of the CovPall-Rehab survey data.** Palliat. Med. 2021;2692163211063397Bayly J, Bradshaw A, Fettes L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964384>
38. **The return of RSV during the COVID-19 pandemic.** Pediatr Pulmonol 2021; Ferrero F, Ossorio MF, Rial MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951156>
39. **Phototherapy and dermatologic radiotherapy during the COVID-19 emergency: The experience from the frontline of Milan.** Photodermatol Photoimmunol Photomed 2021; Spigariolo CB, Piccinno R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957602>
40. **Shedding the light on Pharmacists' roles during COVID-19 global pandemic.** Saudi Pharm J 2022; 30:14-27Mohamed Ibrahim O, Ibrahim RM, Ibrahim YA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961807>
41. **Reductions in the Frequency of Going Out Due to the COVID-19 Pandemic Negatively Affect Patients with Spinal Disorders.** Spine Surg Relat Res 2021; 5:365-374Terai H, Iwamae M, Tamai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966862>
42. **Heparin and SARS-CoV-2: Multiple Pathophysiological Links.** Viruses 2021; 13Di Micco P, Imbalzano E, Russo V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960754>
43. **Impact of COVID-19 on non-COVID intensive care unit service utilization, case mix and outcomes: A registry-based analysis from India.** Wellcome Open Res 2021; 6:159Kj Adhikari N, Beane A, Devaprasad D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957335>
44. **Acute appendicitis-advances and controversies.** World J. Gastrointest. Surg. 2021; 13:1293-1314Teng TZJ, Thong XR, Lau KY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950421>
45. **The impact of treatment delay on skin cancer in COVID-19 era: a case-control study.** World J. Surg. Oncol. 2021; 19:350Seretis K, Boptsi E, Boptsi A, Lykoudis EG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34949189>

Management (35 articles)

1. **Tracheostomy care and communication during COVID-19: Global interprofessional perspectives.** Am. J. Otolaryngol. 2021; 43:103354Moser CH, Freeman-Sanderson A, Keeven E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968814>
2. **[Prevention of infections related to health care in primary care. Lessons from the pandemic].** Aten. Primaria 2021; 53 Suppl 1:102225Palacio Lapuente J, Martín Rodríguez MD, Aibar Remón C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961578>
3. **'Who will do it if I don't?' Nurse anaesthetists' experiences of working in the intensive care unit during the COVID-19 pandemic.** Aust. Crit. Care 2022; 35:52-58Hallgren J, Larsson M, Kjellén M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955333>

4. **Cost estimates of COVID-19 clinical management in Myanmar.** BMC Health Serv. Res. 2021; 21:1365Thant PW, Htet KT, Win WY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961536>
5. **Successful endovascular mechanical thrombectomy in anticoagulation-resistant COVID-19 associated cerebral venous sinus thrombosis.** BMJ Case Rep. 2021; 14Sajjad A, Khan AF, Jafri L, Kamal AK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34972772>
6. **Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study.** BMJ Open 2021; 11:e050051Wallace AW, Cirillo PM, Ryan JC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34972763>
7. **Association between tracheostomy timing and outcomes for older critically ill COVID-19 patients: prospective observational study in European intensive care units.** Br J Anaesth 2021; Polok K, Fronczek J, van Heerden PV *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955167>
8. **Oxygen: Friend or foe in the COVID-19 battle.** Clin Case Rep 2021; 9:e05254Chudasama K, Sangey E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963816>
9. **Description, Health Care Utilization, and Outcomes for Home Health Care (HHC) COVID-19 Patients Early in the Pandemic: A Comparison to the General HHC Population.** Home Health Care Manag Pract 2021; 33:296-304Videon TM, Rosati RJ, Landers SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955629>
10. **Prone Positioning in Patients With COVID-19: Analysis of Multicenter Registry Data and Meta-analysis of Aggregate Data.** In Vivo 2022; 36:361-370Kollias A, Kyriakoulis KG, Rapti V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972735>
11. **"Compassion Cannot Choose:" A Call for Family-centered Critical Care during the COVID-19 Pandemic.** Indian J. Crit. Care Med. 2021; 25:1049-1050Mohan M, Joy LF, Sivasankar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963725>
12. **Recurrent appendicitis following successful drainage of appendicular abscess in adult without interval appendectomy during COVID-19. Prospective cohort study.** Int J Surg 2022; 97:106200Habeeb T, Hussain A, Schlottmann F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34971815>
13. **Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register.** Intern Emerg Med 2022;1-9Poli D, Antonucci E, Ageno W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34973126>
14. **The other side of COVID-19: Preliminary results of a descriptive study on the COVID-19-related psychological impact and social determinants in Portugal residents.** J Affect Disord Rep 2022; 7:100294Aguiar A, Maia I, Duarte R, Pinto M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961856>
15. **Association Between Metformin Use and Mortality among Patients with Type 2 Diabetes Mellitus Hospitalized for COVID-19 Infection.** J ASEAN Fed Endocr Soc 2021; 36:133-141Ong AN, Tan CC, Cañete MT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966196>
16. **Pathways to recovery from COVID-19: characterizing input-output linkages of a targeted sector.** J Econ Struct 2021; 10:29Temel T, Phumpiu P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961836>
17. **A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic.** J Med Virol 2021; Dragioti E, Li H, Tsitsas G *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958144>
18. **Nurses' spiritual well-being and the COVID-19 pandemic: A thematic approach.** J. Nurs. Manag. 2021; Alquwez N, Cruz JP, Balay-Odao EM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34965000>
 19. **Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic.** J Obsessive Compuls Relat Disord 2022; 32:100706 Flannery MK, Coyne AF, Carlson EJ, Haaga DAF.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956828>
 20. **The impact of multiple non-pharmaceutical interventions on controlling COVID-19 outbreak without lockdown in Hong Kong: A modelling study.** Lancet Reg Health West Pac 2021;100343 Yuan HY, Blakemore C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957427>
 21. **Mediterranean Diet a Potential Strategy against SARS-CoV-2 Infection: A Narrative Review.** Medicina (Kaunas) 2021; 57 Ferro Y, Pujia R, Maurotti S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946334>
 22. **Nursing Surge Capacity Strategies for Management of Critically Ill Adults with COVID-19.** Nurs Rep 2020; 10:23-32 Al Mutair A, Amr A, Ambani Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34968261>
 23. **Nurses' Knowledge and Anxiety Levels toward COVID-19 in Saudi Arabia.** Nurs Rep 2021; 11:356-363 Alsharif F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968212>
 24. **The Year of the Nurse during the COVID-19 Pandemic.** Nurs Rep 2021; 11:753-757 Bartosiewicz A, Harpula K, Łuszczki E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968265>
 25. **Nurses and Doctors Heroes? A Risky Myth of the COVID19 Era.** Nurs Rep 2020; 10:37-40 Bellieni CV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968347>
 26. **The Impact of the Coronavirus Disease (COVID-19) Pandemic on Nurses' Turnover Intention: An Integrative Review.** Nurs Rep 2021; 11:787-810 Falatah R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968269>
 27. **Healthcare Management and Quality during the First COVID-19 Wave in a Sample of Spanish Healthcare Professionals.** Nurs Rep 2021; 11:536-546 Torrent-Ramos P, González-Chordá VM, Mena-Tudela D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34968329>
 28. **Vitamin D Dosing: Basic Principles and a Brief Algorithm (2021 Update).** Nutrients 2021; 13 Bleizgys A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959969>
 29. **Beneficial Properties of Bromelain.** Nutrients 2021; 13 Hikisz P, Bernasinska-Slomczewska J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959865>
 30. **Psychological withdrawal and mental health during the COVID-19 pandemic: a longitudinal study.** Psychol. Health 2021;1-17 Ubillos-Landa S, Puente-Martínez A, González-Castro JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955057>
 31. **National hospital readiness for COVID-19 in Lesotho: evidence for oxygen ecosystem strengthening.** Public Health Action 2021; 11:180-185 Sanders JE, Chakare T, Mapota-Masoabi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956845>
 32. **Enoxaparin dose impacts blood cell phenotypes during mild SARS-CoV-2 infection: the observational single-center study.** Rev Cardiovasc Med 2021; 22:1685-1691 Buryachkovskaya L, Lomakin N, Melkumyants A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957811>

33. **Safety assessment for temporary hospitals during the COVID-19 pandemic: A simulation approach.** Saf Sci 2022; 147:105642 Campos AT, Dos Santos CH, Gabriel GT, Montevechi JAB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955606>
34. **Rehabilitation in post acute COVID-19.** Sports Orthopaedics and Traumatology 2021; 37:242-248 Jarosch I, Koczulla AR.
35. **[Hyperbaric oxygenation in outpatient rehabilitation of COVID-19 convalescents].** Vopr. Kurortol. Fizioter. Lech. Fiz. Kult. 2021; 98:16-21 Turova EA, Shchikota AM, Pogonchenkova IV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965691>

Mental – public health (126 articles)

1. **Substance, use in relation to COVID-19: A scoping review.** Addict. Behav. 2022; 127:107213 Kumar N, Janmohamed K, Nyhan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959077>
2. **Enhancing the effectiveness of contact tracing interviews: A randomized controlled experiment of an enhanced cognitive interview protocol.** Am. J. Infect. Control 2021; Evans JR, Dawson HR, Chae H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971713>
3. **Changes in the body mass of adult residents of rural and urban areas in the initial months of the COVID-19 pandemic vs. their mental, physical and sexual health.** Ann. Agric. Environ. Med. 2021; 28:667-675 Białorudzki M, Izdebski Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969227>
4. **Ageing policy in Poland during the COVID-19 pandemic.** Ann. Agric. Environ. Med. 2021; 28:551-557 Lutomski P, Kaczoruk M, Florek-Łuszczki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969210>
5. **Adherence to Recommended Preventive Behaviors During the COVID-19 Pandemic: The Role of Empathy and Perceived Health Threat.** Ann. Behav. Med. 2021; Morstead T, Zheng J, Sin NL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964460>
6. **Symptom changes in patients with pre-existing psychiatric disorders in the initial phase of the COVID-19 pandemic: Vulnerability of female patients and patients with mood disorders.** Asian J Psychiatr 2021; 68:102966 Kurose S, Funayama M, Takata T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974375>
7. **Rising incidence and changing demographics of suicide in India: Time to recalibrate prevention policies?** Asian J Psychiatr 2021; 69:102983 Menon V, Cherian AV, Vijayakumar L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974320>
8. **Monitoring Australian parents' shifting receptiveness to digital mental health interventions during the COVID-19 pandemic.** Aust. N. Z. J. Psychiatry 2021:48674211065985 Linardon J, Westrupp EM, Macdonald JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963330>
9. **Randomized clinical trial of a brief, scalable intervention for mental health sequelae in college students during the COVID-19 pandemic.** Behav. Res. Ther. 2021; 149:104015 Rizvi SL, Finkelstein J, Wacha-Montes A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958980>
10. **The effects of the COVID-19 pandemic on psychological stress in breast cancer patients.** BMC Cancer 2021; 21:1356 Bartmann C, Fischer LM, Hübner T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972520>

11. **Psychological impacts of the COVID-19 pandemic on one-month postpartum mothers in a metropolitan area of Japan.** BMC Pregnancy Childbirth 2021; 21:845Takubo Y, Tsujino N, Aikawa Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963448>
12. **Mind the "worry fatigue" amid Omicron scares.** Brain Behav Immun 2021; 101:60-61Su Z, McDonnell D, Ahmad J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973394>
13. **Depression and anxiety among College Students in Slovakia - Comparison of the Year 2018 and during COVID-19 pandemic.** Bratisl. Lek. Listy 2022; 123:44-49Hajduk M, Dancik D, Januska J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967657>
14. **COVID-19 distress, negative parenting, and child behavioral problems: The moderating role of parent adverse childhood experiences.** Child Abuse Negl. 2021:105450Hails KA, Petts RA, Hostutler CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969517>
15. **Prevalence of and risk factors for depressive and anxiety symptoms in a large sample of Chinese adolescents in the post-COVID-19 era.** Child Adolesc Psychiatry Ment Health 2021; 15:80Zhang X, Yang H, Zhang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961519>
16. **Perceived impact of lockdown on daily life in children with physical disabilities and their families during the COVID-19 pandemic.** Child Care Health Dev. 2021; Vargue R, Brochard S, Bouvier S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964148>
17. **Psychological trauma and emotional upheaval as revealed in academic writing: The case of COVID-19.** Cogn. Emot. 2021:1-14Markowitz DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965201>
18. **Impact of COVID-19 on Children's and Adolescent's Mental Health in Saudi Arabia.** Cureus 2021; 13:e19786Almhizai RA, Almogren SH, Altwijery NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963826>
19. **Heterogeneity in maternal and child mental health responses to the COVID-19 pandemic.** Early Child Res Q 2022; 59:203-214Saleem S, Burns S, Falenchuk O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955597>
20. **Psychological factors affecting COVID-19 vaccine acceptance in Indonesia.** Egypt J Neurol Psychiatr Neurosurg 2021; 57:177Yanto TA, Octavius GS, Heriyanto RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955630>
21. **Evaluating the Factors (Stress, Anxiety and Depression) Affecting the Mental Health Condition of Nurses During the COVID-19 Pandemic.** Eval. Health Prof. 2021:1632787211062660Işık O, Tengilimoğlu D, Tosun N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968162>
22. **A Perspective on Intimate Partner Violence Since COVID-19.** Front Glob Womens Health 2021; 2:788061Khan R, David S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957468>
23. **SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After Vaccination.** Front. Immunol. 2021; 12:798859Pinilla YT, Heinzl C, Caminada LF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956236>
24. **How Is the History of Early Traumatic Exposure Associated With the Psychopathological Outcomes of COVID-19 Related Lockdown and Subsequent Re-opening in People With Eating Disorders?** Front Psychiatry

- 2021; 12:789344Cascino G, Marciello F, Abbate-Daga G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955933>
25. **The Association Between Changes in the University Educational Setting and Peer Relationships: Effects in Students' Depressive Symptoms During the COVID-19 Pandemic.** *Front Psychiatry* 2021; 12:783776Conceição V, Rothes I, Gusmão R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970167>
 26. **Psychosocial Factors Associated With Increased Adolescent Non-suicidal Self-Injury During the COVID-19 Pandemic.** *Front Psychiatry* 2021; 12:743526Du N, Ouyang Y, Xiao Y, Li Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955911>
 27. **Association Between Time Spent With Family and Loneliness Among Japanese Workers During the COVID-19 Pandemic: A Cross-Sectional Study.** *Front Psychiatry* 2021; 12:786400Fujii R, Konno Y, Tateishi S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955931>
 28. **Liaison Psychiatry During the Peak of the Coronavirus Pandemic: A Description of Referrals and Interventions.** *Front Psychiatry* 2021; 12:555080López-Atanes M, González-Briceño JP, Abeal-Adham A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955903>
 29. **Pre-pandemic Predictors of Loneliness in Adult Men During COVID-19.** *Front Psychiatry* 2021; 12:775588Mansour KA, Greenwood CJ, Biden EJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955922>
 30. **Bidirectional Associations Between Depressive and Anxiety Symptoms and Loneliness During the COVID-19 Pandemic: Dynamic Panel Models With Fixed Effects.** *Front Psychiatry* 2021; 12:738892McDowell CP, Meyer JD, Russell DW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955910>
 31. **Physical and Psychosocial Well-Being of Hospitalized and Non-Hospitalized Patients With COVID-19 Compared to the General Population in Qatar.** *Front Psychiatry* 2021; 12:792058Ouanes S, Al-Amin H, Hussein NB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966311>
 32. **Financial Difficulties Correlate With Mental Health Among Bangladeshi Residents Amid COVID-19 Pandemic: Findings From a Cross-Sectional Survey.** *Front Psychiatry* 2021; 12:755357Siddique AB, Nath SD, Islam MS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955916>
 33. **Relationships Between Cross-Cultural Adaption, Perceived Stress and Psychological Health Among International Undergraduate Students From a Medical University During the COVID-19 Pandemic: A Moderated Mediation Model.** *Front Psychiatry* 2021; 12:783210Wang X, Lu L, Wang X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955929>
 34. **Analysis of Anxiety and Depression Status in Patients Undergoing Radiotherapy During the COVID-19 Epidemic.** *Front Psychiatry* 2021; 12:771621Yang L, Yang J, He J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955920>
 35. **Post-secondary Student Mental Health During COVID-19: A Meta-Analysis.** *Front Psychiatry* 2021; 12:777251Zhu J, Racine N, Xie EB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955924>
 36. **Cross-Lagged Analysis of COVID-19-Related Worry and Media Consumption in a Socioeconomically Disadvantaged Sample of Community Adults.** *Front. Psychol.* 2021; 12:728629Bounoua N, Goodling S, Sadeh N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955958>

37. **Teaching and Learning in COVID-19 Lockdown in Scotland: Teachers' Engaged Pedagogy.** *Front. Psychol.* 2021; 12:733633Colville T, Hulme S, Kerr C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955961>
38. **Components of Unrealistic Optimism of College Students: The Case of the COVID-19 Pandemic.** *Front. Psychol.* 2021; 12:763581Eshel Y, Kimhi S, Marciano H, Adini B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966325>
39. **Cultural Management of Terror and Worry During the COVID-19 Pandemic: How Religiosity and a Dream of Human Solidarity Help the Polish People Cope.** *Front. Psychol.* 2021; 12:790333Gut A, Miciuk Ł, Gorbaniuk O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956016>
40. **Psychological Impact of the COVID-19 Pandemic on Healthcare Professionals in Tunisia: Risk and Protective Factors.** *Front. Psychol.* 2021; 12:754047Hammami AS, Jellazi M, Mahjoub L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970189>
41. **Push-Pull-Mooring Analysis of Massive Open Online Courses and College Students During the COVID-19 Pandemic.** *Front. Psychol.* 2021; 12:755137Kang K, Wang T, Chen S, Su YS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955974>
42. **Risk and Protective Factors for the Mental Wellbeing of Deployed Healthcare Workers During the COVID-19 Pandemic in China: A Qualitative Study.** *Front. Psychol.* 2021; 12:773510Khoo VPH, Ting RS, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955992>
43. **Cognitive and Affective-Motivational Factors as Predictors of Students' Home Learning During the School Lockdown.** *Front. Psychol.* 2021; 12:751120Lockl K, Attig M, Nusser L, Wolter I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955970>
44. **Is Posttraumatic Growth Helpful in Overcoming Mental Health Disorders Due to COVID-19?: The Moderating Effect of Posttraumatic Growth in the Relationship Between COVID-19 and Psychological Health.** *Front. Psychol.* 2021; 12:773326Park SR, Im SY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955990>
45. **Analysis of Factors That Influenced the Mental Health Status of Public Health Workers During the COVID-19 Epidemic Based on Bayesian Networks: A Cross-Sectional Study.** *Front. Psychol.* 2021; 12:755347Peng X, Pu Y, Jiang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955975>
46. **Corrigendum: Individual, Sociodemographic, and Environmental Factors Related to Physical Activity During the Spring 2020 COVID-19 Lockdown.** *Front. Psychol.* 2021; 12:816463Teran-Escobar C, Forestier C, Ginoux C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956034>
47. **Influence of Parental Psychological Flexibility on Pediatric COVID-19 Vaccine Hesitancy: Mediating Role of Self-Efficacy and Coping Style.** *Front. Psychol.* 2021; 12:783401Wang Y, Zhang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956003>
48. **Editorial: COVID-19 and Existential Positive Psychology (PP2.0): The New Science of Self-Transcendence.** *Front. Psychol.* 2021; 12:800308Wong PTP, Mayer CH, Arslan G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956025>
49. **Positive Emotion Regulations Among English as a Foreign Language Teachers During COVID-19.** *Front. Psychol.* 2021; 12:807541Zhao H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966341>
50. **Challenges and Opportunities for Public Health Service in Oman From the COVID-19 Pandemic: Learning Lessons for a Better Future.** *Front Public Health*

- 2021; 9:770946Al Khalili S, Al Maani A, Al Wahaibi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957024>
51. **Knowledge, Attitudes, and Practices Toward COVID-19 Among the General Public in the Border Region of Jazan, Saudi Arabia: A Cross-Sectional Study.** Front Public Health 2021; 9:733125Almalki MJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957005>
 52. **Anxiety, Anger and Depression Amongst Low-Income Earners in Southwestern Uganda During the COVID-19 Total Lockdown.** Front Public Health 2021; 9:590458Archibong V, Usman IM, Kasozi KI *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956994>
 53. **COVID-19 Related Experiences Among College Students With and Without Disabilities: Psychosocial Impacts, Supports, and Virtual Learning Environments.** Front Public Health 2021; 9:782793McMaughan DJ, Rhoads KE, Davis C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957033>
 54. **Occupational Stress and Mental Health Among Healthcare Workers Serving Socially Vulnerable Populations During the COVID-19 Pandemic.** Front Public Health 2021; 9:782846Salgado de Snyder VN, Villatoro AP, McDaniel MD *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957034>
 55. **Psychometric Properties of the Persian Version of the Center for Epidemiological Studies Depression Scale Among the Iranian Public People During COVID-19 Pandemic.** Front Public Health 2021; 9:728904Sharif Nia H, Rahmatpour P, Sivarajan Froelicher E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970522>
 56. **Mental Disorders and Emotional Competence Among Chinese Adolescents Before and During COVID-19 Pandemic: A Longitudinal Mediation Model.** Front Public Health 2021; 9:767004Shi W, Yuan GF, Hall BJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957019>
 57. **The Impact of COVID-19 on Physical Performance and Mental Health-A Retrospective Case Series of Belgian Male Professional Football Players.** Front Sports Act Living 2021; 3:803130Wagemans J, Catteeuw P, Vandenhouten J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966896>
 58. **Medical students' mental burden and experiences of voluntary work in COVID-19 patient support and treatment services: a qualitative analysis.** GMS J Med Educ 2021; 38:Doc120Nikendei C, Dinger-Ehrenthal U, Schumacher F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957325>
 59. **Evaluating child maltreatment and family violence risk during the COVID-19 Pandemic: Using a telehealth home visiting program as a conduit to families.** Infant Ment Health J 2021; Bullinger LR, Marcus S, Reuben K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969151>
 60. **Taking care of the caregivers: The moderating role of reflective supervision in the relationship between COVID-19 stress and the mental and professional well-being of the IECMH workforce.** Infant Ment Health J 2022; Morelen D, Najm J, Wolff M, Daniel K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973059>
 61. **When the Bough Breaks: A systematic review and meta-analysis of mental health symptoms in mothers of young children during the COVID-19 pandemic.** Infant Ment Health J 2021; Racine N, Eirich R, Cooke J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34962649>
 62. **Increased behavioral health needs and continued psychosocial stress among children with medical complexity and their families during the COVID-19**

- pandemic.** *Infant Ment Health J* 2022; von Schulz J, Serrano V, Buchholz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973062>
63. **Gender Inequality and Mental Health During the COVID-19 Pandemic.** *Int J Public Health* 2021; 66:1604220Borrescio-Higa F, Valenzuela P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955701>
 64. **Mental health of Turkish medical students during the COVID-19 pandemic.** *Int J Soc Psychiatry* 2021;207640211066734Çimen İ D, Alvur TM, Coşkun B, Şükür N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961373>
 65. **Trend and gender-based association of the Bangladeshi student suicide during the COVID-19 pandemic: a GIS-based nationwide distribution.** *Int J Soc Psychiatry* 2021;207640211065670Mamun MA, Mamun MA, Hosen I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961356>
 66. **Experiences and perceptions of Turkish intensive care nurses providing care to Covid-19 patients: A qualitative study.** *Int Nurs Rev* 2021; Sezgin D, Dost A, Esin MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962292>
 67. **Miasmas, mental models and preventive public health: some philosophical reflections on science in the COVID-19 pandemic.** *Interface Focus* 2021; 11:20210017Greenhalgh T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956591>
 68. **Insights into the impact on daily life of the COVID-19 pandemic and effective coping strategies from free-text analysis of people's collective experiences.** *Interface Focus* 2021; 11:20210051Hampshire A, Hellyer PJ, Trender W, Chamberlain SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956602>
 69. **A year of living distantly: global trends in the use of stay-at-home orders over the first 12 months of the COVID-19 pandemic.** *Interface Focus* 2021; 11:20210041Phillips T, Zhang Y, Petherick A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956599>
 70. **Effects of an internet-based self-help intervention for psychological distress due to COVID-19: Results of a randomized controlled trial.** *Internet Interv* 2022; 27:100492Brog NA, Hegy JK, Berger T, Znoj H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956841>
 71. **Children and Adolescents' Behavioral Patterns in Response to Escalating COVID-19 Restriction Reveal Sex and Age Differences.** *J. Adolesc. Health* 2021; Paulsen M, Zychlinsky Scharff A, de Cassan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972613>
 72. **Assessment of the difference in depressive symptoms of the Korean adult population before and during the COVID-19 pandemic using a community health survey.** *J. Affect. Disord.* 2021; 300:130-136Kim SY, Yoo DM, Min C, Choi HG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965394>
 73. **Evaluation of peritraumatic distress at the point of care: A cross-sectional study.** *J. Affect. Disord.* 2021; 300:563-570Pontoni G, Caiolo S, Miola A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965402>
 74. **The other side of COVID-19: Preliminary results of a descriptive study on the COVID-19-related psychological impact and social determinants in Portugal residents.** *J Affect Disord Rep* 2022; 7:100294Aguiar A, Maia I, Duarte R, Pinto M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961856>
 75. **Learning it the hard way - how enjoying life and positive appraisal buffer the negative effects of stressors on mental health in the COVID-19 pandemic.** *J Affect Disord Rep* 2021; 6:100200Daniels A, Wellan SA, Walter H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957432>

76. **An analysis of antidepressant prescribing trends in England 2015-2019.** J Affect Disord Rep 2021; 6:100205Lalji HM, McGrogan A, Bailey SJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957433>
77. **Factors associated with county-level mental health during the COVID-19 pandemic.** J. Community Psychol. 2021; Lupton-Smith C, Badillo-Goicochea E, Chang TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969152>
78. **Lockdown, essential sectors, and Covid-19: Lessons from Italy.** J. Health Econ. 2021; 81:102572Porto ED, Naticchioni P, Scrutinio V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34958981>
79. **The relationship between COVID-19-induced death thoughts and depression during a national lockdown.** J Health Psychol 2021:13591053211067102Fairlamb S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964383>
80. **The Continuing Effect of COVID-19 Pandemic on Physical Well-Being and Mental Health of ICU Healthcare Workers in Turkey: A Single-Centre Cross-Sectional Later-Phase Study.** J. Intensive Care Med. 2021:8850666211070740Duru H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967250>
81. **"Everyone is Living in the Same Storm, but our Boats are all Different": Safety and Safety Planning for Survivors of Intimate Partner and Sexual Violence During the COVID-19 Pandemic.** J Interpers Violence 2021:8862605211062998Schrag RV, Leat S, Wood L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34964394>
82. **Nurses' mental health from early COVID-19 pandemic to vaccination.** J. Nurs. Scholarsh. 2021; Kim SC, Rankin L, Ferguson J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967492>
83. **Efficacy of intensive CBT telehealth for obsessive-compulsive disorder during the COVID-19 pandemic.** J Obsessive Compuls Relat Disord 2022; 32:100705Pinciotti CM, Bulkes NZ, Horvath G, Riemann BC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956827>
84. **Tackling the Pandemic a year later: Burnout among Home Palliative Care Clinicians.** J Pain Symptom Manage 2021; Ercolani G, Varani S, Ostan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973353>
85. **Association between mask wearing and anxiety symptoms during the outbreak of COVID 19: A large survey among 386,432 junior and senior high school students in China.** J. Psychosom. Res. 2021; 153:110709Xu Q, Mao Z, Wei D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963065>
86. **Experiences of Stress - A Focus Group Interview Study Among Swedish Adolescents During the COVID-19 Pandemic.** J. Sch. Nurs. 2021:10598405211071002Hörbo M, Johansson C, Garnow T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967254>
87. **Impact of the COVID-19 Pandemic on the Psychosexual Functions of Healthcare Workers.** J. Sex. Med. 2021; Eroglu U, Balci M, Coser S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963570>
88. **Disturbances in sleep, circadian rhythms and daytime functioning in relation to coronavirus infection and Long-COVID - A multinational ICOS study.** J. Sleep Res. 2021:e13542Merikanto I, Dauvilliers Y, Chung F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964184>
89. **Professional and psychological perceptions of emergency nurses during the COVID-19 pandemic: A qualitative study.** Jpn. J. Nurs. Sci.

- 2021:e12470Kandemir D, Yılmaz A, Sönmez B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34970852>
90. **The profile of musculoskeletal pain and its associations with sleep quality and depression during the COVID-19 in Turkey.** Korean J. Pain 2022; 35:78-85Karatel M, Bulut ZI, Sari EO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966014>
 91. **COVID-19 Related Fears of Patients Admitted to a Psychiatric Emergency Department during and Post-Lockdown in Switzerland: Preliminary Findings to Look Ahead for Tailored Preventive Mental Health Strategies.** Medicina (Kaunas) 2021; 57Costanza A, Macheret L, Folliet A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946305>
 92. **Protective and Non-Protective Factors of Mental Health Distress in the United States during the COVID-19 Pandemic: A Systematic Review.** Medicina (Kaunas) 2021; 57Lieneck C, Bosworth M, Weaver E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946322>
 93. **Mental Health and Associated Demographic and Occupational Factors among Health Care Workers during the COVID-19 Pandemic in Latvia.** Medicina (Kaunas) 2021; 57Valaine L, Ancāne G, Utināns A, Brīģis Ģ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946326>
 94. **Risk mitigation behaviors to prevent infection in the mitochondrial disease community during the COVID-19 pandemic.** Mol Genet Metab Rep 2022; 30:100837Gordon-Lipkin E, Kruk S, Thompson E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956836>
 95. **Nurses' Knowledge and Anxiety Levels toward COVID-19 in Saudi Arabia.** Nurs Rep 2021; 11:356-363Alsharif F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968212>
 96. **Stress and Coping Strategies among Nursing Students in Clinical Practice during COVID-19.** Nurs Rep 2021; 11:629-639Hamadi HY, Zakari NMA, Jibreel E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968338>
 97. **Impacts of Coping Mechanisms on Nursing Students' Mental Health during COVID-19 Lockdown: A Cross-Sectional Survey.** Nurs Rep 2021; 11:36-44Kim SC, Sloan C, Montejano A, Quiban C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968310>
 98. **Stressors and Coping Strategies among Nursing Students during the COVID-19 Pandemic: Scoping Review.** Nurs Rep 2021; 11:444-459Majrashi A, Khalil A, Nagshabandi EA, Majrashi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968220>
 99. **Destructive Role of COVID-19 Fear on Nurses Performance: Mediating Role of Stress.** Nurs Rep 2021; 11:955-964Yousaf Z, Nassani AA, Haffar M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34968281>
 100. **The Relationship Between Death Anxiety and Religious Coping Styles in Patients Diagnosed With COVID-19: A Sample in the East of Turkey.** Omega (Westport) 2021; 302228211065256Özer Z, Aksoy M, Turan GB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969296>
 101. **Social determinants of adherence to COVID-19 preventive guidelines: a comprehensive review.** Osong Public Health Res Perspect 2021; 12:346-360Shushtari ZJ, Salimi Y, Ahmadi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965686>
 102. **[Development of loneliness in old age in times of COVID-19].** OZS Osterr Z Soziol 2021; 46:443-455Richter L, Heidinger T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955620>

103. **Counseling Veterans with Chronic Pain during the COVID-19 Pandemic: A Secondary Analysis of a Randomized Controlled Trial.** Pain Med. 2021; Lazar CM, Rosen MI, Sellinger J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958381>
104. **Factors associated with psychosocial problems in Korean nursing and non-nursing students during the COVID-19 pandemic.** PeerJ 2021; 9:e12541Ha J, Park D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966583>
105. **A cross-sectional study for the mental health status and sleep quality among college students in Macao during the COVID-19 pandemic.** PeerJ 2021; 9:e12520Tao X, Chen D, Fan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966578>
106. **All about that trait: Examining extraversion and state anxiety during the SARS-CoV-2 pandemic using a machine learning approach.** Pers. Individ. Dif. 2022; 188:111461Gruda D, Ojo A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961802>
107. **A prospective study of college student depressive symptoms, sense of purpose, and response to a COVID-19 campus shutdown.** Pers. Individ. Dif. 2022; 189:111475Ratner K, Burrow AL, Mendle J, Hill PL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955576>
108. **ANXIOUSNESS AND QUALITY OF SLEEP IN CHILDREN WHO WERE IN QUARANTINE DURING THE COVID-19 PANDEMIC.** Probl Radiac Med Radiobiol 2021; 26:464-478Stepanova EI, Poznysh VA, Gudz NM, Vdovenko VY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965567>
109. **Risk of post-traumatic stress symptoms in hospitalized and non-hospitalized COVID-19 recovered patients. A cross-sectional study.** Psychiatry Res 2021; 308:114353Craparo G, La Rosa VL, Marino G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968807>
110. **How did the COVID-19 pandemic affect older adults? Investigation in terms of disability, state-trait anxiety and life satisfaction: Samsun, Turkey example.** Psychogeriatrics 2021; Özpınar S, Bayçelebi S, Demir Y, Yazıcıoğlu B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963192>
111. **Well-Being and the Pandemic: Trust in People Matters More Than Trust in Institutions.** Psychol. Rep. 2021:332941211061692Jovanović V, Sarracino F, Lazić M, Gavrilov-Jerković V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964386>
112. **The Influence of COVID-19 Stress and Self-Concealment on Professional Help-Seeking Attitudes: A Cross-Sectional Study of University Students.** Psychol. Res. Behav. Manag. 2021; 14:2081-2091Tran-Chi VL, Ly TT, Luu-Thi HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34949944>
113. **Curating the Evidence About COVID-19 for Frontline Public Health and Clinical Care: The Novel Coronavirus Research Compendium.** Public Health Rep. 2021:333549211058732Redd AD, Peetluk LS, Jarrett BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969294>
114. **Strategizing COVID-19 lockdowns using mobility patterns.** R Soc Open Sci 2021; 8:210865Buchel O, Ninkov A, Cathel D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966552>
115. **[Management of COVID-19 in Brazil: a humanitarian catastrophe.].** Rev. Fac. Cien. Med. Univ. Nac. Cordoba 2021; 78:437-438Tovani-Palone MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962744>
116. **Mental Health Disorders During COVID-19 Pandemic Among Southwest Ethiopia University Students: An Institutional-Based Cross-Sectional Study.**

- SAGE Open Nurs 2021; 7:23779608211064374Assefa ZM, Haile TG, Wazema DH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950769>
117. **Factors influencing compliance with public health directives and support for government's actions against COVID-19: A Nigerian case study.** Sci Afr 2022; 15:e01089Nwakasi C, Esiaka D, Uchendu I, Bosun-Arije S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957353>
 118. **Loneliness and psychological distress before and during the COVID-19 pandemic: Relationships with social media identity bubbles.** Soc. Sci. Med. 2021; 293:114674Latikka R, Koivula A, Oksa R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959045>
 119. **An Integrated Approach to COVID-19 Preventive Behaviour Intentions: Protection Motivation Theory, Information Acquisition, and Trust.** Soc Work Public Health 2021:1-16Kicali Ü, Acar D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962187>
 120. **Uncertainty and agency in COVID-19 hotel quarantine in Australia.** SSM Qual Res Health 2022; 2:100034Williams J, Gilbert G, Dawson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950927>
 121. **Coping strategies moderate the effect of perceived stress on sleep and health in older adults during the COVID-19 pandemic.** Stress Health 2021; Tracy EL, Chin B, Lehrer HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951930>
 122. **From Office-Based Treatment to Telehealth: Comparing Clinical Outcomes and Patient Participation in a Psychiatric Intensive Outpatient Program with a Large Transdiagnostic Sample.** Telemed J E Health 2021; Gannon JM, Brar JS, Zawacki S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964653>
 123. **Psychological trauma and depression in recovered COVID-19 patients: A telecommunication based observational study.** Trends Psychiatry Psychother 2021; Srivastava A, Bala R, Devi TP, Anal L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967182>
 124. **Can parkland mitigate mental health burden imposed by the COVID-19? A national study in China.** Urban For Urban Green 2022; 67:127451Yao Y, Lu Y, Guan Q, Wang R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955700>
 125. **Impact of Anxiety on Readiness for COVID-19 Vaccination among Polish Nursing Undergraduate Students: Nationwide Cross-Sectional Study.** Vaccines (Basel) 2021; 9Gotlib J, Jaworski M, Wawrzuta D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960130>
 126. **A Year of Pandemic-Comparison of Depression Among Neurosurgeons After the Advent of the COVID-19 Vaccine.** World Neurosurg 2021; Sharif S, Amin F, Hafiz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973442>

Meta-analyses - systematic reviews (9 articles)

1. **Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis.** Brain Behav Immun 2021; 101:93-135Ceban F, Ling S, Lui LMW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973396>
2. **The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients. A systematic review, meta-analysis and meta-regression.** Diabetes Metab Res Rev 2021:e3517Tentolouris N, Samakidou G, Eleftheriadou I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965318>

3. **Post-secondary Student Mental Health During COVID-19: A Meta-Analysis.** Front Psychiatry 2021; 12:777251Zhu J, Racine N, Xie EB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955924>
4. **When the Bough Breaks: A systematic review and meta-analysis of mental health symptoms in mothers of young children during the COVID-19 pandemic.** Infant Ment Health J 2021; Racine N, Eirich R, Cooke J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34962649>
5. **Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis.** Int J Infect Dis 2021; 116:59-67Jahan N, Brahma A, Kumar MS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34968773>
6. **A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic.** J Med Virol 2021; Dragioti E, Li H, Tsitsas G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34958144>
7. **Which criteria were used to describe patients with COVID-19? A systematic review and meta analysis of clinical, laboratory, and imaging features.** Med. J. Islam. Repub. Iran 2021; 35:112Amanollahi A, Sotoodeh Ghorbani S, Basir Ghafouri H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956958>
8. **Protective and Non-Protective Factors of Mental Health Distress in the United States during the COVID-19 Pandemic: A Systematic Review.** Medicina (Kaunas) 2021; 57Lieneck C, Bosworth M, Weaver E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946322>
9. **Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials.** Pathogens 2021; 10Ma KS, Lee CC, Liu KJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959492>

Mortality (17 articles)

1. **Pre-infection HDL-cholesterol levels and mortality among elderly patients infected with SARS-CoV-2.** Atherosclerosis 2022; 341:13-19Mostaza JM, Salinero-Fort MA, Cardenas-Valladolid J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959204>
2. **No Effects of Meteorological Factors on the SARS-CoV-2 Infection Fatality Rate.** Biomed. Environ. Sci. 2021; 34:871-880Solanes A, Laredo C, Guasp M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955147>
3. **Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study.** BMJ Open 2021; 11:e050051Wallace AW, Cirillo PM, Ryan JC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34972763>
4. **Hospitalization and death after recovery from acute COVID-19 among renal transplant recipients.** Clin. Transplant. 2021:e14572Basic-Jukic N, Racki S, Tolj I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967958>
5. **Clinical and Laboratory Factors in Predicting Mortality Among COVID-19 RT-PCR Positive Patients: A Retrospective Observational Study From a Tertiary Care Center.** Cureus 2021; 13:e19791Sundaramurthy R, Balasubramanian S, Ganesan V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956783>
6. **Overweight and Obesity Are Associated With Acute Kidney Injury and Acute Respiratory Distress Syndrome, but Not With Increased Mortality in**

- Hospitalized COVID-19 Patients: A Retrospective Cohort Study.** Front. Endocrinol. (Lausanne) 2021; 12:747732 van Son J, Oussaada SM, Şekercan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970220>
7. **Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.** Front. Immunol. 2021; 12:707159 Cyprian FS, Suleman M, Abdelhafez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966381>
 8. **Determinants of all-cause in-hospital mortality among patients who presented with COVID-19 to a community teaching hospital in Michigan.** Heliyon 2021; 7:e08566 Zakaria A, Piper M, Douda L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957338>
 9. **County-level socio-economic disparities in COVID-19 mortality in the USA.** Int J Epidemiol 2021; Dukhovnov D, Barbieri M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957523>
 10. **Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa.** Int J Infect Dis 2021; 116:38-42 Abdullah F, Myers J, Basu D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971823>
 11. **Association Between Metformin Use and Mortality among Patients with Type 2 Diabetes Mellitus Hospitalized for COVID-19 Infection.** J ASEAN Fed Endocr Soc 2021; 36:133-141 Ong AN, Tan CC, Cañete MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966196>
 12. **The association between Memorial Sloan Kettering Frailty Index with 30-day survival among patients aged ≥ 75 with cancer and COVID-19.** J. Geriatr. Oncol. 2021; Kim SJ, Fessele KL, Tin AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955444>
 13. **Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19.** J Med Virol 2021; Kerget B, Kerget F, Aydın M, Karaşahin Ö. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958142>
 14. **Predictors of death in patients with COVID-19: A cross-sectional study in West of Iran.** Med. J. Islam. Repub. Iran 2021; 35:103 Karami M, Mirzaei M, Shahbazi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956949>
 15. **Occupation and COVID-19 mortality in England: a national linked data study of 14.3 million adults.** Occup. Environ. Med. 2021; Nafilyan V, Pawelek P, Ayoubkhani D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965981>
 16. **COVID-19 In-Hospital Mortality in People with Diabetes Is Driven by Comorbidities and Age-Propensity Score-Matched Analysis of Austrian National Public Health Institute Data.** Viruses 2021; 13 Aziz F, Aberer F, Bräuer A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960670>
 17. **The Impact of COVID-19 on Mortality in Spain: Monitoring Excess Mortality (MoMo) and the Surveillance of Confirmed COVID-19 Deaths.** Viruses 2021; 13 León-Gómez I, Mazagatos C, Delgado-Sanz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960692>

Online – IT – Apps (45 articles)

1. **Covid-19: exploring the "new normal" in gastroenterology training.** Acta Gastroenterol. Belg. 2021; 84:627-635 Ekmektzoglou K, Tziatzios G, Siau K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965045>

2. **Laypeople's activity for seeking telephone number of EMS before and during the COVID-19 outbreak: An analysis of web search data.** Am J Emerg Med 2021; 53:1-5Birkun A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968968>
3. **Transition to telemedicine and its impact on missed appointments in community-based clinics.** Ann. Med. 2022; 54:98-107Adepoju OE, Chae M, Liaw W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969330>
4. **Assigning green hospitals during the COVID-19 pandemic assure continuous and safe resumption of surgical services.** Ann Med Surg (Lond) 2022; 73:103207AlShareef Y, AlShammary SA, Abuzied Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956643>
5. **GROUPS 2 CONNECT: An online activity to maintain social connection and well-being during COVID-19.** Appl Psychol Health Well Being 2021; Bentley SV, Haslam C, Haslam SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958172>
6. **COVID-19 Symptoms app analysis to foresee healthcare impacts: Evidence from Northern Ireland.** Appl Soft Comput 2022; 116:108324Sousa J, Barata J, Woerden HCV, Kee F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955697>
7. **Experiences with alternative online lectures in medical education in obstetrics and gynecology during the COVID-19 pandemic-possible efficient and student-orientated models for the future?** Arch. Gynecol. Obstet. 2021:1-13Riedel M, Eisenkolb G, Amann N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961899>
8. **Monitoring Australian parents' shifting receptiveness to digital mental health interventions during the COVID-19 pandemic.** Aust. N. Z. J. Psychiatry. 2021:48674211065985Linardon J, Westrupp EM, Macdonald JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963330>
9. **Direct capture and smartphone quantification of airborne SARS-CoV-2 on a paper microfluidic chip.** Biosens. Bioelectron. 2022; 200:113912Kim S, Akarapipad P, Nguyen BT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973565>
10. **Exploration of implementation, financial and technical considerations within allied health professional (AHP) telehealth consultation guidance: a scoping review including UK AHP professional bodies' guidance.** BMJ Open 2021; 11:e055823Leone E, Eddison N, Healy A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969656>
11. **COVID-19 screening: use of an artificial neural network.** BMJ Support Palliat Care 2021; Roustaei N, Allahyari E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972690>
12. **Regional mobility during the Covid-19 pandemic: Analysis of trends and repercussions using mobile phones data across the EU.** Case Stud Transp Policy 2021; Christidis P, Ciuffo B, Vespe M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956834>
13. **Evolving Applications of Artificial Intelligence and Machine Learning in Infectious Diseases Testing.** Clin Chem 2021; 68:125-133Tran NK, Albahra S, May L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969102>
14. **Who endorses conspiracy theories? A moderated mediation model of Chinese and international social media use, media skepticism, need for cognition, and COVID-19 conspiracy theory endorsement in China.** Comput. Human Behav. 2021; 120:106760Su Y, Lee DKL, Xiao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955595>

15. **Management of safe distancing on construction sites during COVID-19: A smart real-time monitoring system.** Comput Ind Eng 2022; 163:107847Goh YM, Tian J, Chian EYT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955588>
16. **Overcoming language barriers to provide telerehabilitation for COVID-19 patients: a two-case report.** Disabil Rehabil Assist Technol 2021;1-8Tatemoto T, Mukaino M, Kumazawa N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958627>
17. **Synchronous online learning during movement control order in higher education institutions: a systematic review.** F1000Res 2021; 10:1056Lee YW, Dorasamy M, Bin Ahmad AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950456>
18. **Factors Associated With Use of Telemedicine for Follow-Up of SLE in the COVID-19 Outbreak.** Front Med (Lausanne) 2021; 8:790652So H, Chow E, Cheng IT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966764>
19. **A Systematic Review of Telemedicine for Older Adults With Dementia During COVID-19: An Alternative to In-person Health Services?** Front. Neurol. 2021; 12:761965Elbaz S, Cinalioglu K, Sekhon K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970210>
20. **Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System.** Front. Pharmacol. 2021; 12:740707Fusaroli M, Raschi E, Gatti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955821>
21. **Associations of Delay in Doctor Consultation With COVID-19 Related Fear, Attention to Information, and Fact-Checking.** Front Public Health 2021; 9:797814Lai AY, Sit SM, Wu SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966717>
22. **COVID-19 Highlights a Critical Need for Efficient Health Information Systems for Managing Epidemics of Emerging Infectious Diseases.** Front Public Health 2021; 9:767835Pooransingh S, Abdullah R, Battersby S, Kercheval R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957023>
23. **Re: Evaluation of a telemedicine-based training for final-year medical students including simulated patient consultations, documentation, and case presentation.** GMS J Med Educ 2021; 38:Doc113Harendza S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957318>
24. **Letter to the editor regarding "Evaluation of a telemedicine-based training for final-year medical students including simulated patient consultations, documentation, and case presentation".** GMS J Med Educ 2021; 38:Doc114Majeed M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957319>
25. **A Storytelling Robot Managing Persuasive and Ethical Stances via ACT-R: An Exploratory Study.** Int J Soc Robot 2021:1-17Augello A, Città G, Gentile M, Lieto A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956417>
26. **Effects of an internet-based self-help intervention for psychological distress due to COVID-19: Results of a randomized controlled trial.** Internet Interv 2022; 27:100492Brog NA, Hegy JK, Berger T, Znoj H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956841>
27. **Telemedicine in French Memory Clinics During the COVID-19 Pandemic.** J. Alzheimers Dis. 2021; Morin A, Pressat-Laffouilhère T, Sarazin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974434>

28. **Integrating Principles of Safety Culture and Just Culture Into Nursing Homes: Lessons From the Pandemic.** J. Am. Med. Dir. Assoc. 2021; Gaur S, Kumar R, Gillespie SM, Jump RLP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958744>
29. **Perceptions and attitudes of University of Johannesburg chiropractic students toward a blended learning approach and a shift to an e-learning approach necessitated by the COVID-19 pandemic.** J Chiropr Educ 2021; Ismail F, Yelverton C, Rademan R, Peterson C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965578>
30. **Efficacy of intensive CBT telehealth for obsessive-compulsive disorder during the COVID-19 pandemic.** J Obsessive Compuls Relat Disord 2022; 32:100705Pinciotti CM, Bulkes NZ, Horvath G, Riemann BC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956827>
31. **Testing Our Children When the World Shuts Down: Analyzing Recommendations for Adapted Tele-Assessment during COVID-19.** J. Psychoeduc. Assess. 2020; 38:923-941Krach SK, Paskiewicz TL, Monk MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955591>
32. **Telemedicine for veterans in the setting of the COVID-19 pandemic: Lessons learned from a virtual urgent care center.** J Telemed Telecare 2021:1357633x211069018Sikka V, King C, Klinker S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970932>
33. **Positive impact of a telemedicine education program on practicing health care workers during the COVID-19 pandemic in Ontario, Canada: A mixed methods study of an Extension for Community Healthcare Outcomes (ECHO) program.** J Telemed Telecare 2021:1357633x211059688Zhao QJ, Rozenberg D, Nourouzpour S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962167>
34. **Ethical and Legal Challenges of Telemedicine in the Era of the COVID-19 Pandemic.** Medicina (Kaunas) 2021; 57Solimini R, Busardò FP, Gibelli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946259>
35. **[Remote presentation of thesis and final postgraduate works during the COVID-19 pandemic. Are there advantages in the non-face-to-face presentations?].** Rev. Fac. Cien. Med. Univ. Nac. Cordoba 2021; 78:353-358Soto Perez AR, Eymann A, Ladenheim R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962732>
36. **Predictive Machine Learning Models and Survival Analysis for COVID-19 Prognosis Based on Hematochemical Parameters.** Sensors (Basel) 2021; 21Altini N, Brunetti A, Mazzoleni S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960595>
37. **Wearable Devices, Smartphones, and Interpretable Artificial Intelligence in Combating COVID-19.** Sensors (Basel) 2021; 21Hijazi H, Abu Talib M, Hasasneh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960517>
38. **Loneliness and psychological distress before and during the COVID-19 pandemic: Relationships with social media identity bubbles.** Soc. Sci. Med. 2021; 293:114674Latikka R, Koivula A, Oksa R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959045>
39. **Development and Assessment of an Inexpensive Smartphone-Based Respiratory Droplet Simulation Model.** Surg. Innov. 2021:15533506211065845Hakimi AA, Hutchison DM, Park A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962218>
40. **EpidemiXs: Harnessing digital technology in the fight against COVID-19 and the associated infodemic.** Technol. Health Care 2021; Lemaire J, Ramil E,

- Thouvenot VI, Pons JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957971>
41. **Telehealth Utilization in Response to the COVID-19 Pandemic: Current State of Medical Provider Training.** *Telemed J E Health* 2021; DuBose-Morris R, Coleman C, Ziniel SI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967677>
 42. **Analysis of the Impact of Media Trust on the Public's Motivation to Receive Future Vaccinations for COVID-19 Based on Protection Motivation Theory.** *Vaccines (Basel)* 2021; 9Li Z, Sun X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960147>
 43. **Austria's Digital Vaccination Registry: Stakeholder Views and Implications for Governance.** *Vaccines (Basel)* 2021; 9Paul KT, Janny A, Riesinger K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960241>
 44. **Trusted Sources of COVID-19 Vaccine Information among Hesitant Adopters in the United States.** *Vaccines (Basel)* 2021; 9Purvis RS, Hallgren E, Moore RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960164>
 45. **Students' Views on Vaccination against COVID-19 Virus and Trust in Media Information about the Vaccine: The Case of Serbia.** *Vaccines (Basel)* 2021; 9Šiđanin I, Njegovan BR, Sokolović B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960176>

Other – Miscellaneous (72 articles)

1. **Association between positive psychological traits and changes in dietary behaviour related to first COVID-19 lockdown: A general population-based study.** *Appetite* 2021; 171:105885Robert M, Deschasaux-Tanguy M, Shankland R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958832>
2. **Moving beyond mistrust: Centering institutional change by decentering the white analytical lens.** *Bioethics* 2021; Newman AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969146>
3. **No Effects of Meteorological Factors on the SARS-CoV-2 Infection Fatality Rate.** *Biomed. Environ. Sci.* 2021; 34:871-880Solanes A, Laredo C, Guasp M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955147>
4. **'We weren't checked in on, nobody spoke to us': an exploratory qualitative analysis of two focus groups on the concerns of ethnic minority NHS staff during COVID-19.** *BMJ Open* 2021; 11:e053396Jesuthasan J, Powell RA, Burmester V, Nicholls D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972767>
5. **Sorry, I am sneezing and coughing but I do not have COVID-19.** *Brain Behav Immun* 2021; 101:57-58Bouayed J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968716>
6. **Cooperation dynamics under pandemic risks and heterogeneous economic interdependence.** *Chaos Solitons Fractals* 2022; 155:111655Chica M, Hernández JM, Santos FC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955615>
7. **Impact of COVID-19 on perceived wellbeing, self-management and views of novel modalities of care among medically vulnerable patients in Singapore.** *Chronic Illn* 2021; 17423953211067458Yoon S, Hoe PS, Chan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964364>
8. **Small Business Post-COVID-19: Motivational Needs through Uncertain Times.** *Compens. Benefits Rev.* 2021; 53:8-15Ertel S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955600>

9. **State and Local Government Pension Funding on the Eve of the COVID-19 Recession.** *Compens. Benefits Rev.* 2021; 53:16-23 Kilgour JG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955601>
10. **Employer-Sponsored Benefits in the United States: The Past, Present, and Future.** *Compens. Benefits Rev.* 2021; 53:24-42 Lester GV, Brock Baskin ME, Clinton MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955602>
11. **Did the COVID-19 Pandemic Dampen Americans' Tipping for Food Services? Insights From Two Studies.** *Compens. Benefits Rev.* 2021; 53:130-143 Lynn M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955604>
12. **Infectious Disease: Protecting Workers and Organizations-The Role of Compensation & Benefits.** *Compens. Benefits Rev.* 2021; 53:43-55 Marty Martin W, Lopez Y, Flannery TP, Dixon B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955603>
13. **COVID Booster Shots: The Need of the Hour.** *Cureus* 2021; 13:e19874 Maheshwari M, Athiraman H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956797>
14. **Faster or slower decarbonization? Policymaker and stakeholder expectations on the effect of the COVID-19 pandemic on the global energy transition.** *Energy Res Soc Sci* 2021; 76:102025 Pianta S, Brutschin E, van Ruijven B, Bosetti V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956837>
15. **COVID-19 exposure risk level in daily activity in adapting to new habits in the pandemic period.** *Enferm. Clin.* 2021; 31:S840-s846 Haerana BT, Jalaluddin S, Satrianegara MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955633>
16. **Influence of meteorological patterns on the 2020 COVID-19 pandemic in the Mexico City region.** *Environ Adv* 2022; 7:100157 Salcido A, Castro T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957431>
17. **Improving PM(2.5) predictions during COVID-19 lockdown by assimilating multi-source observations and adjusting emissions.** *Environ Pollut* 2022; 297:118783 Chen L, Mao F, Hong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974086>
18. **Elucidating the responses of highly time-resolved PM(2.5) related elements to extreme emission reductions.** *Environ. Res.* 2021; 206:112624 Cheng K, Chang Y, Kuang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973195>
19. **The COVID-19 pandemic reshapes the plastic pollution research - A comparative analysis of plastic pollution research before and during the pandemic.** *Environ. Res.* 2021; 208:112634 Wang Q, Zhang M, Li R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34973197>
20. **Did Climate Change Influence the Emergence, Transmission, and Expression of the COVID-19 Pandemic?** *Front Med (Lausanne)* 2021; 8:769208 Gupta S, Rouse BT, Sarangi PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957147>
21. **Neurology Telemusic Program at the Time of the COVID-19 Pandemic: Turning Hospital Time Into Aesthetic Time During Crisis.** *Front. Neurol.* 2021; 12:749782 Bonakdarpour B, McFadden A, Zlotkowski S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966344>
22. **Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System.** *Front. Pharmacol.* 2021; 12:740707 Fusaroli M, Raschi E, Gatti M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955821>

23. **Lifestyle Behaviors and Quality of Life Among Older Adults After the First Wave of the COVID-19 Pandemic in Hubei China.** Front Public Health 2021; 9:744514Duan Y, Peiris D, Yang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957009>
24. **Discussing the Drawbacks of the Implementation of Access and Benefit Sharing of the Nagoya Protocol Following the COVID-19 Pandemic.** Front Public Health 2021; 9:639581Mueni Katee S, Keambou Tiambo C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956996>
25. **The Impact of COVID-19 on Risky Behaviors and Health Changes in African-American Smokers Who Are Eligible for LDCT Screening.** Front Public Health 2021; 9:745925Tseng TS, Li M, Kao YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957010>
26. **Learning From Each Other in the Management of Natural Disaster and COVID-19 Pandemic: A Case Study in Taiwan.** Front Public Health 2021; 9:777255Wang HW, Chen GW, Lee WL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957028>
27. **Dietary Patterns and Changes in Weight Status Among Chinese Men and Women During the COVID-19 Pandemic.** Front Public Health 2021; 9:709535Xu X, Yan AF, Wang Y, Shi Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966710>
28. **Explaining Chinese Reactions to COVID-19 During the Outbreak: A Systematic Illustration.** Front Public Health 2021; 9:727369Yuan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957002>
29. **Social risks, economic dynamics and the local politics of COVID-19 prevention in Eldoret town, Kenya.** Glob Public Health 2021:1-16Bosire EN, Kamau LW, Bosire VK, Mendenhall E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962853>
30. **Barriers to Meeting Community Needs in New York State during COVID-19: Results From a Pilot Survey of Nongovernmental Population and Community Health Professionals.** Health Promot Pract 2021:15248399211065412Schiavo R, Arana M, Levy N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963360>
31. **Food and healthcare accessibility during COVID-19 pandemic.** Heliyon 2021; 7:e08656Uche E, Marcus SN, Effiom L, Okoronkwo C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957341>
32. **Assessing customer financial risk perception and attitude in the hotel industry: Exploring the role of protective measures against COVID-19.** Int J Hosp Manag 2022; 101:103123Quan L, Al-Ansi A, Han H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955585>
33. **Moral Injury during the COVID-19 pandemic: A delphi model survey of family medicine residents.** Int. J. Psychiatry Med. 2021:912174211054385Ngo SB, Clark PJ, Parr SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961337>
34. **The Ethical Unjustifications of COVID-19 Triage Committees.** J. Bioeth. Inq. 2021; 18:621-628Tian YJA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964927>
35. **Perspective of dairy producers from California, Idaho, South Dakota, and Washington: Health and business implications of the COVID-19 pandemic during the second wave.** J. Dairy Sci. 2022; 105:1788-1796Valdecabres A, Wenz J, Ferreira FC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955251>
36. **Green bonds and other assets: Evidence from extreme risk transmission.** J. Environ. Manage. 2022; 305:114358Naeem MA, Conlon T, Cotter J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974217>
37. **Assessment of health benefit of PM(2.5) reduction during COVID-19 lockdown in China and separating contributions from anthropogenic emissions and**

- meteorology.** *J. Environ. Sci. (China)* 2022; 115:422-431 Bai H, Gao W, Zhang Y, Wang L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969470>
38. **Investigation of PM(2.5) pollution during COVID-19 pandemic in Guangzhou, China.** *J. Environ. Sci. (China)* 2022; 115:443-452 Wen L, Yang C, Liao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969472>
 39. **Curtailment of Civil Liberties and Subjective Life Satisfaction.** *J Happiness Stud* 2021;1-14 Windsteiger L, Ahlheim M, Konrad KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955681>
 40. **Meeting the COVID-19 Deadlines: Choosing Assessments to Determine Eligibility.** *J. Psychoeduc. Assess.* 2021; 39:50-73 Krach SK, Paskiewicz TL, Ballard SC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955592>
 41. **Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy.** *Life Sci* 2022; 291:120267 Zaki MO, Elsherbiny DA, Salama M, Azab SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974076>
 42. **Welcome to 2022: the Year of the Tiger!** *Med. J. Aust.* 2022; 216:20-23 Talley NJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972246>
 43. **Microorganisms as Shapers of Human Civilization, from Pandemics to Even Our Genomes: Villains or Friends? A Historical Approach.** *Microorganisms* 2021; 9 Rodríguez-Frías F, Quer J, Tabernero D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946123>
 44. **Dietary Changes and Anxiety during the Coronavirus Pandemic: Differences between the Sexes.** *Nutrients* 2021; 13 Boaz M, Navarro DA, Raz O, Kaufman-Shriqui V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959744>
 45. **The Impact of the COVID-19 Pandemic on Food Distribution at Emergency Food Assistance Organizations in the Southwestern United States: A Qualitative Investigation.** *Nutrients* 2021; 13 Castro AN, White MA, Ishdorj A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959818>
 46. **The Association of Restrained Eating and Overeating during COVID-19: A Cross-Lagged Model.** *Nutrients* 2021; 13 Cui Y, Liu X, Xiang G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960087>
 47. **The Impact of COVID-19 on Eating Environments and Activity in Early Childhood Education and Care in Alberta, Canada: A Cross-Sectional Study.** *Nutrients* 2021; 13 Lafave LMZ, Webster AD, McConnell C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959799>
 48. **Affordability of Healthy, Equitable and More Sustainable Diets in Low-Income Households in Brisbane before and during the COVID-19 Pandemic.** *Nutrients* 2021; 13 Lee AJ, Patay D, Herron LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959938>
 49. **Changes in Eating Habits and Physical Activity after COVID-19 Pandemic Lockdowns in Italy.** *Nutrients* 2021; 13 Lombardo M, Guseva E, Perrone MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960077>
 50. **Effect and Tolerability of a Nutritional Supplement Based on a Synergistic Combination of β -Glucans and Selenium- and Zinc-Enriched *Saccharomyces cerevisiae* (ABB C1®) in Volunteers Receiving the Influenza or the COVID-19 Vaccine: A Randomized, Double-Blind, Placebo-Controlled Study.** *Nutrients* 2021; 13 Rodríguez JAM, Bifano M, Roca Goma E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959898>
 51. **A Pilot, Phase II, Observational, Case-Control, 1-Month Study on Asthenopia in Video Terminal Operators without Dry Eye: Contrast Sensitivity and Quality**

- of Life before and after the Oral Consumption of a Fixed Combination of Zinc, L-Carnitine, Extract of Elderberry, Currant and Extract of Eleutherococcus. Nutrients 2021; 13Rossi GCM, Scudeller L, Bettio F, Milano G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960000>
52. **"Five Keys to Safer Food" and COVID-19.** Nutrients 2021; 13San Onofre N, Soler C, Merino-Torres JF, Soriano JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960042>
 53. **COVID-19 Pandemic and Eating Disorders among University Students.** Nutrients 2021; 13Tavolacci MP, Ladner J, Dechelotte P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959846>
 54. **Combatting Sedentary Behaviors by Delivering Remote Physical Exercise in Children and Adolescents with Obesity in the COVID-19 Era: A Narrative Review.** Nutrients 2021; 13Vandoni M, Codella R, Pippi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960011>
 55. **Legal issues and challenges in addressing the coronavirus outbreak on large cruise ships: A critical examination of port state measures.** Ocean Coast Manag 2022; 217:105995Sun S, Zhao LL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955616>
 56. **E-cigarette or vaping product use associated lung injury (EVALI) in the time of COVID-19: A clinical dilemma.** Pediatr Pulmonol 2021; Helfgott D, Capozzoli G, Madray J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964550>
 57. **Change in alcohol consumption and physical activity during the COVID-19 pandemic amongst 76 medical students.** PeerJ 2021; 9:e12580Sandell C, Saltychev M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966589>
 58. **Utilization of a SARS-CoV-2-positive donor for liver transplantation.** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:62-63Wall AE, McKenna GJ, Onaca N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970035>
 59. **Supporting Vulnerable Populations During the Pandemic: Stakeholders' Experiences and Perceptions of Social Prescribing in Scotland During Covid-19.** Qual. Health Res. 2021:10497323211064229Fixsen DA, Barrett DS, Shimonovich M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969344>
 60. **"Furry tales": pet ownership's influence on subjective well-being during Covid-19 times.** Qual Quant 2021:1-20Damberg S, Frömbling L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955563>
 61. **Oil prices volatility and economic performance during COVID-19 and financial crises of 2007-2008.** Resour Policy 2022; 75:102531Yu Y, Guo S, Chang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961804>
 62. **Pharmaceutical compounds used in the COVID-19 pandemic: A review of their presence in water and treatment techniques for their elimination.** Sci Total Environ 2021; 814:152691Morales-Paredes CA, Rodríguez-Díaz JM, Boluda-Botella N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974020>
 63. **SAGE advice and political decision-making: 'Following the science' in times of epistemic uncertainty.** Soc Stud Sci 2022; 52:53-78Evans R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963397>
 64. **COVID-19 in Homelessness: A Worldwide Scoping Review on Vulnerabilities, Risks, and Risk Management.** Soc Work Public Health 2021:1-16Nouri M, Ostadtaghizadeh A, Sari AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963409>
 65. **Impact of the COVID-19 Pandemic on German Paralympic Athletes.** Sports Orthopaedics and Traumatology 2021; 37:235-241Kubosch EJ, Meidl V, Bretthauer

B *et al.*

66. **Resource integration and dynamic capability of frontline employee during COVID-19 pandemic: From value creation and engineering management perspectives.** Technol Forecast Soc Change 2022; 176:121446 Chatterjee S, Chaudhuri R, González VI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955564>
67. **Biotech value chain and technologies for COVID-19 research areas for collaboration on cost quality tradeoff with tool companies.** Technol. Health Care 2021; Huttin CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957966>
68. **Integrating COVID-19 health risks into crowding costs for transit schedule planning.** Transp Res Interdiscip Perspect 2022; 13:100522 Devasurendra KW, Saidi S, Wirasinghe SC, Kattan L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957387>
69. **Customer perceptions of COVID-19 countermeasures on passenger ships during the pandemic.** Transp Res Interdiscip Perspect 2022; 13:100518 Långstedt J, Spohr J, Hellström M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961849>
70. **Demand for mitigating the risk of COVID-19 infection in public transport: The role of social trust and fatalistic beliefs.** Transp. Res. Part F Traffic Psychol. Behav. 2022; 84:348-362 Fallah Zavareh M, Mehdizadeh M, Nordfjærn T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963755>
71. **First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain.** Viruses 2021; 13: Fernández-Bastit L, Rodon J, Pradenas E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960795>
72. **Food security, poverty and household resilience to COVID-19 in Burkina Faso: Evidence from urban small traders' households.** World Dev Perspect 2022; 25:100387 Ouoba Y, Sawadogo N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961846>

Pathology (5 articles)

1. **Clinical-Pathological Correlations in the Acute Surgical Abdomen in the Pre and Post-Pandemic Period Covid-19.** Chirurgia (Bucur.) 2021; 116:748-755 Nicolescu C, Butiurca VO, Cosma C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967719>
2. **Detection of SARS-CoV-2-RNA in post-mortem samples of human eyes.** Graefes Arch Clin Exp Ophthalmol 2021; 1-9 Penkava J, Muenchhoff M, Badell I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962592>
3. **COVID-19-associated necrotizing encephalopathy presenting without active respiratory symptoms: a case report with histopathology.** J. Neurovirol. 2021; 1-5 Rettenmaier LA, Abdel-Wahed L, Abdelmotilib H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970720>
4. **Social determinants of adherence to COVID-19 preventive guidelines: a comprehensive review.** Osong Public Health Res Perspect 2021; 12:346-360 Shushtari ZJ, Salimi Y, Ahmadi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965686>
5. **Clinical Application of Ultraviolet C Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 in Contaminated Hospital Environments.** Viruses 2021; 13: Su WL, Lin CP, Huang HC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960637>

Protection (27 articles)

1. **P2/N95 filtering facepiece respirators: Results of a large-scale quantitative mask fit testing program in Australian health care workers.** Am. J. Infect. Control 2021; Milosevic M, Kishore Biswas R, Innes L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971710>
2. **Health care worker knowledge and attitudes towards uniform laundering during the COVID-19 pandemic.** Am. J. Infect. Control 2021; Owen L, Apps L, Stanulewicz N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971711>
3. **North Carolina public school teachers' contact patterns and mask use within and outside of school during the pre-vaccine phase of the COVID-19 pandemic.** Am. J. Infect. Control 2021; Powers KA, Sullivan KM, Zadrozny SL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971715>
4. **Surgical helmets can be converted into efficient disinfectable powered air-purifying respirators.** Am. J. Infect. Control 2021; Temmesfeld MJ, Gorzkowska-Sobas AA, Hedlund K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958857>
5. **Particle scattering during otolaryngological examinations.** Am. J. Otolaryngol. 2021; 43:103358 Tüzemen G, Tüzemen N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973663>
6. **[Patient safety training and a safe teaching in primary care].** Aten. Primaria 2021; 53 Suppl 1:102199 Saura Llamas J, Astier Peña MP, Puntos Felipe B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961575>
7. **[Health worker safety as an essential condition for patient safety].** Aten. Primaria 2021; 53 Suppl 1:102216 Torijano Casalengua ML, Maderuelo-Fernández JA, Astier Peña MP, Añel Rodríguez R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961585>
8. **The interactional production and breach of new norms in the time of COVID-19: Achieving physical distancing in public spaces.** Br. J. Soc. Psychol. 2021; Drury J, Stokoe E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958691>
9. **Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control.** Drug Deliv 2022; 29:10-17 Mac Giolla Eain M, Cahill R, MacLoughlin R, Nolan K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962221>
10. **Airborne Transmission of SARS-CoV-2 Delta Variant within Tightly Monitored Isolation Facility, New Zealand (Aotearoa).** Emerg Infect Dis 2021; 28 Fox-Lewis A, Williamson F, Harrower J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965365>
11. **What Have We Learnt About the Sourcing of Personal Protective Equipment During Pandemics? Leadership and Management in Healthcare Supply Chain Management: A Scoping Review.** Front Public Health 2021; 9:765501 Best S, Williams SJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957018>
12. **Fear of COVID-19 contagion and consumption: Evidence from a survey of Italian households.** Health Econ. 2021; Immordino G, Jappelli T, Oliviero T, Zazzaro A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962332>
13. **A year of living distantly: global trends in the use of stay-at-home orders over the first 12 months of the COVID-19 pandemic.** Interface Focus 2021; 11:20210041 Phillips T, Zhang Y, Petherick A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956599>

14. **Contact transmission of SARS-CoV-2 on fomite surfaces: surface survival and risk reduction.** Interface Focus 2022; 12:20210042Tharayil A, Rajakumari R, Mozetic M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956610>
15. **A cross sectional study found differential risks for COVID-19 seropositivity amongst health care professionals in Chile.** J. Clin. Epidemiol. 2021; 144:72-83Zuñiga M, Lagomarcino AJ, Muñoz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965480>
16. **The Effect of Masks and Respirators on Acoustic Voice Analysis During the COVID-19 Pandemic.** J. Voice 2021; Gojayev EK, Büyükatalay Z, Akyüz T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961655>
17. **Aerosol Dispersion During Different Phonatory Tasks in Amateur Singers.** J. Voice 2021; Hermann LA, Tur B, Köberlein MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963518>
18. **Evidence for the Use of Mouthwash as a Preprocedural Preventive Measure Against COVID-19: Should We Rinse and Repeat?** JAAD Int 2021; Gao JC, Hood C, Safai B, Marmon S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961850>
19. **The impact of multiple non-pharmaceutical interventions on controlling COVID-19 outbreak without lockdown in Hong Kong: A modelling study.** Lancet Reg Health West Pac 2021:100343Yuan HY, Blakemore C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957427>
20. **Ozone as an alternative decontamination process for N95 facemask and biosafety gowns.** Mater Lett 2022; 311:131554Ibáñez-Cervantes G, Lugo-Zamudio GE, Cruz-Cruz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963705>
21. **An unprecedented increase in burn injuries due to alcohol-based hand sanitizers during the COVID-19 outbreak.** Med. J. Islam. Repub. Iran 2021; 35:107Dahmardehei M, Khadem Rezaiyan M, Safarnejad F, Ahmadabadi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956953>
22. **The Association between Using Personal Protective Equipment and Headache among Healthcare Workers in Saudi Arabia Hospitals during the COVID-19 Pandemic.** Nurs Rep 2021; 11:568-583Alreshidi NM, Alghamdi S, Shibily F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968332>
23. **Healthcare Workers' Experiences and Views of Using Surgical Masks and Respirators, and Their Attitudes on the Sustainability: A Semi-Structured Survey Study during COVID-19.** Nurs Rep 2021; 11:615-628Venesoja A, Grönman K, Tella S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968337>
24. **Nanocoatings: Universal antiviral surface solution against COVID-19.** Prog Org Coat 2022; 163:106670Vijayan PP, P GC, Abraham P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955586>
25. **Group-based trajectories and predictors of adherence to physical distancing during the COVID-19 pandemic.** Psychol. Health 2021:1-19MacNeil S, Deschênes S, Knäuper B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951559>
26. **Graphene-based nanomaterials as antimicrobial surface coatings: A parallel approach to restrain the expansion of COVID-19.** Surf Interfaces 2021; 27:101460Ayub M, Othman MHD, Khan IU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957347>
27. **Sampling for SARS-CoV-2 Aerosols in Hospital Patient Rooms.** Viruses 2021; 13Lane MA, Walawender M, Webster AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960615>

Pulmonary disease (17 articles)

1. **Substance, use in relation to COVID-19: A scoping review.** *Addict. Behav.* 2022; 127:107213Kumar N, Janmohamed K, Nyhan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959077>
2. **Diagnostic performance of the RSNA-proposed classification for COVID-19 pneumonia versus pre-pandemic controls.** *Braz. J. Infect. Dis.* 2021; 26:101665Rocha CO, Prioste TAD, Faccin CS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958741>
3. **Effusion fluid cytology and COVID-19 infection.** *Cancer Cytopathol* 2021; Xia R, Hsu Lin L, Sun W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958719>
4. **[Influence of the COVID-19 pandemic on the epidemiology of acute Bronchiolitis.].** *Enferm. Infecc. Microbiol. Clin.* 2021; Barrezueta LB, Zamorano MG, Casillas PL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955579>
5. **[Not Available].** *Enferm. Infecc. Microbiol. Clin.* 2021; Hernández-Rivas L, Pedraz T, Calvo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955580>
6. **Vascular Damage, Thromboinflammation, Plasmablast Activation, T-Cell Dysregulation and Pathological Histiocytic Response in Pulmonary Draining Lymph Nodes of COVID-19.** *Front. Immunol.* 2021; 12:763098Haslbauer JD, Zinner C, Stalder AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966385>
7. **The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.** *Front. Pharmacol.* 2021; 12:731453Zhang T, Tong X, Zhang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955820>
8. **Current Recommendations on the Management of Pediatric Asthma and Allergic Rhinitis during the COVID-19 Pandemic versus Real-Life Practice.** *Int. Arch. Allergy Immunol.* 2021;1-8Gokmirza Ozdemir P, Celik V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963116>
9. **Prevalence, attitude, knowledge, and risk perception towards COVID-19 in COPD patients associated to biomass exposure.** *Int. J. Environ. Health Res.* 2021;1-10Montiel-Lopez F, Rodríguez-Ramírez D, Miranda-Márquez MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965789>
10. **Facts and Challenges about Asthma and COVID-19 among the Paediatric Population: A Systematic Literature Review.** *Medicina (Kaunas)* 2021; 57Moreno-Sánchez E, Castillo-Viera E, Vélez-Moreno E, Gago-Valiente FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946251>
11. **Clinical and Functional Predictors of Response to a Comprehensive Pulmonary Rehabilitation in Severe Post-COVID-19 Patients.** *Microorganisms* 2021; 9Spielmanns M, Buelow MM, Pekacka-Egli AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946054>
12. **Increasing incidence of lung transplantation in patients with post-COVID-19 pulmonary fibrosis.** *Pan Afr. Med. J.* 2021; 40:169Khajotia R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970411>
13. **Progression to a severe form of COVID-19 among patients with chronic respiratory diseases.** *Respir Med Res* 2021; 81:100880Basin S, Valentin S, Maurac A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974204>
14. **Incidence of COVID-19 after pulmonary function tests: a retrospective cohort study.** *Rev. Fac. Cien. Med. Univ. Nac. Cordoba* 2021; 78:367-370Wainstein EJ, Peroni HJ, Ferreyro BL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962729>

15. **Histologic pulmonary lesions of SARS-CoV-2 in 4 nonhuman primate species: An institutional comparative review.** Vet. Pathol. 2021:3009858211067468Clancy CS, Shaia C, Munster V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963391>
16. **Pulmonary lesions induced by SARS-CoV-2 infection in domestic cats.** Vet. Pathol. 2021:3009858211066840Patania OM, Chiba S, Halfmann PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963403>
17. **Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity.** Viruses 2021; 13Rahman M, Irmeler M, Keshavan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960806>

Renal disease (11 articles)

1. **Hospitalization and death after recovery from acute COVID-19 among renal transplant recipients.** Clin. Transplant. 2021:e14572Basic-Jukic N, Racki S, Tolj I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967958>
2. **Overweight and Obesity Are Associated With Acute Kidney Injury and Acute Respiratory Distress Syndrome, but Not With Increased Mortality in Hospitalized COVID-19 Patients: A Retrospective Cohort Study.** Front. Endocrinol. (Lausanne) 2021; 12:747732van Son J, Oussaada SM, Şekercan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970220>
3. **Acute ischemic events after COVID-19 infection in patients undergoing maintenance hemodialysis.** Hemodial Int 2021; Ozkaya E, Taskent I, Somay R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962048>
4. **Presepsin as a Predictive Biomarker of Severity in COVID-19: A Systematic Review.** Indian J. Crit. Care Med. 2021; 25:1051-1054Ahmed S, Mansoor M, Shaikh MS, Siddiqui I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963726>
5. **Invasive Candida kefyr infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case report and review of the literature.** J. Mycol. Med. 2021; 32:101236Spiliopoulou A, Kolonitsiou F, Vrioni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974339>
6. **The global impact of the Coronavirus 2019 pandemic on in-centre haemodialysis services: an International Society of Nephrology -Dialysis Outcomes Practice Patterns Study survey.** Kidney Int Rep 2021; Aylward R, Bieber B, Guedes M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957349>
7. **First snapshot on behavioral characteristics and related factors of patients with chronic kidney disease in South Korea during the COVID-19 pandemic (June to October 2020).** Kidney Res Clin Pract 2021; Kim Y, Lee I, Lee J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974659>
8. **Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients.** Medicina (Kaunas) 2021; 57Vaiciuniene R, Sitkauskienė B, Bumblyte IA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946272>
9. **Impact of coronavirus disease-2019 on pediatric nephrology practice and education: an ESPN survey.** Pediatr. Nephrol. 2021; Yazıcıoğlu B, Bakkaloğlu SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971403>
10. **Exercise-based cardiac rehabilitation programs in the era of COVID-19: a critical review.** Rev Cardiovasc Med 2021; 22:1143-1155Stefanakis M, Batalik L, Papathanasiou J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957758>

11. **Humoral Immune Response to SARS-CoV-2 Vaccination after a Booster Vaccine Dose in Two Kidney Transplant Recipients with Fabry Disease and Variable Secondary Immunosuppressive Regimens.** Vaccines (Basel) 2021; 9:Bernea L, Ailioaie OR, Benhamouda N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960158>

Reviews (39 articles)

1. **Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.** Acta Neurol. Scand. 2021; Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967005>
2. **Impact of Nationwide Lockdowns Resulting from The First Wave of the COVID-19 Pandemic on Food Intake, Eating Behaviours and Diet Quality: A Systematic Review.** Adv. Nutr. 2021; Mignogna C, Costanzo S, Ghulam A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967842>
3. **Review of studies on SARS-CoV-2 infection inhibitors.** Ann. Agric. Environ. Med. 2021; 28:541-550 Michalski A, Wójcicka P, Bielawska-Drózd A, Bartoszcze M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969209>
4. **Clinically suspected myocarditis in COVID-19 patients: Case series and review of the literature.** Clin Case Rep 2021; 9:e05236 Amin A, Eftekhari SP, Ziaie N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963812>
5. **Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases.** Egypt J Neurol Psychiatr Neurosurg 2021; 57:179 Finsterer J, Zarrouk S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955632>
6. **Looking to the future: is a universal coronavirus vaccine feasible?** Expert Rev Vaccines 2021; 1-4 Vashishtha VM, Kumar P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968153>
7. **A Systematic Review of Telemedicine for Older Adults With Dementia During COVID-19: An Alternative to In-person Health Services?** Front. Neurol. 2021; 12:761965 Elbaz S, Cinalioglu K, Sekhon K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970210>
8. **COVID-19 Outcome Relates With Circulating BDNF, According to Patient Adiposity and Age.** Front Nutr 2021; 8:784429 Minuzzi LG, Seelaender M, Silva BSA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957187>
9. **The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.** Front. Pharmacol. 2021; 12:731453 Zhang T, Tong X, Zhang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955820>
10. **Appealing to Tacit Knowledge and Axiology to Enhance Medical Practice in the COVID-19 Pandemic: A Systematic Review and Hermeneutic Bioethical Analysis.** Front Public Health 2021; 9:686773 Serrano-Zamago AB, Altamirano-Bustamante MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956997>
11. **Advances in clinical outcomes: what we have learned during the COVID-19 pandemic.** J Allergy Clin Immunol 2021; Al-Musa A, LaBere B, Habiballah S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958811>
12. **Cardiovascular and haematological events post COVID-19 vaccination: A systematic review.** J Cell Mol Med 2021; Al-Ali D, Elshafeey A, Mushannen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967105>
13. **The association between Memorial Sloan Kettering Frailty Index with 30-day survival among patients aged ≥ 75 with cancer and COVID-19.** J. Geriatr. Oncol.

- 2021; Kim SJ, Fessele KL, Tin AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955444>
14. **Invasive *Candida kefyr* infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case report and review of the literature.** J. Mycol. Med. 2021; 32:101236Spiliopoulou A, Kolonitsiou F, Vrioni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974339>
 15. **Acute Mesenteric Ischemia in Patients with COVID-19: Review of the literature.** J. Natl. Med. Assoc. 2021; Chen C, Li YW, Shi PF, Qian SX. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973847>
 16. **COVID-19 in Iran: What was done and what should be done.** Med. J. Islam. Repub. Iran 2021; 35:97Nojomi M, Moradi-Lakeh M, Pourmalek F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956943>
 17. **Mediterranean Diet a Potential Strategy against SARS-CoV-2 Infection: A Narrative Review.** Medicina (Kaunas) 2021; 57Ferro Y, Pujia R, Maurotti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946334>
 18. **Protective and Non-Protective Factors of Mental Health Distress in the United States during the COVID-19 Pandemic: A Systematic Review.** Medicina (Kaunas) 2021; 57Lieneck C, Bosworth M, Weaver E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946322>
 19. **Facts and Challenges about Asthma and COVID-19 among the Paediatric Population: A Systematic Literature Review.** Medicina (Kaunas) 2021; 57Moreno-Sánchez E, Castillo-Viera E, Vélez-Moreno E, Gago-Valiente FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946251>
 20. **Microorganisms as Shapers of Human Civilization, from Pandemics to Even Our Genomes: Villains or Friends? A Historical Approach.** Microorganisms 2021; 9Rodríguez-Frías F, Quer J, Tabernero D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946123>
 21. **COVID-19 Induced Miller Fisher Syndrome Presenting With Autonomic Dysfunction: A Unique Case Report and Review of Literature.** Neurohospitalist 2022; 12:111-116Biswas S, Ghosh R, Mandal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950397>
 22. **The Impact of the Coronavirus Disease (COVID-19) Pandemic on Nurses' Turnover Intention: An Integrative Review.** Nurs Rep 2021; 11:787-810Falatah R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968269>
 23. **Vitamin D Dosing: Basic Principles and a Brief Algorithm (2021 Update).** Nutrients 2021; 13Bleizgys A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959969>
 24. **Role of the otolaryngologist in nasopharyngeal swab training: A case report and review of the literature.** Otolaryngol Case Rep 2021; 20:100316Liu M, Roychowdhury P, Ito CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957363>
 25. **CSF rhinorrhea after nasopharyngeal swab testing for COVID-19: A case report and review of literature.** Otolaryngol Case Rep 2021; 21:100370Samadian M, Maroufi SF, Taheri MS, Jafari A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957364>
 26. **Understanding COVID-19 Pathogenesis: A Drug-Repurposing Effort to Disrupt Nsp-1 Binding to Export Machinery Receptor Complex.** Pathogens 2021; 10Vasudevan S, Baraniuk JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959589>
 27. **Molnupiravir: A new candidate for COVID-19 treatment.** Pharmacol Res Perspect 2022; 10:e00909Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968008>

28. **Compounders of the COVID crisis: the "perfect storm".** Proc. (Bayl. Univ. Med. Cent.) 2022; 35:133-136 Franklin BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970063>
29. **Why we still need drugs for COVID-19 and can't just rely on vaccines.** Respirology 2022; 27:109-111 Robinson BWS, Tai A, Springer K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970812>
30. **An overall protective effect of antipsychotic drugs against COVID-19 seems implausible.** Schizophr Res 2021; Ruiz de Pellón-Santamaría Á, Sarasqueta-Eizaguirre C, Basterrechea-Peña FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969568>
31. **[Andrological aspects of new coronavirus infection Covid-19].** Urologia 2021:130-135 Akhvlediani ND, Reva IA, Chernushenko AS, Pushkar DY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967175>
32. **Bilateral renal Mucor mycosis presenting as anuria in a Covid 19 recovered patient: A case report and review of literature.** Urology 2021; Vaddi SP, Khetavath SM, Babu DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968570>
33. **Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021.** Vaccines (Basel) 2021; 9 Cheng CJ, Lu CY, Chang YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960235>
34. **Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review.** Vaccines (Basel) 2021; 9 Lee YK, Huang YH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960150>
35. **Factors Associated with COVID-19 Vaccine Hesitancy among Visible Minority Groups from a Global Context: A Scoping Review.** Vaccines (Basel) 2021; 9 Ochieng C, Anand S, Mutwiri G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960192>
36. **COVID-19 in Low- and Middle-Income Countries (LMICs): A Narrative Review from Prevention to Vaccination Strategy.** Vaccines (Basel) 2021; 9 Pasquale S, Gregorio GL, Caterina A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960223>
37. **Heparin and SARS-CoV-2: Multiple Pathophysiological Links.** Viruses 2021; 13 Di Micco P, Imbalzano E, Russo V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960754>
38. **Excess Body Mass-A Factor Leading to the Deterioration of COVID-19 and Its Complications-A Narrative Review.** Viruses 2021; 13 Gryczyńska W, Litvinov N, Bitew B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960696>
39. **Iron Related Biomarkers Predict Disease Severity in a Cohort of Portuguese Adult Patients during COVID-19 Acute Infection.** Viruses 2021; 13 Moreira AC, Teles MJ, Silva T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960751>

Risk factors (34 articles)

1. **Pre-infection HDL-cholesterol levels and mortality among elderly patients infected with SARS-CoV-2.** Atherosclerosis 2022; 341:13-19 Mostaza JM, Salinero-Fort MA, Cardenas-Valladolid J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959204>
2. **The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males.** Autophagy 2021:1-11 Croci S, Venneri MA, Mantovani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964709>

3. **No Effects of Meteorological Factors on the SARS-CoV-2 Infection Fatality Rate.** *Biomed. Environ. Sci.* 2021; 34:871-880Solanes A, Laredo C, Guasp M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955147>
4. **Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent manner.** *Br. J. Haematol.* 2021; Garnier Y, Claude L, Hermand P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962643>
5. **Impact of Latent Tuberculosis on Severity and Outcomes in Admitted COVID-19 Patients.** *Cureus* 2021; 13:e19882Madan M, Baldwa B, Raja A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966601>
6. **Clinical and Laboratory Factors in Predicting Mortality Among COVID-19 RT-PCR Positive Patients: A Retrospective Observational Study From a Tertiary Care Center.** *Cureus* 2021; 13:e19791Sundaramurthy R, Balasubramanian S, Ganesan V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956783>
7. **Overweight and Obesity Are Associated With Acute Kidney Injury and Acute Respiratory Distress Syndrome, but Not With Increased Mortality in Hospitalized COVID-19 Patients: A Retrospective Cohort Study.** *Front. Endocrinol. (Lausanne)* 2021; 12:747732van Son J, Oussaada SM, Şekercan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970220>
8. **High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome.** *Front. Endocrinol. (Lausanne)* 2021; 12:791476Wang W, Chai Z, Cooper ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956098>
9. **Host Genetic Liability for Severe COVID-19 Associates with Alcohol Drinking Behavior and Diabetic Outcomes in Participants of European Descent.** *Front. Genet* 2021; 12:765247Wendt FR, De Lillo A, Pathak GA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966408>
10. **Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.** *Front. Immunol.* 2021; 12:707159Cyprian FS, Suleman M, Abdelhafez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966381>
11. **Association of the Serum Levels of the Nucleocapsid Antigen of SARS-CoV-2 With the Diagnosis, Disease Severity, and Antibody Titers in Patients With COVID-19: A Retrospective Cross-Sectional Study.** *Front. Microbiol.* 2021; 12:791489Yokoyama R, Kurano M, Nakano Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956158>
12. **Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19.** *Front Public Health* 2021; 9:778340Luo K, Chen Y, Yang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970527>
13. **Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters.** *Gut Microbes* 2022; 14:2018900Sencio V, Machelart A, Robil C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965194>
14. **Early Occurrence of Adverse Events in Hospitalized Patients With COVID-19 and Beneficial Effect of Anticoagulation.** *In Vivo* 2022; 36:381-383Dimakakos E, Kollias A, Rapti V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972738>
15. **Impact of Pectoral Muscle Values on Clinical Outcomes in Patients With Severe Covid-19 Disease.** *In Vivo* 2022; 36:375-380Kardas H, Thormann M, Bär C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972737>

16. **Presepsin as a Predictive Biomarker of Severity in COVID-19: A Systematic Review.** Indian J. Crit. Care Med. 2021; 25:1051-1054 Ahmed S, Mansoor M, Shaikh MS, Siddiqui I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963726>
17. **Does the initial chest radiograph severity in COVID-19 impact the short- and long-term outcome? - a perspective from India.** Infect Dis (Lond) 2021;1-10 D'Souza M M, Kaushik A, Dsouza JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961400>
18. **County-level socio-economic disparities in COVID-19 mortality in the USA.** Int J Epidemiol 2021; Dukhovnov D, Barbieri M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957523>
19. **Nasopharyngeal microbiota as an early severity biomarker in COVID-19 hospitalised patients: A retrospective cohort study in a Mediterranean area.** J Infect 2021; Ventero MP, Moreno-Perez O, Molina-Pardines C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963638>
20. **Hyperglycemia and blood glucose deterioration are risk factors for severe COVID-19 with diabetes: A two-center cohort study.** J Med Virol 2021; Xiao F, Zhou YC, Zhang MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967028>
21. **A high neutrophil to lymphocyte ratio at ICU admission is associated with nutritional risk in COVID-19 patients.** JPEN J. Parenter. Enteral Nutr. 2021; Martins PM, Gomes TLN, Franco EP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961953>
22. **Predictors of critical COVID-19 in an Iranian population: Age and disabilities play a special role.** Med. J. Islam. Repub. Iran 2021; 35:94 Bidari A, Hassanzadeh M, Naderkhani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956940>
23. **Predictors of death in patients with COVID-19: A cross-sectional study in West of Iran.** Med. J. Islam. Repub. Iran 2021; 35:103 Karami M, Mirzaei M, Shahbazi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956949>
24. **Factors Associated with ICU Admission in Patients with COVID-19: The GOL2DS Score.** Medicina (Kaunas) 2021; 57 Candelli M, Pignataro G, Ferrigno M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946301>
25. **Association between Prehospital Hypoxemia and Admission to Intensive Care Unit during the COVID-19 Pandemic: A Retrospective Cohort Study.** Medicina (Kaunas) 2021; 57 Midez R, Fehlmann CA, Marti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946307>
26. **Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.** Nat Cancer 2021; 2:1321-1337 Fendler A, Shepherd STC, Au L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950880>
27. **Vitamin D Dosing: Basic Principles and a Brief Algorithm (2021 Update).** Nutrients 2021; 13 Bleizgys A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959969>
28. **Occupation and COVID-19 mortality in England: a national linked data study of 14.3 million adults.** Occup. Environ. Med. 2021; Nafilyan V, Pawelek P, Ayoubkhani D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965981>
29. **COVID-19 transmission risk factors.** Pathog Glob Health 2021;1-32 Notari A, Torrieri G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962231>
30. **Estimating the impact of influenza on the epidemiological dynamics of SARS-CoV-2.** PeerJ 2021; 9:e12566 Domenech de Cellès M, Casalegno JS, Lina B, Opatowski L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950537>

31. **Disaggregating Asian Race Reveals COVID-19 Disparities Among Asian American Patients at New York City's Public Hospital System.** Public Health Rep. 2021:333549211061313Kalyanaraman Marcello R, Dolle J, Tariq A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965776>
32. **sTREM-1 Predicts Disease Severity and Mortality in COVID-19 Patients: Involvement of Peripheral Blood Leukocytes and MMP-8 Activity.** Viruses 2021; 13da Silva-Neto PV, de Carvalho JCS, Pimentel VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960790>
33. **COVID-19 Modulates Inflammatory and Renal Markers That May Predict Hospital Outcomes among African American Males.** Viruses 2021; 13Fonseca W, Asai N, Yagi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960684>
34. **Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?** Viruses 2021; 13Parra-Lucare A, Toro L, Weitz-Muñoz S, Ramos C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960761>

Safety (37 articles)

1. **Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.** Acta Neurol. Scand. 2021; Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967005>
2. **A case of aseptic meningitis following AZD1222 COVID-19 vaccination.** Am J Emerg Med 2021; Zavari A, Hamidabad NM, Hassanzadeh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955313>
3. **Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.** Ann. Rheum. Dis. 2021; Machado PM, Lawson-Tovey S, Strangfeld A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972811>
4. **Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.** BMC Cancer 2021; 21:1354Greenberg RS, Ruddy JA, Boyarsky BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961488>
5. **Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine.** BMJ Case Rep. 2021; 14Atta SN, Othman N, Babar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969796>
6. **Graves' disease following administration of second dose of SARS-CoV-2 vaccine.** BMJ Case Rep. 2021; 14Goblirsch TJ, Paulson AE, Tashko G, Mekonnen AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969799>
7. **Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE Monte Carlo simulations, and in vitro activity inhibition.** Chem. Phys. Lett. 2021:139294Liang JJ, Pitsillou E, Ververis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961797>
8. **SARS-CoV-2 vaccination triggered Guillain-Barre syndrome.** Clin. Neurol. Neurosurg. 2021; 213:107106Scorza FA, Finsterer J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974378>
9. **De-novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19.** Cureus 2021; 13:e19616Feghali EJ, Zafar M, Abid S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956751>

10. **Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?** Cureus 2021; 13:e19919Maheshwari M, Athiraman H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956798>
11. **Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases.** Egypt J Neurol Psychiatr Neurosurg 2021; 57:179Finsterer J, Zarrouk S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34955632>
12. **Successes of the CDC monitoring systems in evaluating post-authorization safety of COVID-19 vaccines.** Expert Rev Vaccines 2022:1-4Moro PL, McNeil MM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957900>
13. **Portal Vein Thrombosis Might Develop by COVID-19 Infection or Vaccination: A Systematic Review of Case-Report Studies.** Front Med (Lausanne) 2021; 8:794599Kheyrandish S, Rastgar A, Arab-Zozani M, Sarab GA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34970570>
14. **New-onset autoimmune phenomena post-COVID-19 vaccination.** Immunology 2021; Chen Y, Xu Z, Wang P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957554>
15. **Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination.** Int J Infect Dis 2021; 116:114-121Hwang J, Han YJ, Yon DK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34958931>
16. **Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks.** Int J Surg 2022; 97:106204Dhawan M, Priyanka, Parmar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974199>
17. **Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccination-Associated Hypersensitivity Reactions.** J Allergy Clin Immunol Pract 2021; Macy E, Pandya S, Sheikh J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971845>
18. **Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination.** J Autoimmun 2021; 127:102783Fiorillo G, Pancetti S, Cortese A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34973526>
19. **Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring.** J Infect Dis 2021; Abara WE, Gee J, Delorey M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958099>
20. **Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults.** J Infect Dis 2021; Bruxvoort KJ, Ackerson B, Sy LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962997>
21. **Adult-onset Still's Disease after BNT162b2 mRNA COVID-19 Vaccine.** J Korean Med Sci 2021; 36:e344Park SY, Lee KH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962116>
22. **Axillary adenopathy after COVID-19 vaccine in patients undergoing breast ultrasound.** J Ultrason 2021; 21:e361-e364Giorgis S, Garlaschi A, Brunetti N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34970450>
23. **Temporary exacerbation of pre-existing psoriasis and eczema in the context of COVID-19 messenger RNA booster vaccination: A case report and review of the literature.** JAAD Int 2022; 6:94-96Phuan CZY, Choi EC, Oon HH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34957419>
24. **Melting and Re-Freezing Leads to Irreversible Changes in the Morphology and Molecular-Level Dynamics of Pfizer-BioNTech COVID-19 Vaccine.** Medicina

- (Kaunas) 2021; 57 Mamontov E, Daemen LL, Novak E, Stone MB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34946288>
25. **COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021.** *Osong Public Health Res Perspect* 2021; 12:396-402 Hwang I, Park K, Kim TE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965689>
 26. **Sudden sensorineural hearing loss after covid-19 vaccine; A possible adverse reaction?** *Otolaryngol Case Rep* 2021; 21:100384 Pisani D, Leopardi G, Viola P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957365>
 27. **Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office.** *Pharmaceuticals (Basel)* 2021; 14 Dri DA, Praticò G, Gaucci E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959722>
 28. **Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.** *Thorac Cancer* 2021; Tamura T, Ninomiya K, Kubo T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34964270>
 29. **Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination.** *Vaccines (Basel)* 2021; 9 Bagella CF, Corda DG, Zara P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960248>
 30. **Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.** *Vaccines (Basel)* 2021; 9 Intapiboon P, Seepathomnarong P, Ongarj J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960122>
 31. **Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review.** *Vaccines (Basel)* 2021; 9 Lee YK, Huang YH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960150>
 32. **Herpetic Keratitis Preceded by COVID-19 Vaccination.** *Vaccines (Basel)* 2021; 9 Li S, Jia X, Yu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960139>
 33. **Immune Thrombocytopenia Induced by the Chimpanzee Adenovirus-Vectored Vaccine against SARS-CoV-2 Infection.** *Vaccines (Basel)* 2021; 9 Liao PW, Teng CJ, Chou CW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960232>
 34. **Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection.** *Vaccines (Basel)* 2021; 9 Parés-Badell O, Martínez-Gómez X, Pinós L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960209>
 35. **Opposing Mechanisms Involving Perceived Benefits versus Safety Partially Explained an Increase in COVID-19 Vaccination Intention among Unvaccinated Chinese Adults during a Post-Rollout Period: Results of Two Serial Surveys.** *Vaccines (Basel)* 2021; 9 Yu Y, Lau JTF, Lau MMC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960160>
 36. **JAK-STAT Pathway: A Novel Target to Tackle Viral Infections.** *Viruses* 2021; 13 Ezeonwumelu IJ, Garcia-Vidal E, Ballana E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960648>
 37. **Experience of the first 1127 COVID-19 Vaccine Allergy Safety patients in Hong Kong - Clinical outcomes, barriers to vaccination, and urgency for reform.** *World Allergy Organ J* 2022; 15:100622 Chiang V, Mok SWS, Chan JKC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956434>

Treatment options (53 articles)

1. **Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19.** Am J Transl Res 2021; 13:12575-12587 Ruzhentsova TA, Oseshnyuk RA, Soluyanov TN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956474>
2. **Clinical update on the use of mesenchymal stem cells in COVID-19.** Am J Transl Res 2021; 13:12195-12205 Saleh FA, Ghazzawi J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956446>
3. **Review of studies on SARS-CoV-2 infection inhibitors.** Ann. Agric. Environ. Med. 2021; 28:541-550 Michalski A, Wójcicka P, Bielawska-Drózd A, Bartoszcze M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969209>
4. **Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.** Ann. Clin. Microbiol. Antimicrob. 2021; 20:85 Taha Y, Wardle H, Evans AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969393>
5. **Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein.** Bioorg. Chem. 2021; 119:105574 Power H, Wu J, Turville S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971947>
6. **Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study.** Braz. J. Infect. Dis. 2021; 26:101702 Dolci G, Cassone G, Besutti G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963560>
7. **Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation.** Brief. Bioinform. 2022; 23 Serra A, Fratello M, Federico A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962256>
8. **Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers.** Cell Host Microbe 2022; 30:69-82.e10 Vanshylla K, Fan C, Wunsch M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973165>
9. **Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern.** Cell Rep. 2022; 38:110210 Li W, Chen Y, Prévost J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971573>
10. **Compassionate Use of REGEN-COV® in Patients with COVID-19 and Immunodeficiency-Associated Antibody Disorders.** Clin Infect Dis 2021; Stein D, Oviedo-Orta E, Kampman WA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971385>
11. **Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?** Cureus 2021; 13:e19919 Maheshwari M, Athiraman H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956798>
12. **Remdesivir: Mechanism of Metabolic Conversion from Prodrug to Drug.** Curr Drug Metab 2021; Kapoor S, Dubey G, Khatun S, Bharatam PV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963432>
13. **The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients. A systematic review, meta-analysis and meta-regression.** Diabetes Metab Res Rev 2021:e3517 Tentolouris N, Samakidou G, Eleftheriadou I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965318>
14. **Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial.** EBioMedicine 2021; 75:103789 Shi L, Yuan X, Yao W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963099>

15. **Integrated Chinese herbal medicine and Western medicine successfully resolves spontaneous subcutaneous emphysema and pneumomediastinum in a patient with severe COVID-19 in Taiwan: A case report.** Explore (NY) 2021; Hung SW, Liao YC, Chi IC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955379>
16. **Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.** Front. Immunol. 2021; 12:790469Zhang L, Poorbaugh J, Dougan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956222>
17. **A Case-Control Study for the Effectiveness of Oral Zinc in the Prevention and Mitigation of COVID-19.** Front Med (Lausanne) 2021; 8:756707Gordon AM, Hardigan PC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966750>
18. **Screening of Microbial Natural Products and Biological Evaluation of Trichomicin as Potential Anti-Cytokine Storm Agents.** Front. Pharmacol. 2021; 12:770910Chen Y, Zhuang Z, Yang J, Bai L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955842>
19. **The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.** Front. Pharmacol. 2021; 12:731453Zhang T, Tong X, Zhang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955820>
20. **Early Experience of High-dose Intravenous Mycobacterium w in Critically Ill Patients of COVID-19.** Indian J. Crit. Care Med. 2021; 25:1066-1068Patel PS, Patel S, Shah V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963729>
21. **Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry.** Int J Infect Dis 2021; 116:51-58Calderón-Parra J, Cuervas-Mons V, Moreno-Torres V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971824>
22. **Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks.** Int J Surg 2022; 97:106204Dhawan M, Priyanka, Parmar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974199>
23. **SARS-CoV-2-host cell surface interactions and potential antiviral therapies.** Interface Focus 2022; 12:20200081Butnariu AB, Look A, Grillo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956606>
24. **Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm.** Interface Focus 2022; 12:20210006Morgulchik N, Athanasopoulou F, Chu E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956607>
25. **Menthol-assisted homogenous liquid-liquid microextraction for HPLC/UV determination of favipiravir as an antiviral for COVID-19 in human plasma.** J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2022; 1189:123087Abdallah IA, Hammad SF, Bedair A, Mansour FR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974319>
26. **Platelet-Rich Plasma Treatment for Accelerated Androgenetic Alopecia Pattern Hair Loss After COVID-19 Infection: A Case Series.** J Cosmet Dermatol 2021; İşlek A, Karaaslan E, Şimşek S, Merve Çetin F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965004>
27. **Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naïve and COVID-19 convalescent individuals.** J Infect Dis 2021; Luczkowiak J, Labiod N, Rivas G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963008>

28. **Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19.** *J Med Virol* 2021; Kerget B, Kerget F, Aydın M, Karaşahin Ö. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958142>
29. **Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.** *MAbs* 2022; 14:2002236Yuan TZ, Garg P, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967699>
30. **The effect of opium on severity of COVID-19 infection:An original study from Iran.** *Med. J. Islam. Repub. Iran* 2021; 35:115Riahi T, Sadeghzadeh-Bazargan A, Shokri S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956961>
31. **Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs "Remdesivir and Favipiravir": Green assessment with application to pharmaceutical formulations and human plasma.** *Microchem. J.* 2022; 174:107101Noureldeen DAM, Boushra JM, Lashien AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955554>
32. **Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources.** *Microorganisms* 2021; 9Razali R, Asis H, Budiman C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946083>
33. **Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection.** *Mol. Med.* 2021; 27:162Chapoval SP, Keegan AD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961486>
34. **A Dispersion Corrected DFT Investigation of the Inclusion Complexation of Dexamethasone with β -Cyclodextrin and Molecular Docking Study of Its Potential Activity against COVID-19.** *Molecules* 2021; 26Belhocine Y, Rahali S, Allal H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946702>
35. **Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.** *Molecules* 2021; 26Elzupir AO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946540>
36. **Polyphenols as Potential Inhibitors of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp).** *Molecules* 2021; 26Wu Y, Crich D, Pegan SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946521>
37. **Reducing the viral load of SARS-CoV-2 in the saliva of patients with COVID-19.** *Oral Dis* 2021; Guimarães TC, Marques BBF, Castro MV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963033>
38. **Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials.** *Pathogens* 2021; 10Ma KS, Lee CC, Liu KJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959492>
39. **Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office.** *Pharmaceuticals (Basel)* 2021; 14Dri DA, Praticò G, Gaucci E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959722>
40. **Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.** *Pharmaceuticals (Basel)* 2021; 14Kawazoe M, Kihara M, Nanki T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959657>
41. **Computational and In Vitro Experimental Investigations Reveal Anti-Viral Activity of Licorice and Glycyrrhizin against Severe Acute Respiratory Syndrome Coronavirus 2.** *Pharmaceuticals (Basel)* 2021; 14Tolah AM, Altayeb LM, Alandijany TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959616>

42. **Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?** Pharmaceuticals (Basel) 2021; 14:Vimberg V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959628>
43. **Molnupiravir: A new candidate for COVID-19 treatment.** Pharmacol Res Perspect 2022; 10:e00909Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968008>
44. **Global Innovation Trends for Plant-Based Vaccines Production: A Patent Analysis.** Plants (Basel) 2021; 10:Frisio DG, Ventura V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961028>
45. **Impairment of T cells' antiviral and anti-inflammation immunities may be critical to death from COVID-19.** R Soc Open Sci 2021; 8:211606Zhang L, Li R, Song G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950497>
46. **Why we still need drugs for COVID-19 and can't just rely on vaccines.** Respirology 2022; 27:109-111Robinson BWS, Tai A, Springer K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970812>
47. **Potential COVID-19 therapeutic approaches targeting angiotensin-converting enzyme 2; An updated review.** Rev Med Virol 2021:e2321Zanganeh S, Goodarzi N, Doroudian M, Movahed E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958163>
48. **Antiviral activity of aframomum melegueta against severe acute respiratory syndrome coronaviruses type 1 and 2.** S Afr J Bot 2022; 146:735-739Mahoney O, Melo C, Lockhart A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955582>
49. **An overall protective effect of antipsychotic drugs against COVID-19 seems implausible.** Schizophr Res 2021; Ruiz de Pellón-Santamaría Á, Sarasqueta-Eizaguirre C, Basterrechea-Peña FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969568>
50. **Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer.** Sci Afr 2021:e01084Batiha GE, Al-Gareeb DAI, Qusti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957352>
51. **Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial.** Thromb Res 2021; Rashidi F, Barco S, Rezaeifar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969528>
52. **Soliris to Stop Immune-Mediated Death in COVID-19 (SOLID-C19)-A Compassionate-Use Study of Terminal Complement Blockade in Critically Ill Patients with COVID-19-Related Adult Respiratory Distress Syndrome.** Viruses 2021; 13:Pitts TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960699>
53. **[The open observational study of aceclofenac and vinpocetine effectiveness and tolerability in treatment of patients with chronic cerebrovascular disease after COVID-19 (AQUA study)].** Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2021; 121:s1-s8Samartsev IN, Zhivolupov SA, Butakova JS, Parshin MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968019>

Trials (22 articles)

1. **Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19.** Am J Transl Res 2021; 13:12575-12587Ruzhentsova TA, Oseshnyuk RA, Soluyanov TN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956474>
2. **Interpreting recent clinical studies for COVID-19: A continual process with more new data.** Anaesth Crit Care Pain Med 2021; 41:101016Connors JM, Moll M, Levy JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958999>

3. **Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.** Ann. Rheum. Dis. 2021; Machado PM, Lawson-Tovey S, Strangfeld A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972811>
4. **Randomized clinical trial of a brief, scalable intervention for mental health sequelae in college students during the COVID-19 pandemic.** Behav. Res. Ther. 2021; 149:104015Rizvi SL, Finkelstein J, Wacha-Montes A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958980>
5. **Suspend or amend? Randomized controlled trial on neuropsychological rehabilitation for epilepsy: A COVID-19 impact.** Epilepsy Behav Rep 2022; 17:100516Sharma S, Nehra A, Pandey S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957386>
6. **Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial.** Eur. J. Clin. Invest. 2021:e13735Morici N, Podda G, Birocchi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958123>
7. **Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.** Front. Immunol. 2021; 12:781843Pitzalis M, Idda ML, Lodde V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956211>
8. **A Case-Control Study for the Effectiveness of Oral Zinc in the Prevention and Mitigation of COVID-19.** Front Med (Lausanne) 2021; 8:756707Gordon AM, Hardigan PC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966750>
9. **Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants.** Front Med (Lausanne) 2021; 8:769845Seree-Aphinan C, Chanprapaph K, Rattanakaemakorn P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957149>
10. **Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study.** Int J Infect Dis 2021; 116:47-50Chan EWW, Leung MTY, Lau LKW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965462>
11. **Social Determinants of Health Amplify the Association Between Ethnicity and COVID19: A Retrospective-Cohort study.** Int J Med Stud 2021; 9:282-287Verdini N, LeClair J, Quinn E, El-Haddad A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956659>
12. **Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register.** Intern Emerg Med 2022:1-9Poli D, Antonucci E, Ageno W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973126>
13. **The global impact of the Coronavirus 2019 pandemic on in-centre haemodialysis services: an International Society of Nephrology -Dialysis Outcomes Practice Patterns Study survey.** Kidney Int Rep 2021; Aylward R, Bieber B, Guedes M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957349>
14. **Older Americans' Perceptions of the Federal Government's Pandemic Response: Voices From the COVID-19 Coping Study.** Res. Aging 2021:1640275211062111Gallo HB, Kobayashi LC, Finlay JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967234>
15. **Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial.** Thromb Res 2021; Rashidi F, Barco S,

- Rezaeifar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969528>
16. **[Features of a new corOnavirUs infection course and optioNs therapy DEpending on the andRogenic status (FOUNDER): androgenic status in men with COVID-19 and its relationship with the disease severity].** Urologiia 2021;85-99Kamalov AA, Mareev VY, Orlova IA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967512>
 17. **Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination.** Vaccines (Basel) 2021; 9Bagella CF, Corda DG, Zara P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960248>
 18. **Knowledge, Perception, and Willingness towards Immunization among Bangladeshi Population during COVID-19 Vaccine Rolling Period.** Vaccines (Basel) 2021; 9Bari MS, Hossain MJ, Ahmmed F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960195>
 19. **Equity in Vaccine Trials for Higher Weight People? A Rapid Review of Weight-Related Inclusion and Exclusion Criteria for COVID-19 Clinical Trials.** Vaccines (Basel) 2021; 9Campbell J, Sutherland J, Bucknall D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960212>
 20. **Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).** Viruses 2021; 13Ruetalo N, Flehmig B, Schindler M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960605>
 21. **Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population.** Viruses 2021; 13Sariol CA, Serrano-Collazo C, Ortiz EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960674>
 22. **[The open observational study of aceclofenac and vinpocetine effectiveness and tolerability in treatment of patients with chronic cerebrovascular disease after COVID-19 (AQUA study)].** Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2021; 121:s1-s8Samartsev IN, Zhivolupov SA, Butakova JS, Parshin MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968019>

Vaccines (136 articles)

1. **Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.** Acta Neurol. Scand. 2021; Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967005>
2. **A case of aseptic meningitis following AZD1222 COVID-19 vaccination.** Am J Emerg Med 2021; Zavari A, Hamidabad NM, Hassanzadeh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955313>
3. **How many lives do COVID vaccines save? Evidence from Israel.** Am. J. Infect. Control 2021; Arbel R, Moore CM, Sergienko R, Pliskin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971714>
4. **Trends in COVID-19 vaccination receipt and intention to vaccinate, United States, April to August, 2021.** Am. J. Infect. Control 2021; Nguyen KH, Nguyen K, Geddes M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973356>
5. **Fear about adverse effect on fertility is a major cause of COVID-19 vaccine hesitancy in the United States.** Andrologia 2021:e14361Diaz P, Zizzo J, Balaji NC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970749>

6. **Vaccine inequity and hesitancy: Dual factors in the emergence of novel SARS-CoV-2 variants.** Ann Med Surg (Lond). 2022; 73:103186Dhawan M, Priyanka, Sahni A, Choudhary OP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961829>
7. **COVID-19 vaccination and breakthrough infections in patients with cancer.** Ann Oncol 2021; Schmidt AL, Labaki C, Hsu CY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958894>
8. **Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.** Ann. Rheum. Dis. 2021; Machado PM, Lawson-Tovey S, Strangfeld A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972811>
9. **A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.** Biomed. Pharmacother. 2022; 146:112550Li CX, Noreen S, Zhang LX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959116>
10. **Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.** BMC Cancer 2021; 21:1354Greenberg RS, Ruddy JA, Boyarsky BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961488>
11. **Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine.** BMJ Case Rep. 2021; 14Atta SN, Othman N, Babar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969796>
12. **Graves' disease following administration of second dose of SARS-CoV-2 vaccine.** BMJ Case Rep. 2021; 14Goblirsch TJ, Paulson AE, Tashko G, Mekonnen AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969799>
13. **COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoral and cellular immunity.** Br. J. Haematol. 2021; Shen Y, Freeman JA, Holland J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962656>
14. **SARS-CoV-2 vaccination triggered Guillain-Barre syndrome.** Clin. Neurol. Neurosurg. 2021; 213:107106Scorza FA, Finsterer J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974378>
15. **Determinants for Acceptance of COVID-19 Vaccine in Nigeria.** Cureus 2021; 13:e19801Eze UA, Ndoh KI, Ibisola BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963828>
16. **De-novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19.** Cureus 2021; 13:e19616Feghali EJ, Zafar M, Abid S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956751>
17. **Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Healthcare Workers After Vaccine Administration in an Intensive Care Unit.** Cureus 2021; 13:e20579Lemos C, Ferreira S, Gouveia C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963873>
18. **The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response.** DNA Cell Biol. 2022; 41:25-29Kapnick SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958232>
19. **Adenovirus vector-based vaccine for infectious diseases.** Drug Metab. Pharmacokinet. 2021; 42:100432Sakurai F, Tachibana M, Mizuguchi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974335>

20. **Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases.** Egypt J Neurol Psychiatr Neurosurg 2021; 57:179 Finsterer J, Zarrouk S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955632>
21. **Psychological factors affecting COVID-19 vaccine acceptance in Indonesia.** Egypt J Neurol Psychiatr Neurosurg 2021; 57:177 Yanto TA, Octavius GS, Heriyanto RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955630>
22. **Successes of the CDC monitoring systems in evaluating post-authorization safety of COVID-19 vaccines.** Expert Rev Vaccines 2022:1-4 Moro PL, McNeil MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957900>
23. **Vaccination strategies between compulsion and incentives. The Italian Green Pass experience.** Expert Rev Vaccines 2022:1-3 Stefanizzi P, Bianchi FP, Brescia N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962214>
24. **Looking to the future: is a universal coronavirus vaccine feasible?** Expert Rev Vaccines 2021:1-4 Vashishtha VM, Kumar P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968153>
25. **Who is more likely to hesitate to accept COVID-19 vaccine: a cross-sectional survey in China.** Expert Rev Vaccines 2022:1-10 Zhang P, Zhang Q, Guan H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961405>
26. **SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After Vaccination.** Front. Immunol. 2021; 12:798859 Pinilla YT, Heinzel C, Caminada LF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956236>
27. **Portal Vein Thrombosis Might Develop by COVID-19 Infection or Vaccination: A Systematic Review of Case-Report Studies.** Front Med (Lausanne) 2021; 8:794599 Kheyrandish S, Rastgar A, Arab-Zozani M, Sarab GA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970570>
28. **The Second Wave of COVID-19 in South and Southeast Asia and the Effects of Vaccination.** Front Med (Lausanne) 2021; 8:773110 Song H, Fan G, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970562>
29. **Influence of Vaccination Characteristics on COVID-19 Vaccine Acceptance Among Working-Age People in Hong Kong, China: A Discrete Choice Experiment.** Front Public Health 2021; 9:793533 Wang K, Wong EL, Cheung AW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957038>
30. **Vaccine hesitancy and acceptance: an examination of predictive factors in COVID-19 vaccination in Saudi Arabia.** Health Promot. Int. 2021; Fadhel FH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967862>
31. **Kinetics and persistence of anti-SARS-CoV-2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort.** Immun Inflamm Dis 2021; Šošić L, Paolucci M, Duda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965032>
32. **New-onset autoimmune phenomena post-COVID-19 vaccination.** Immunology 2021; Chen Y, Xu Z, Wang P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957554>
33. **Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy.** Infect Dis Ther 2021:1-9 Homan T, Fortunato F, Corso G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964938>
34. **Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination.** Int J Infect

- Dis 2021; 116:114-121Hwang J, Han YJ, Yon DK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34958931>
35. **Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccination-Associated Hypersensitivity Reactions.** J Allergy Clin Immunol Pract 2021; Macy E, Pandya S, Sheikh J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971845>
 36. **Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination.** J Autoimmun 2021; 127:102783Fiorillo G, Pancetti S, Cortese A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973526>
 37. **Cardiovascular and haematological events post COVID-19 vaccination: A systematic review.** J Cell Mol Med 2021; Al-Ali D, Elshafeey A, Mushannen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967105>
 38. **The thoughts of parents to vaccinate their children against COVID-19: An assessment of situations that may affect them.** J. Child Adolesc. Psychiatr. Nurs. 2021; Çelik MY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962336>
 39. **Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring.** J Infect Dis 2021; Abara WE, Gee J, Delorey M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958099>
 40. **Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults.** J Infect Dis 2021; Bruxvoort KJ, Ackerson B, Sy LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962997>
 41. **Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naïve and COVID-19 convalescent individuals.** J Infect Dis 2021; Luczkowiak J, Labiod N, Rivas G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963008>
 42. **SARS-CoV-2 infection during pregnancy and associated perinatal health outcomes: a national US cohort study.** J Infect Dis 2021; Regan AK, Arah O, Fell DB, Sullivan SG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958090>
 43. **Adult-onset Still's Disease after BNT162b2 mRNA COVID-19 Vaccine.** J Korean Med Sci 2021; 36:e344Park SY, Lee KH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962116>
 44. **Association between perceived organizational support and COVID-19 vaccination intention: A cross-sectional study.** J Occup Health 2021; 63:e12308Kobayashi Y, Nagata T, Fujino Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964221>
 45. **Axillary adenopathy after COVID-19 vaccine in patients undergoing breast ultrasound.** J Ultrason 2021; 21:e361-e364Giorgis S, Garlaschi A, Brunetti N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970450>
 46. **Temporary exacerbation of pre-existing psoriasis and eczema in the context of COVID-19 messenger RNA booster vaccination: A case report and review of the literature.** JAAD Int 2022; 6:94-96Phuan CZY, Choi EC, Oon HH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957419>
 47. **Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study.** Lancet Reg Health Am 2022; 6:100154Cerqueira-Silva T, Oliveira VA, Boaventura VS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957437>
 48. **Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-**

- centre cohort study. Lancet Reg Health Eur 2021;100287Lombardi A, Butta GM, Donnici L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961855>
49. **The effect of influenza vaccine on severity of COVID-19 infection: An original study from Iran.** Med. J. Islam. Repub. Iran 2021; 35:114Kalantari S, Sadeghzadeh-Bazargan A, Ebrahimi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956960>
 50. **Melting and Re-Freezing Leads to Irreversible Changes in the Morphology and Molecular-Level Dynamics of Pfizer-BioNTech COVID-19 Vaccine.** Medicina (Kaunas) 2021; 57Mamontov E, Daemen LL, Novak E, Stone MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946288>
 51. **Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.** Medicina (Kaunas) 2021; 57Olariu TR, Ursoniu S, Marincu I, Lupu MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946275>
 52. **Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients.** Medicina (Kaunas) 2021; 57Vaiciuniene R, Sitkauskienė B, Bumblyte IA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34946272>
 53. **COVID-19 vaccinations: does the mRNA go into breast milk?** Monatsschr. Kinderheilkd. 2021; Kerbl R.
 54. **Healthcare Provider Attitudes toward the Newly Developed COVID-19 Vaccine: Cross-Sectional Study.** Nurs Rep 2021; 11:187-194Ahmed G, Almoosa Z, Mohamed D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968323>
 55. **COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021.** Osong Public Health Res Perspect 2021; 12:396-402Hwang I, Park K, Kim TE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965689>
 56. **Sudden sensorineural hearing loss after covid-19 vaccine; A possible adverse reaction?** Otolaryngol Case Rep 2021; 21:100384Pisani D, Leopardi G, Viola P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957365>
 57. **Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel.** Prev. Med. 2021; 155:106947Saciuk Y, Kertes J, Mandel M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974072>
 58. **Ensuring Equitable COVID-19 Vaccination for People With Disabilities and Their Caregivers.** Public Health Rep. 2021:333549211058733Wiggins LD, Jett H, Meunier J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969301>
 59. **COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information.** Rev. Recent Clin. Trials 2021; Davide M, Kamposioras K, Lampriani T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967300>
 60. **Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.** Thorac Cancer 2021; Tamura T, Ninomiya K, Kubo T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964270>
 61. **Global impact of vaccine nationalism during COVID-19 pandemic.** Trop Med Health 2021; 49:101Riaz MMA, Ahmad U, Mohan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963494>
 62. **Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.** Vaccine 2022; 40:587-593Manomaipiboon A,

- Phumisantiphong U, Maneerit J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969542>
63. **COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhône-Alpes region (France): An ecological study.** *Vaccine* 2022; 40:695-700 Romain-Scelle N, Elias C, Vanhems P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969543>
 64. **Predicting vaccine uptake during COVID-19 crisis: A motivational approach.** *Vaccine* 2022; 40:288-297 Schmitz M, Luminet O, Klein O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961635>
 65. **Reduced COVID-19 hospitalizations among New York City residents following age-based SARS-CoV-2 vaccine eligibility: Evidence from a regression discontinuity design.** *Vaccine X* 2022; 10:100134 Greene SK, Levin-Rector A, McGibbon E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961848>
 66. **Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis.** *Vaccines (Basel)* 2021; 9:Achtnichts L, Jakopp B, Oberle M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960216>
 67. **Impact of Vaccination on the Sense of Security, the Anxiety of COVID-19 and Quality of Life among Polish. A Nationwide Online Survey in Poland.** *Vaccines (Basel)* 2021; 9:Babicki M, Malchrzak W, Hans-Wytrychowska A, Mastalerz-Migas A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960190>
 68. **Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination.** *Vaccines (Basel)* 2021; 9:Bagella CF, Corda DG, Zara P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960248>
 69. **Knowledge, Perception, and Willingness towards Immunization among Bangladeshi Population during COVID-19 Vaccine Rolling Period.** *Vaccines (Basel)* 2021; 9:Bari MS, Hossain MJ, Ahmmed F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960195>
 70. **Humoral Immune Response to SARS-CoV-2 Vaccination after a Booster Vaccine Dose in Two Kidney Transplant Recipients with Fabry Disease and Variable Secondary Immunosuppressive Regimens.** *Vaccines (Basel)* 2021; 9:Bernea L, Ailioaie OR, Benhamouda N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960158>
 71. **Equity in Vaccine Trials for Higher Weight People? A Rapid Review of Weight-Related Inclusion and Exclusion Criteria for COVID-19 Clinical Trials.** *Vaccines (Basel)* 2021; 9:Campbell J, Sutherland J, Bucknall D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960212>
 72. **Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021.** *Vaccines (Basel)* 2021; 9:Cheng CJ, Lu CY, Chang YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960235>
 73. **Comparison of the Development of SARS-Coronavirus-2-Specific Cellular Immunity, and Central Memory CD4+ T-Cell Responses Following Infection versus Vaccination.** *Vaccines (Basel)* 2021; 9:Dennehy KM, Löll E, Dhillon C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960185>
 74. **Predictors of COVID-19 Vaccine Acceptance and Hesitancy among Healthcare Workers in Southern California: Not Just "Anti" vs. "Pro" Vaccine.** *Vaccines (Basel)* 2021; 9:Dubov A, Distelberg BJ, Abdul-Mutakabbir JC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960171>

75. **Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study.** *Vaccines (Basel)* 2021; 9Firin D, Perra A, Campagna M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960224>
76. **Human Papilloma Virus Vaccination: Focus on the Italian Situation.** *Vaccines (Basel)* 2021; 9Gabutti G, d'Anchera E, De Motoli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960120>
77. **Effects of Pope Francis' Religious Authority and Media Coverage on Twitter User's Attitudes toward COVID-19 Vaccination.** *Vaccines (Basel)* 2021; 9Gawel A, Mańdziuk M, Żmudziński M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960233>
78. **Investigating the Influence of Vaccine Literacy, Vaccine Perception and Vaccine Hesitancy on Israeli Parents' Acceptance of the COVID-19 Vaccine for Their Children: A Cross-Sectional Study.** *Vaccines (Basel)* 2021; 9Gendler Y, Ofri L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960137>
79. **mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship.** *Vaccines (Basel)* 2021; 9Giannotta G, Giannotta N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960249>
80. **Impact of Anxiety on Readiness for COVID-19 Vaccination among Polish Nursing Undergraduate Students: Nationwide Cross-Sectional Study.** *Vaccines (Basel)* 2021; 9Gotlib J, Jaworski M, Wawrzuta D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960130>
81. **Evaluating Rates and Determinants of COVID-19 Vaccine Hesitancy for Adults and Children in the Singapore Population: Strengthening Our Community's Resilience against Threats from Emerging Infections (SOCRATES) Cohort.** *Vaccines (Basel)* 2021; 9Griva K, Tan KYK, Chan FHF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960161>
82. **Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection.** *Vaccines (Basel)* 2021; 9Guerrieri M, Francavilla B, Fiorelli D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960244>
83. **Differences in COVID-19 Vaccine Acceptance, Hesitancy, and Confidence between Healthcare Workers and the General Population in Japan.** *Vaccines (Basel)* 2021; 9Hara M, Ishibashi M, Nakane A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960135>
84. **Promising Expectations for Pneumococcal Vaccination during COVID-19.** *Vaccines (Basel)* 2021; 9Im H, Ser J, Sim U, Cho H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960253>
85. **Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.** *Vaccines (Basel)* 2021; 9Intapiboon P, Seepathomnarong P, Ongarj J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960122>
86. **Comparison of SARS-CoV-2-Specific Antibodies in Human Milk after mRNA-Based COVID-19 Vaccination and Infection.** *Vaccines (Basel)* 2021; 9Juncker HG, Mulleners SJ, van Gils MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960222>
87. **"Until I Know It's Safe for Me": The Role of Timing in COVID-19 Vaccine Decision-Making and Vaccine Hesitancy.** *Vaccines (Basel)* 2021; 9Kennedy EB, Daoust JF, Vikse J, Nelson V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960162>

88. **COVID-19 Vaccination Acceptance among Health Science Students in Morocco: A Cross-Sectional Study.** *Vaccines (Basel)* 2021; 9Khalis M, Boucham M, Luo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960197>
89. **A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues.** *Vaccines (Basel)* 2021; 9Khandker SS, Godman B, Jawad MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960133>
90. **COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study.** *Vaccines (Basel)* 2021; 9Klugar M, Riad A, Mohanan L, Pokorná A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960183>
91. **Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study.** *Vaccines (Basel)* 2021; 9Lai X, Zhu H, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960208>
92. **Motivating Seasonal Influenza Vaccination and Cross-Promoting COVID-19 Vaccination: An Audience Segmentation Study among University Students.** *Vaccines (Basel)* 2021; 9Lee D, Rundle-Thiele S, Li G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960143>
93. **Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review.** *Vaccines (Basel)* 2021; 9Lee YK, Huang YH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960150>
94. **Herpetic Keratitis Preceded by COVID-19 Vaccination.** *Vaccines (Basel)* 2021; 9Li S, Jia X, Yu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960139>
95. **Analysis of the Impact of Media Trust on the Public's Motivation to Receive Future Vaccinations for COVID-19 Based on Protection Motivation Theory.** *Vaccines (Basel)* 2021; 9Li Z, Sun X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960147>
96. **Immune Thrombocytopenia Induced by the Chimpanzee Adenovirus-Vectored Vaccine against SARS-CoV-2 Infection.** *Vaccines (Basel)* 2021; 9Liao PW, Teng CJ, Chou CW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960232>
97. **COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity.** *Vaccines (Basel)* 2021; 9Liu Y, Han J, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960204>
98. **Overview of Neutralizing Antibodies and Their Potential in COVID-19.** *Vaccines (Basel)* 2021; 9Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960121>
99. **Optimising COVID-19 Vaccination Policy to Mitigate SARS-CoV-2 Transmission within Schools in Zimbabwe.** *Vaccines (Basel)* 2021; 9Murewanhema G, Mukwenha S, Dzinamarira T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960227>
100. **COVID-19 Vaccination: The Mainspring of Challenges and the Seed of Remonstrance.** *Vaccines (Basel)* 2021; 9Najjar H, Al-Jighefee HT, Qush A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960220>
101. **Role of Vaccine Hesitancy, eHealth Literacy, and Vaccine Literacy in Young Adults' COVID-19 Vaccine Uptake Intention in a Lower-Middle-Income Country.** *Vaccines (Basel)* 2021; 9Nath R, Imtiaz A, Nath SD, Hasan E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960151>
102. **Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients-Is It Related to Immunosuppression Only?**

- Vaccines (Basel)_2021; 9Nazaruk P, Monticolo M, Jędrzejczak AM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960200>
103. **Factors Associated with COVID-19 Vaccine Hesitancy among Visible Minority Groups from a Global Context: A Scoping Review.** Vaccines (Basel)_2021; 9Ochieng C, Anand S, Mutwiri G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960192>
 104. **Who Got Vaccinated for COVID-19? Evidence from Japan.** Vaccines (Basel)_2021; 9Okubo T, Inoue A, Sekijima K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960251>
 105. **Expected Evolution of COVID-19 Epidemic in France for Several Combinations of Vaccination Strategies and Barrier Measures.** Vaccines (Basel)_2021; 9Pageaud S, Pothier C, Rigotti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960207>
 106. **Parents' Decisions to Vaccinate Children against COVID-19: A Scoping Review.** Vaccines (Basel)_2021; 9Pan F, Zhao H, Nicholas S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960221>
 107. **Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection.** Vaccines (Basel)_2021; 9Parés-Badell O, Martínez-Gómez X, Pinós L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960209>
 108. **COVID-19 in Low- and Middle-Income Countries (LMICs): A Narrative Review from Prevention to Vaccination Strategy.** Vaccines (Basel)_2021; 9Pasquale S, Gregorio GL, Caterina A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960223>
 109. **Austria's Digital Vaccination Registry: Stakeholder Views and Implications for Governance.** Vaccines (Basel)_2021; 9Paul KT, Janny A, Riesinger K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960241>
 110. **COVID-19 Vaccinations: Perceptions and Behaviours in People with Primary Ciliary Dyskinesia.** Vaccines (Basel)_2021; 9Pedersen ESL, Mallet MC, Lam YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960242>
 111. **Group Vaccination Five Days before a COVID-19 Outbreak in a Long-Term Care Facility.** Vaccines (Basel)_2021; 9Pletz MW, Trommer S, Kolanos S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960196>
 112. **VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.** Vaccines (Basel)_2021; 9Prates-Syed WA, Chaves LCS, Crema KP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960155>
 113. **Trusted Sources of COVID-19 Vaccine Information among Hesitant Adopters in the United States.** Vaccines (Basel)_2021; 9Purvis RS, Hallgren E, Moore RA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960164>
 114. **Evaluation of Treatment Outcome for Pneumonia among Pre-Vaccinated COVID-19 Patients with/without Comorbidity in a Public Hospital in Bengkulu, Indonesia.** Vaccines (Basel)_2021; 9Ramatillah DL, Gan SH, Sulaiman SAS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960157>
 115. **Intention of Parents to Immunize Children against SARS-CoV-2 in Italy.** Vaccines (Basel)_2021; 9Russo L, Croci I, Campagna I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960215>
 116. **Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.** Vaccines (Basel)_2021; 9Shehab M, Alrashed F, Alfadhli A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960217>

117. **Students' Views on Vaccination against COVID-19 Virus and Trust in Media Information about the Vaccine: The Case of Serbia.** *Vaccines (Basel)*. 2021; 9Šiđanin I, Njegovan BR, Sokolović B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960176>
118. **PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio.** *Vaccines (Basel)*. 2021; 9Suah JL, Tok PSK, Ong SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960126>
119. **Perceptions towards COVID-19 Vaccines and Willingness to Vaccinate in Nepal.** *Vaccines (Basel)*. 2021; 9Subedi D, Pantha S, Subedi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960194>
120. **Data-Driven Decision Making and Proactive Citizen-Scientist Communication: A Cross-Sectional Study on COVID-19 Vaccination Adherence.** *Vaccines (Basel)*. 2021; 9Syundyukov E, Mednis M, Zaharenko L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960129>
121. **Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients.** *Vaccines (Basel)*. 2021; 9Timmermann L, Globke B, Lurje G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960168>
122. **Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers.** *Vaccines (Basel)*. 2021; 9Trunfio M, Verga F, Ghisetti V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960123>
123. **COVID-19 Passport as a Factor Determining the Success of National Vaccination Campaigns: Does It Work? The Case of Lithuania vs. Poland.** *Vaccines (Basel)*. 2021; 9Walkowiak MP, Walkowiak JB, Walkowiak D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960245>
124. **COVID-19 Immunisation, Willingness to Be Vaccinated and Vaccination Strategies to Improve Vaccine Uptake in Australia.** *Vaccines (Basel)*. 2021; 9Wang B, Nolan R, Marshall H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960213>
125. **Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population.** *Vaccines (Basel)*. 2021; 9Weinberger B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960181>
126. **Race-ethnicity and COVID-19 Vaccination Beliefs and Intentions: A Cross-Sectional Study among the General Population in the San Francisco Bay Area.** *Vaccines (Basel)*. 2021; 9Weng Y, Lu D, Bollyky J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960152>
127. **COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination.** *Vaccines (Basel)*. 2021; 9Wieteska-Milek M, Szmit S, Florczyk M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960141>
128. **Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT162b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection.** *Vaccines (Basel)*. 2021; 9Wolszczak-Biedrzycka B, Bieńkowska A, Dorf J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960254>
129. **Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study.** *Vaccines (Basel)*. 2021; 9Yadete T, Batra K, Netski DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960170>

130. **Opposing Mechanisms Involving Perceived Benefits versus Safety Partially Explained an Increase in COVID-19 Vaccination Intention among Unvaccinated Chinese Adults during a Post-Rollout Period: Results of Two Serial Surveys.** Vaccines (Basel) 2021; 9Yu Y, Lau JTF, Lau MMC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960160>
131. **Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant.** Vaccines (Basel) 2021; 9Zhang R, Khong KW, Leung KY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960189>
132. **COVID-19 Vaccination Acceptance in China after It Becomes Available: A Cross-Sectional Study.** Vaccines (Basel) 2021; 9Zhou Q, Tian T, Ni J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960144>
133. **Modeling the Influence of Vaccine Administration on COVID-19 Testing Strategies.** Viruses 2021; 13Forde JE, Ciupe SM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960814>
134. **Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?** Viruses 2021; 13Parra-Lucare A, Toro L, Weitz-Muñoz S, Ramos C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34960761>
135. **Experience of the first 1127 COVID-19 Vaccine Allergy Safety patients in Hong Kong - Clinical outcomes, barriers to vaccination, and urgency for reform.** World Allergy Organ J 2022; 15:100622Chiang V, Mok SWS, Chan JKC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34956434>
136. **A Year of Pandemic-Comparison of Depression Among Neurosurgeons After the Advent of the COVID-19 Vaccine.** World Neurosurg 2021; Sharif S, Amin F, Hafiz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973442>

Women – pregnancy (22 articles)

1. **Early impact of the COVID-19 pandemic on promotion of infant activity, strength and communication: A qualitative exploration.** Acta Psychol. (Amst.) 2022; 222:103480Snyder K, Chaudhary P, Pereira A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34971950>
2. **Comprehensive serologic profile and specificity of maternal and neonatal cord blood SARS-CoV-2 antibodies.** AJOG Glob Rep 2022; 2:100046Boelig RC, Chaudhury S, Aghai ZH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961853>
3. **Effects of the Covid-19 pandemic on maternity staff in 2020 - a scoping review.** BMC Health Serv. Res. 2021; 21:1364Schmitt N, Mattern E, Cignacco E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961510>
4. **Pregnant during the COVID-19 pandemic: an exploration of patients' lived experiences.** BMC Pregnancy Childbirth 2021; 21:851Kolker S, Biringer A, Bytautas J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34972506>
5. **Psychological impacts of the COVID-19 pandemic on one-month postpartum mothers in a metropolitan area of Japan.** BMC Pregnancy Childbirth 2021; 21:845Takubo Y, Tsujino N, Aikawa Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963448>
6. **Maternal and Neonatal Outcomes of Healthy Pregnant Women With COVID-19 Versus High-risk Pregnant Women: A Multi-Center Case-Control Comparison Study.** Clin. Nurs. Res. 2021:10547738211064027Al Hashmi I, Khalaf A, Seshan V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955040>

7. **Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France.** Contraception 2021; Roland N, Drouin J, Desplas D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34971603>
8. **Impact of COVID-19 on Antenatal Care Utilization Among Pregnant Women in Qassim, Saudi Arabia.** Cureus 2021; 13:e19554Rabbani U, Saigul AA, Sulaiman A, Ibrahim TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956742>
9. **Heterogeneity in maternal and child mental health responses to the COVID-19 pandemic.** Early Child Res Q 2022; 59:203-214Saleem S, Burns S, Falenchuk O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955597>
10. **The Impact of Postponed Fertility Treatment on the Sexual Health of Infertile Patients Owing to the COVID-19 Pandemic.** Front Med (Lausanne) 2021; 8:730994Dong M, Wu S, Tao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957137>
11. **Maternal Transmission of SARS-CoV-2: Safety of Breastfeeding in Infants Born to Infected Mothers.** Front Pediatr 2021; 9:738263Al-Kuraishy HM, Al-Gareeb Al, Atanu FO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956971>
12. **Neuroleptic Malignant Syndrome due to Atypical Antipsychotics in a COVID-19-positive Pregnant Woman.** Indian J. Crit. Care Med. 2021; 25:1073-1074Burad J, Kodange S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963731>
13. **Maternal-Newborn Health System Changes and Outcomes in Ontario Canada during Wave 1 of the COVID-19 Pandemic - A Retrospective Study.** J. Obstet. Gynaecol. Can. 2021; Roberts NF, Sprague AE, Taljaard M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973435>
14. **Re: SARS-CoV-2 behavior, through the eyes of a perinatologist?** J. Perinat. Med. 2021; Volpe N, Ghi T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34962365>
15. **Development and psychometric properties of the Pandemic-Related Postpartum Stress Scale (PREPS-PP).** J. Psychosom. Obstet. Gynaecol. 2021;1-7Levinson A, Mahaffey B, Lobel M, Preis H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967691>
16. **Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection.** J Transl Med 2021; 19:524Liu Y, Ebinger JE, Mostafa R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965855>
17. **COVID-19 vaccinations: does the mRNA go into breast milk?** Monatsschr. Kinderheilkd. 2021; Kerbl R.
18. **Blessings and Curses: Exploring the Experiences of New Mothers during the COVID-19 Pandemic.** Nurs Rep 2020; 10:207-219Joy P, Aston M, Price S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34968364>
19. **Effects of the COVID-19 pandemic on obstetrics and gynecology residency training in Turkey.** Turk J Obstet Gynecol 2021; 18:304-310Topçu G, Özçivit İ B, Erkilinc S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34955024>
20. **Comparison of SARS-CoV-2-Specific Antibodies in Human Milk after mRNA-Based COVID-19 Vaccination and Infection.** Vaccines (Basel) 2021; 9Juncker HG, Mulleners SJ, van Gils MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960222>
21. **Decreased Fetal Movements: A Sign of Placental SARS-CoV-2 Infection with Perinatal Brain Injury.** Viruses 2021; 13Favre G, Mazzetti S, Gengler C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960786>
22. **Vaginal birth after caesarean section before and during COVID-19 pandemic. Factors associated with successful vaginal birth.** Women Birth 2021; Hidalgo-

Lopezosa P, Cubero-Luna AM, Huertas-Marín J *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34972660>

to subscribe click [here](#)

mailing address is:
lansberg@gmail.com

© P.J. Lansberg